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Abstract 
The goal of precision medicine is to use molecular profiles of disease to identify a targeted 
treatment that results in the best available patient outcomes. Although the concept of 
individualizing treatment is not new to medicine, genomic technologies and therapies targeted to 
genetic drivers of disease have inspired an era of precision medicine. Obtaining molecular profiles 
of disease requires analyzing biological samples that present daunting analytical challenges with 
thousands of potentially interfering analytes, often at concentrations much higher than the analytes 
of interest. Many analytes harbor fragile chemical modifications, such as phosphorylation of 
signaling proteins, and therefore, require careful design of protocols for sample handling to 
preserve the relevant biological information. Classifying patients into subgroups that will benefit 
from tailored therapies demands moving beyond single biomarker diagnostics to multiplexed 
detection methods. The analytical toolbox for studying the molecular basis of human disease has 
grown tremendously in recent decades and has been motivated in part by the human genome 
project, with the most dramatic changes seen in sequencing technologies. The next frontier for 
molecular diagnostics is the development of diagnostic tools for non-genomic molecular profiles 
of disease, such as non-coding RNAs and proteins. This thesis details efforts to improve 
multiplexed protein detection for precision medicine diagnostics. Most of the following work uses 
microring resonator arrays as the detection platform, a versatile silicon photonic biosensing 
technology. 
Chapter 1 reviews the applications of optical resonators in analytical chemistry. Microring 
resonators arrays are a class of whispering gallery mode resonators featured throughout the review. 
A conventional focus of optical resonator development has been on designing label-free sensors 
for biomolecule detection. However, much of the recent work pushing limits of detection for the 
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microring resonator platform have used immunoaffinity labels and enzymatic enhancement to 
perform detection in clinically relevant samples. Initially, we had anticipated needing to fractionate 
interfering species out of these biological samples to perform multiplex measurements on the 
fractions of interest using the microring resonator platform. We found solutions that avoided 
separations prior to sample analysis, but the microring resonators offered an interesting property 
uncommon among chromatography detectors: a universal detector with an enormous dynamic 
range. Chapter 2 details interfacing the microring resonator platform with liquid chromatography. 
Optical resonators are surface sensitive and most commonly used to observe binding events on a 
modified sensor, but they can also serve as bulk refractive index detectors. In comparison to 
commercial refractive index detectors, the microring resonator platform is compatible with solvent 
gradient chromatography because of the large dynamic range. Commonly studied small molecule 
pharmaceuticals were used for proof-of-concept experiments, and ongoing work seeks to extend 
the platform to polymer analysis, an analyte class that lacks chromogenic signatures. 
The next two chapters detail my contributions to protein detection on the microring 
resonator platform and can be summarized as the implementation of protein and phosphoprotein 
detection in whole cell lysates and tissue homogenates. Protein detection in cell lysate was 
achieved by modifying the signaling amplification schemes developed by previous lab members 
and altering the chemical strategy for covalent modification of proteins to the sensor surface. 
Chapters 3 and 4 describe the specifics of this strategy. These projects were designed in part as 
proof-of-principle studies to demonstrate the application of microring resonators to novel samples 
and biomolecules. Signaling pathways are often dysregulated in tumors, resulting in uncontrolled 
growth and proliferation, and these signaling pathways are driven by phosphorylation cascades. In 
Chapter 3, a multiplex protein and phosphoprotein panel was used to monitor the levels across 
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multiple signaling pathways in glioblastoma, the most common and aggressive brain cancer in 
adults. Chapter 4 builds on the phosphoprotein panel developed in Chapter 3 to dynamically 
monitor signaling networks of patient derived xenografts in response to targeted therapeutics. The 
phosphoprotein levels in these samples indicated pathway signatures unique to treatment time and 
mutational status of the sample. This approach could potentially be used to provide actionable 
information to clinicians by determining tumor susceptibility to treatment based off its signaling 
state. 
The phosphoprotein panels described in Chapters 3 and 4 center around the 
PI3K/Akt/mTOR signaling network. However, these panels lack the membrane proteins that 
initiate the signaling cascade. To include membrane protein analysis, I developed a microfluidic 
platform for Nanodisc assembly and purification, referred  to as the μNAP platform and detail in 
Chapter 5. The μNAP platform capitalizes on sample preservation and small volume processing 
inherent to miniaturization and microfluidics and achieves Nanodisc assembly by combining a 
reagent mixing chamber and packed detergent removal bed onto a microfluidic device. The 
platform also includes an affinity chromatography module for rapid purification on the 
microfluidic scale. Cytochrome P450 3A4 was used to demonstrate the capabilities of the μNAP 
platform. 
Chapter 6 details the future directions for each of the described projects. The next steps for 
phosphoprotein detection with microring resonator arrays is to use the targeted panel to reconstruct 
the aberrant signaling networks from tumor biopsy samples. Network reconstruction has been 
performed using global profiling methods, such as next generation sequencing and proteomics 
with mass spectrometry, but reconstructing key signaling networks from minimal network data 
could provide a less cumbersome approach to obtain actionable information with higher 
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throughput. The future work for the μNAP platform will include generating Nanodisc libraries 
from valuable samples, such as tumor biopsies. Nanodisc libraries have been shown to accurately 
represent the membrane protein composition of the sample, and these libraries formed from patient 
samples could be used for functional screening of membrane proteins in response to targeted 
therapeutics. Finally, interfacing the microring resonator platform with on-chip electrophoresis 
could prove to be a remarkably useful combination. The microring resonator platform would allow 
for on-chip multiplexed detection of biomolecules combined with the separation efficiency of 
electrophoresis. The interface would substantially reduce reagent consumption and shrink the 
footprint of the sensor platform by eliminating the need for external pumping. By applying the 
previously developed electrophoretic methods for sample stacking along with the improved mass 
transfer properties of non-laminar flow, on-chip electrophoresis combined with microring 
resonator arrays could represent a significant analytical advancement. 
  
vi 
 
 
 
 
 
 
 
 
 
 
 
 
To all the animals who fill our house and to the woman who brought them all home 
vii 
 
Acknowledgements 
Grad school was lonely at times. Unlike the rest of my education, it demanded 
independence and perseverance and was unique and sometimes scary. I, and I think many fellow 
graduate students, struggled to adjust to the lack of deadlines. Grad school is a race toward a hidden 
finish line. Each year offers a new checkpoint, and we reach them at different times. When I began 
asking the ideal time to schedule my prelim, I received many opinions but common among them 
was the vague phrase “when you’re ready.” Toiling away on a project, I often wondered when I 
had enough data -- “when the story is complete.” The daily slog of experiments, data analysis, 
notebook updating, meetings, conference calls, presentation preparation, and writing were easy 
diversions that distracted from the larger goal of becoming an independent scientist. I am finally 
approaching the end of this race with the finish line in view. Over these years, I have grown as a 
scientist and as a person, and I owe a tremendous amount gratitude to those who supported me 
along the way. 
To start, I would like to thank the educators who motivated me to pursue chemistry as a 
career. In particular, my high school chemistry teacher, Mrs. Dunne, radiated a contagious 
enthusiasm. Many scientists retell stories about their career path beginning with an inspiring 
science teacher, but I owe Mrs. Dunne for more than  her wonderful teaching skills. Mrs. Dunne 
assigned a timid young lady as my lab partner. There is a terrible chemistry joke to be made here 
because that young lady later became my wife. 
I was fantastically lucky with my experience at Furman University. Drs. John and Sandy 
Wheeler were excellent mentors throughout my four years at Furman, and their guidance has 
prepared me for my future in ways that I continue to discover. Sandy is a wonderful advocate, 
mentor, and friend who was always willing to listen to my complaints and problems. I might have 
viii 
 
spent a bit too much time in her office over the years, but I am happy that I did. John tirelessly 
works for the education of his students, and he is one of the most diligent and dedicated professors 
I know. His aspirations are selfless and humble; he has received grant after grant for the betterment 
of the department and of the sciences at Furman. The communal stewardship he demonstrates in 
his professional career has provided an impactful example for me as I begin mine. I owe both John 
and Sandy a debt of gratitude that is hard to express for their support over the years. 
To the Bailey lab past and present, I thank you for your advice, support, and tolerance. 
Specifically, I’d like to thank: Dr. Adam Washburn, Dr. Abe Qavi, Dr. Matt Luchansky, Dr. 
Courtney Sloan, Dr. Jared Kindt, Dr. Josh Tice, Dr. Melinda McClellan, Dr. Rory Alsop, Dr. Jess 
Banks, Dr. Winnie Shia, Dr. Enrique Valera, Dr. Ellen Muehl, Dr. Meng Sun, Heather Robison, 
Alex Stanton, Yi Xu, Steve Doonan, Jamy Lee, Maria Cardenosa, Amit Patel (honorary member), 
John Orlet, Josh Jones, Ruth Londono, Nick Vertin, Emily Mordan, Colleen Riordan, Shannon 
Wetzler, Sarah Lutty, and Cole Chapman. I would also like to give a special thank you to Dr. 
Richard Graybill. You have put up with me as a lab mate in both undergrad and grad school and 
now as a roommate. Thank you for being a sound mind over the years. I wish you and Meg the 
best of luck as you head off to Boston. 
To Prof. Ryan Bailey, I have valued your mentorship and guidance through these formative 
years of graduate school. I have watched as you transitioned from a newly-tenured young 
investigator to an established full professor, and I have learned a lot from your example. As a 
young scientist, struggle and frustration are part of the pathway to growth, and you offered the 
encouragement to help me push through. I am excited to see what we can accomplish in my 
remaining time in lab, and I look forward to the discoveries and developments from the lab in 
years to come. I also want to thank my committee members--Prof. Jonathan Sweedler, Prof. Steve 
ix 
 
Sligar, and Prof. Paul Hergenrother. Thank you for your support and constructive criticism through 
the graduate school process. I owe a special thank you to Julie Sides and Becky Duffield for 
providing me with plenty of chocolate and sugar and for keeping me sane along the way. You two 
were the unsung heroes of the Analytical area. 
To my family and close friends, I need more than an Acknowledgements section to thank 
you for your continued support during graduate school and more. I know that you did not always 
understand what I was doing or why, and that the graduate school process may have seemed 
confusing and a bit ill defined. Thank you for trusting that I mostly knew what I was doing along 
the way. To Mom, Dad, Juliana, and Jonathan, I have missed you, living so far away these past 
few years, but I have come to appreciate the time we spend together much more than before. To 
Charlie, Lori, and Chas, my time in graduate school has also coincided with the time of us being a 
family. I cannot thank you enough for your support of me along with Kayla, Jacob, Bo, Casper, 
and Sabrina. I cannot promise our next move will be closer to home, but I hope it at least has a 
bigger airport. 
To my wife, Kayla, you have seen my successes and failures through graduate school 
more than anyone else. With my deepest love and gratitude, I thank you for all the ways you 
have been by my side. I refuse to imagine going through graduate school without you. We have 
added three more animals to our house since we first moved to Illinois, and I am afraid to think 
of how many more the next chapter of our lives will bring. 
  
x 
 
Table of Contents 
Chapter 1:  Applications of Optical Microcavity Resonators in Analytical Chemistry ................ 1 
Chapter 2:  Refractive Index-Based Detection of Gradient Elution Liquid Chromatography 
Using Chip-Integrated Microring Resonator Arrays .................................................................... 54 
Chapter 3:  Rapid, Multiplexed Phosphoprotein Profiling Using Silicon Photonic Sensor Arrays
....................................................................................................................................................... 82 
Chapter 4:  Monitoring Signaling Networks with Phosphoprotein Profiling of Patient-Derived 
Xenografts ................................................................................................................................... 125 
Chapter 5:  Microfluidic Nanodisc Assembly and Purification ................................................ 161 
Chapter 6:  Conclusions and Future Directions......................................................................... 201 
 
 
1 
 
 
 
Chapter 1 
 
Applications of Optical Microcavity Resonators in 
Analytical Chemistry 
 
 
Acknowledgements 
This chapter has been adapted from the review “Applications of Optical Microcavity 
Resonators in Analytical Chemistry” (Wade, J.H.; Bailey, R.C. Annual Reviews of Analytical 
Chemistry 2016, 9, 1-25). The review has been reproduced here with permission from Annual 
Reviews © 2016.  
The work in this chapter was funded by the National Institutes of Health (NIH) National 
Cancer Institute (NCI) through CA177462-02. JHW was supported by the National Science Foundation 
Graduate Research Fellowship Program. 
The article can be accessed online at: dx.doi.org/10.1146/annurev-anchem-071015-041742 
  
2 
 
1.1 Abstract 
Optical resonator sensors are an emerging class of analytical technologies that use 
recirculating light confined within a microcavity to sensitively measure the surrounding 
environment. Bolstered by advances in microfabrication, these devices can be configured for a 
wide variety of chemical or biomolecular sensing applications. We begin with a brief description 
of optical resonator sensor operation followed by discussions regarding sensor design, including 
different geometries, choices of material systems, methods of sensor interrogation, and new 
approaches to sensor operation. Throughout, key developments are highlighted, including 
advancements in biosensing and other applications of optical sensors. We discuss the potential of 
alternative sensing mechanisms and hybrid sensing for more sensitive and rapid analyses. We 
conclude with our perspective on the future of optical microcavity sensors and their promise as 
versatile detection elements within analytical chemistry. 
1.2 Introduction 
 Advances in micro- and nanofabrication methods have played key roles in analytical 
measurement technologies. Many of these advances have their genesis in the microelectronics 
industry, which has followed Moore’s law toward continuously miniaturized complementary 
metal oxide semiconductor (CMOS) transistors.1 Improved CMOS processing leads to the reliable 
and scalable fabrication of micro- and nanoscale sensing devices.2 Though the principal focus of 
the microelectronics industry has been the manipulation of electrons on microchip devices, light 
can also be manipulated on slightly longer scales by the fabrication of photonic structures such as 
waveguides and other resonant microcavities.3 These photonic circuits are most typically 
fabricated from semiconducting materials and often operate at standard telecommunication 
wavelengths.4-6 Such devices have many applications beyond the realm of traditional optical 
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sensing, including optical interconnects, signal routing and processing, and long range 
telecommunications7-10 By leveraging the ability to precisely and sensitively manipulate light on 
such small scales, optical resonators are playing an increasingly important role in analytical 
chemistry and can be applied to a multitude of analyte classes11-14 Though impressive results have 
been reported, the promise of optical resonators will be realized only through the translation of 
devices beyond proof-of-concept demonstrations and their application to real-world molecular 
detection challenges, ranging from on-site environmental monitoring to personalized medicine. 
 Microcavity sensors confine light into a circular path and enhance the local electromagnetic 
field through a constructive interference resonance condition. Owing to similarities in interference-
based modes that can satisfy propagating resonance conditions, these sensors are commonly called 
whispering gallery mode (WGM) resonators, referring to the acoustic phenomenon first described 
by Lord Rayleigh at the beginning of the 20th century.15 In microcavity resonators, light couples 
into the microcavity only at specific wavelengths, 𝜆𝜆r, under conditions of optical resonance, as 
defined by: 
𝜆𝜆r = 𝐿𝐿𝑛𝑛𝑒𝑒𝑒𝑒𝑒𝑒𝑚𝑚  
where 𝐿𝐿 is the circumference of the cavity,  𝑛𝑛eff is the effective refractive index sampled by the 
optical mode, and 𝑚𝑚 is an integer representing the azimuthal quantum number. Changes in the 
effective refractive index at the sensor surface result in shifts in resonant wavelength coupled 
into the cavity. Light coupled into the resonant cavity results in a drop in the intensity of the light 
transmitted through the linear coupling waveguide as it propagates past the sensor, and 
measurements are most commonly reported as changes in the relative shift of the resonance 
wavelength (Δ𝜆𝜆𝑟𝑟) (Figure 1.1). 
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A defining factor used to compare optical microcavities is the quality (Q) factor, defined 
as the ratio of the resonant wavelength 𝜆𝜆𝑟𝑟 to the spectral linewidth of the resonance (𝛿𝛿𝜆𝜆): 
𝑄𝑄 = 𝜆𝜆𝑟𝑟
𝛿𝛿𝜆𝜆
 
The Q-factor is related to the photon lifetime within the cavity and is proportional to the number 
of times the light circulates within the microcavity. The high sensitivity of optical resonators 
derives from the repeated sampling of analytes near the sensor surface as light continuously 
propagates around the optical microcavity, dramatically increasing the effective path length. Q-
factors ranging from 103 to 1010 have been reported,16,17 correlating to effective path lengths in 
excess of a centimeter. 
 More than a decade has passed since the first demonstrations of sensing with optical 
resonators;3,18-20 however, the rapid increase in their use in recent years is the culmination of 
advances in new sensor designs, increasing speeds of signal readout, and low-cost 
microfabrication, as well as key developments in supporting technologies (e.g., lasers, 
photodetectors, precision optics, microfluidics). The end results are technologies that are 
beginning to make substantive impacts throughout analytical chemistry and related fields. 
 Given the existing literature relating to optical resonator sensors, a number of excellent 
reviews are already available, and we point the reader to other resources with more comprehensive 
coverage of topics only briefly mentioned in this review, such as sensor operation, fabrication, 
material choice, and chemical modification, among others.12-14,21-29 This review seeks to highlight 
key developments in optical resonator sensing with a focus on the practical implementation of 
these devices to solve challenging analytical problems. First, we survey technological 
improvements in device fabrication and discuss the major criteria for designing an optical 
resonator. We then survey notable applications of optical resonators as sensors, such as 
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biomolecule and gas detection and address the practical limits of optical resonators with an eye 
towards what is likely to be developed in the near future. Included in this discussion is the 
emergence of hybrid sensors that seek to combine the benefits of optical sensors with those of 
other existing measurement technologies, ranging from plasmonic materials to optomechanical 
devices and on-chip lasing. 
1.3 Design of Optical Resonator Sensors 
Optical resonator sensor design often involves a compromise between improved sensitivity 
and scalable fabrication. Rigorous micro- and nanofabrication methods, precise manipulation of 
high performance optical components, and advanced data processing methods enable sensors to 
push toward high Q-factors and more robust performance. Conversely, many of these 
improvements to an individual sensor’s performance come at the cost of scalable manufacturing 
and facile sensor operation within practical analytical environments (e.g., benchtop, point-of-care, 
field analysis). 
 Device Geometry. The common feature of WGM sensors is a circular path that defines an 
optical microcavity through which light is confined. Many early resonator geometries were simple 
structures such as spheres,16,20,30-33, toroids,17,34 discs,19,35-37 and rings38-40. Alternative geometries 
including tubes,41-43 capillaries,44-48 bubbles,49 and knots50 have also been used. Figure 1.2 
provides an overview of established sensor geometries. 
An ideal microcavity that perfectly confines light would have an infinite Q-factor. 
However, perfect cavities cannot be experimentally realized because small geometric 
imperfections or absorptive losses prohibit perpetual confinement. Higher Q-factors are due to 
stronger confinement of photons within the waveguide material, which in turn is proportional to 
the mode volume (V). Sensor design often seeks to maximize the Q/V ratio by fabricating smaller 
resonant structures, but optical losses from higher bending radii reduce the Q-factor.51 Sensor 
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development has now focused on improved sensor geometries with a bending radius >5 μm and 
on improved fabrication practices to maximize Q-factor. 
To achieve high Q-factors, microcavities must be fabricated with low surface roughness, 
thereby reducing waveguide scattering losses.17 Microtoroid fabrication includes a reflow 
smoothing process to limit scattering losses, but common reflow techniques are limited to small 
sensor sizes (<500 µm) and the sensor geometry itself is not easily integrated within a conventional 
semiconductor fabrication workflow.52,53 To limit scattering losses, Lee et al52 have utilized 
wedge-shaped waveguides. Because propagating modes in a wedge geometry are pushed away 
from scattering surfaces, fabrication defects have a reduced effect on Q. This approach is also 
compatible with conventional semiconductor processing. 
 Goblet and conical geometries offer Q-factors ranging from 105 to 107 by processing a 
polymer layer directly on top of a silicon substrate.54-56 Though these devices cannot match the Q-
factor of toroidal or wedge geometries, they offer potential lower-cost fabrication that can be 
parallelized. Specifically, the goblet geometry is formed from the surface tension induced by a 
thermal reflow step. The polymeric material has reduced surface roughness compared to standard 
lithographic methods and is compatible with replica molding, though this requires a mold from an 
ultra-high Q-factor device.55 
 Sensor Interrogation. The ability to reproducibly fabricate optical microcavities with Q-
factors >105 has now become routine. Therefore, practical applications of these technologies are 
now tied to the reproducible coupling of light into these ultra-high Q-factor optical microcavities. 
An ideal coupling strategy for many downstream applications would be free from complex optical 
setups (e.g., floated laser table) and capable of operating under ambient conditions. The first 
generation of microsphere resonators coupled light into the microsphere by aligning an adiabatic 
7 
 
fiber taper so that the fiber overlapped with the evanescent field of the microsphere.20,57 Though 
this method allows for efficient coupling into the resonator geometry, optical alignment can be 
tedious and complicates the operation of these devices outside of a well-controlled laboratory 
setting. Additionally, multiplex measurements are difficult to achieve with this arrangement due 
to the rigorous demands of optical alignment and the challenge of simultaneously or serially 
interrogating multiple microcavity sensors. Alternatively, some geometries are well-suited to 
coupling via chip-integrated planar waveguides, obviating the need for fiber extrusion and 
alignment.20,58-61 For integrated waveguides, light is coupled onto the chip by fiber-optic to 
waveguide coupling, edge coupling from the tunable light source to the waveguide, or surface 
couplers (e.g., grating couplers).51 Fiber-optic to waveguide coupling and edge coupling require 
precise optical alignment of either an optical fiber or a laser with the waveguide, which imposes 
similar limits as fiber taper coupling methods. Surface couplers have greater tolerances for optical 
alignment because the size of the surface couplers can be larger than the waveguide.62,63 A 
disadvantage of free space coupling with grating couplers is that often only a fixed polarity of light 
can be used.24 
 There are additional possibilities for coupling light into microspheres. For example, 
microspheres resting on a surface can be interrogated via a prism.32,64,65 Additionally, fluorescent 
microparticles can function as an optical microcavity and eliminate the need for optical 
waveguides or fiber-optics altogether, as the fluorescence generated by a focused laser spot can be 
confined within the fluorescent microparticle.66-68 This approach has been termed WGM imaging, 
and multiplexing can be achieved by using particles of difference sizes and fluorescent 
wavelengths. Mass transfer advantages also come into play with microparticles, as analyte capture 
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can be achieved in free solution prior to interrogation while bound to a planar substrate.64 Figure 
1.3 illustrates several common methods of optical microcavity interrogation. 
Sensor Materials. In addition to considerations in terms of ease of fabrication, the choice 
of material for optical resonator design is also guided by the ability of the resulting cavity to 
strongly confine light. The higher the refractive index contrast between the cavity and the 
surrounding material, the greater the optical confinement. The length of the evanescent field 
extending into the sensing region is inversely proportional to the strength of confinement. Lower 
index contrast between the cavity and sensing region leads to a larger percentage of the evanescent 
field extending into the sensing region, which then samples the local environment. Evanescent 
field strength (𝐼𝐼) decays exponentially from the sensor surface as described by: 
𝐼𝐼(𝑧𝑧) = 𝐼𝐼0𝑒𝑒2𝛾𝛾𝛾𝛾 
where 𝐼𝐼0 is the initial field strength at the sensor surface, 𝑧𝑧 is the distance from the sensor 
surface, and 𝛾𝛾 is an exponential decay constant that describes the rate of field fall off.30,69 Taken 
together, the choice of materials system effects not only the degree of optical confinement (Q-
factor), but also the proportion of light that can interact with the sensing region. Therefore, 
materials system selection should be considered by balancing Q-factor against evanescent field 
penetration depth, as filed penetration depth may vary depending upon the ultimate application 
of the device.  
Due to their general ease of fabrication, silicon-based materials systems have frequently 
been developed for microresonator sensing applications.13 In addition to silicon-on-insulator 
(SOI), materials such as silicon carbide (SiC) and silicon nitride (Si2N3) have been used for sensor 
fabrication due to their impressive near-infrared zero-phonon emission and strong refractive index 
contrast with silicon dioxide (SiO2), respectively.70,71 Hydrogenated amorphous silicon (a-Si:H) 
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has also been used due its high refractive index (~3.5); low loss compared to crystalline SOI; and 
versatility in fabrication, as it can be deposited at  lower temperatures(≤ 300°C).72 Titanium oxide 
(TiO2) is a useful material for WGM sensors due to low absorption in the visible and infrared 
wavelengths, a low thermal expansion coefficient, a negative thermo-optic coefficient, 
biocompatibility, and compatibility with CMOS microfabrication.73 Barium titanate (BaTiO3) 
microspheres have also been used for sensing, offering the nonoptical advantages of the ability to 
perform measurements in small volumes (10 µL), commercial availability, and facile surface 
functionalization.64,65 As improvements in fabrication techniques expand the options for sensor 
material, performance metrics such as Q-factor and scattering losses must be considered for 
optimal sensor design. 
Various organic polymer materials have been used for optical microcavity 
fabrication.54,55,67,74-85 The principal advantage of these materials is low-cost, simple 
manufacturing, and many of the resulting devices, such as the polymer microgoblets, maintain 
remarkable optical qualities, with Q-factors as high as 106.54 Polymers doped with fluorescent dyes 
and quantum dots have also been used to coat the inner walls of optofluidic resonators.46,47 Isolated 
conjugated polymers (ICPs) are a particularly interesting material for WGM sensing, as they 
possess the advantages of free-space coupling (discussed above), inherent fluorescence (i.e., no 
doping needed), and ease of synthesis and fabrication.67 However, additional developments are 
needed to realize full functionality as optical resonator sensors. Specifically, at present ICPs have 
a Q-factor of only 600 and a low refractive index (1.6-1.8), which would make sensing in liquid 
environments challenging.  
Sensing Mechanism. Nearly all applications of optical resonators incorporate some form 
of photodetector that monitor intensity over time. As discussed above, high Q-factor devices can 
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support spectrally narrow resonances that shift as the local refractive index is modulated. As Δ𝑛𝑛eff 
changes at or near the sensor surface, spectral shifts in the positions of the resonances can be 
monitored as a function of time. Often presented as a drop in the intensity, measured by a 
photodetector, of light propagating through the linear waveguide past the microcavity, these 
resonances have a Lorentzian line shape: 
𝐼𝐼(𝜆𝜆) = 𝐼𝐼0 − 𝛽𝛽 � (𝛿𝛿𝜆𝜆 2⁄ )2(𝜆𝜆 −  𝜆𝜆𝑟𝑟)2 + (𝛿𝛿𝜆𝜆 2⁄ )2� , 
where 𝐼𝐼(𝜆𝜆) is the photodetector current as a function of wavelength, 𝐼𝐼0 is the measured current 
under non-resonant conditions (100% transmission--maximum current), and 𝛽𝛽 is the coupling 
efficiency. Importantly, sensing results can be reported in terms of a relative wavelength shift, 
Δ𝜆𝜆𝑟𝑟, as opposed to an absolute wavelength value. 
One limiting factor in the ability to precisely determine shifts in resonance wavelength is 
the tuning precision of the tunable lasers used to interrogate microcavities. Frequency jitter and 
nonideal scan-voltage control can cause wavelength uncertainties as high as 20 pm. One method 
to improve the noise floor while still using a tunable laser is to scan a large spectral window (>12 
nm) through multiple free spectral ranges to track multiple 𝜆𝜆r within a single transmission 
spectrum. This method can reduce the noise for optical resonators with moderate Q-factors (104) 
from >10 pm to as little as 0.1 pm, corresponding to a limit of detection (LOD) on the order of 10-
7 refractive index units.58 Whereas higher Q-factors would assist in lowering the noise floor even 
further, Lu et al86 achieved significant improvements in the noise floor by incorporating a 
thermally stabilized interferometer and successfully resolved a 0.1 fm shift above background. 
Aside from laser-induced noise contributions, thermal fluctuations are often the greatest 
contributor to noise. To circumvent thermal noise, controls can be integrated onto a sensor array 
by coating some of the sensors with an inert polymer.58,87 The coated sensors should readily 
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respond to thermal changes but are shielded from bulk refractive index changes or surface binding 
events. 
As an alternative to measuring shifts in resonance wavelengths, resonance broadening and 
mode splitting can also be monitored for sensing applications. Linewidth broadening refers to the 
increase in 𝛿𝛿𝜆𝜆, which represents a loss in Q-factor. This type of sensing is particularly useful for 
monitoring nanoparticle binding, which causes a loss of Q due to absorption and scattering 
losses.88,89 Mode splitting occurs due to scatter-induced coupling between degenerate, counter-
propagating spectral modes and results in the splitting of a single resonance peak into two 
resonances. This is most commonly observed when a relatively large object, such as a nanoparticle, 
enters the evanescent field and splits a single resonance mode into two via scatter-induced 
coupling.90 One significant benefit of a mode splitting--based detection experiment is that 
environmental noise (e.g., thermal fluctuations) is effectively canceled out, as the susceptibilities 
of degenerate propagating modes are identical. Although the absolute wavelength of resonances 
might shift, the degree of spectral splitting is temperature insensitive. These methods have been 
employed primarily in simultaneous detection and sizing of nanoparticles;90-92 however, this 
approach is limited to applications in which the target(s) being detected has substantial enough 
scattering properties to generate a split resonance. Monitoring of the intensity of back-scattered 
light from the resonator, rather than transmittance, can be used to improve the noise floor of WGM 
sensing below what can be achieved with monitoring of mode splitting alone. Proof-of-concept 
experiments using an atomic force microscopy (AFM) tip to simulate the presence of a 
biomolecule on a microtoroid resonator surface demonstrated a reduction of frequency noise by 7 
dB and a noise floor of 76 kHz.93 
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The utility of microcavity resonators extends beyond simply measuring the presence or 
amount of a bound target. Another interesting measurement approach involved the simultaneous 
interrogation with transverse magnetic and transverse electric propagating modes. When the 
resonator material is birefringent (i.e., the refractive index of the material is dependent on 
polarization of the light), each mode will have a distinct resonance response, which in turn can be 
used to determine biomolecular orientation on the sensor surface.94 
1.4 Applications of Optical Resonators 
The simplest implementation of an optical resonator sensor is bulk refractive index sensing 
using an unmodified sensor surface.46,47,95,96 Unmodified sensors can also be used to monitor 
adsorption and/or desorption of an analyte, such as bovine serum albumin (BSA), onto the sensor 
surface.20,30,55,57 That said, the greatest value of optical resonators in analytical chemistry lies in 
leveraging the exquisite surface sensitivity of the devices when functionalized with target-specific 
capture agents. Capture agents with high binding affinities and target specificities can be bound to 
the sensor surface—often times using standard covalent coupling reactions with chemically 
modified sensors. The most extensively explored application of microcavity resonators has been 
biosensing, which is the focus of the following sections. However, other applications to gas 
sensing, liquid chromatographic eluent detection, and heavy metal detection are also discussed. 
Other intriguing measurement modes that take advantage of unique electromagnetic field, force, 
pressure, and temperature effects of microcavity resonators are beyond the scope of this review; 
interested readers are referred elsewhere.12 
Biosensing. The biosensor community has placed a great deal of emphasis on the 
development of label-free detection strategies. We use the phrase label-free to broadly describe 
detection without chemical modification to the analyte molecule. However, this does require that 
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the sensor surface be modified with a target-specific capture agent (e.g., DNA, antibody). This is 
often achieved by derivatizing the surface with a reactive functional group and then using standard 
bioconjugation techniques,97 though other methods have been utilized.26,97 
Importantly, the performance characteristics of the resulting sensors are almost always 
extremely dependent on the binding properties of the capture agent (affinity and specificity), as 
well as the matrix in which the detection was performed. Therefore, one must take caution when 
comparing LODs from the literature alone to define the relative promise of a particular device. 
That is to say, that for a given device, the LOD for a biotin-streptavidin interaction (KD ~ 1 fM) 
should be 4-orders of magnitude lower than that of even a very good antibody-antigen binding pair 
(KD ~ 10 pM) simply on the basis of binding affinity alone; the difference has absolutely nothing 
to do with sensor performance. Readers should be careful when interpreting the relative 
performance of different devices as applied to different targets and from within more or less 
complex sample matrices. One other caution for readers in this field is to be sure to appreciate the 
difference between moles and molar (moles/L) concentrations. These two units are commonly 
used in reporting LODs, though their significance is highly dependent on the sampled volume. 
Specifically, the absolute number of molecules in a solution may be very small for a small volume 
analysis even though the relative concentration, which relates directly to the number of 
proportionally-bound analyte molecules through the equilibrium dissociation constant KD, is 
equivalent to other reports that simply detected from a larger volume. 
As alluded to above, an extremely simplistic biomolecular binding system is biotin-avidin 
binding.39,40 In the assay, either biotin or an avidin derivative (e.g., streptavidin, neutravidin) is 
tethered to the sensor surface and binding of the corresponding target to the sensor surface is 
monitored. The biotin-avidin interaction is the strongest known non-covalent binding interaction.98 
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Therefore, this biotin-avidin pair can almost be considered a covalent bond, and this binding 
affinity does not adequately represent typical receptor-target interactions. As a result, 
concentration-based LODs determined using this system are not indicative of real-world 
biosensing performance. Sensor validation efforts focusing on more realistic targets and more 
complex matrices should be viewed as more relevant within the biosensing community.  
Nucleic acid detection relies on immobilization of capture strands of DNA onto the sensor 
surface.99,100 Nucleic acids have strong selectivity for binding to specific complementary 
sequences, as dictated by Watson-Crick base pairing interactions. Using microcavity sensors, 
single nucleotide mismatch discrimination is often achievable under appropriate experimental 
conditions.99-101 Recently, Shin et al102 used silicon microring resonators to detect single nucleotide 
polymorphisms of two commonly mutated genes in bladder cancer, FGFR3 and HRAS, in spiked 
urine samples. In cases in which label-free detection of nucleic acids does not provide sufficient 
signal output, amplification strategies, such as the polymerase chain reaction (PCR), can be used. 
Sabaté del Río et al103 designed an on-chip solid-phase recombinase polymerase amplification 
method capable of real time amplification of a DNA target with an LOD  of 780 fM in buffer 
conditions. In an attempt to avoid the need for PCR-based or other amplification methods, Wu et 
al104 implemented a DNA strand displacement circuit for detection using a WGM sphere with an 
LOD of 32 fmol. Binding of the target sequence to its complement triggers a catalytic network 
amplification, in which the binding of a single target molecule triggers the release of multiple 
sequences from a multi-stranded precursor complex. This represents a 25-fold improvement over 
previous microcavity-based methods for DNA detection without PCR-based amplification. 
Detection of methylation patterns in DNA sequences also promises to provide insight into the 
epigenetic regulation of gene transcription, which controls cell and organismal phenotype.105 
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Hawk & Armani106 developed a microtoroid cavity modified with methylation-specific antibodies 
and used it to detect methylated DNA in buffer without the need for PCR amplification or 
fluorescent tagging. 
The aforementioned reports of nucleic acid detection serve as valuable proof-of-concept 
demonstrations; however, further validation in the context of real biological systems has also been 
pursued using microcavity resonators. In a follow up to their earlier study, Shin et al107 developed 
a novel signal amplification method to detect mutant genes from non-small cell lung cancer cells. 
They used isothermal solid-phase amplification/detection and a double mismatched primer (DMP) 
set to improve specificity. The assay took only 20 min to complete and successfully recognized 
mutant epidermal growth factor receptor genes in a mixture of 1% mutant and 99% wild-type cells. 
For the detection of longer sequences, secondary structures can introduce steric interference with 
capture agent binding. Consequently, most assay designs for nucleic acid detection have focused 
on shorter (<150 bp) sequences. Kindt et al108 used short sequences of DNA as chaperones to 
enable the detection of whole mRNA transcripts in isolated total RNA from HL-60 cells. The 
chaperones bound to flanking regions surrounding the target binding sequence of the mRNA 
transcript. By binding to these flanking regions, the chaperones disrupted the secondary structure 
of the mRNA, enabling the mRNA to bind to the capture region on the sensor surface. A bead-
based signal enhancement was then used to enable an LOD of 512 amol. Figure 1.4 provides an 
overview of the nucleic acid detection and amplification methods discussed above. 
As an alternative to signal or analyte amplification methods for nucleic acid detection, 
decreasing the noise floor allows for detection of oligonucleotides reaching the single molecule 
limit. Unlike methods of detection of other biomolecules, such as proteins and metabolites, 
commonly implemented nucleic acid isolation methods result in samples with off-target binding 
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similar to that seen in buffer conditions.109,110 These samples are processed such that biological 
noise may no longer be the dominant contributor to the uncertainty of the measurement. Baaske et 
al111 fabricated a WGM sensor capable of monitoring single-molecule interactions of nucleic acids 
as small as eight nucleotides. The sensor is a glass microsphere with a gold nanoparticle attached 
to the sensor surface. The nanoparticle greatly enhances the optical field strength, enabling the 
discrimination of single-molecule binding events (Figure 1.5). To ensure that specific binding 
events occurred only on the nanoparticle surface, only the nanoparticle was functionalized with 
thiol-modified capture oligonucleotides. The ability to monitor single molecule binding events 
obviates the need for signal or target amplification methods, while also opening up possibilities 
for stochastic sensing.112 Although the detection of an 8-mer DNA strand is an impressive 
analytical feat, practical implementation of such a sensor would likely utilize longer sequences 
that encode greater biological significance. 
Proteins are also routinely targeted for biosensor development. Common capture agents 
utilized in microcavity-based protein detection include antibodies60,77,113 and aptamers114,115. The 
limiting step in the development of protein detection assays for new protein targets is often 
validation of high-affinity and target-specific capture probes. The lack of formulaic antibody 
generation methods (i.e. not simply sequence complementarity as in nucleic acid detection) is a 
significant barrier faced by all antibody-based detection schemes, as is antibody cross-reactivity, 
which limits the potential for multiplexing. Antibodies also impose greater limits on working 
conditions (e.g., pH range, buffer composition) and have a tendency to denature and degrade more 
quickly than nucleic acids. Aptamers are an alternative that may avoid many of the drawbacks of 
antibodies, but generation of high affinity aptamers for a wide range of protein targets has proven 
challenging. Alternative capture agents such as phage proteins116 and genetically modified virus-
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like particles117 have been used for biomolecule detection, which could offer improvements in 
stability and even self-assembly. As an alternative to standard immunoglobulin antibodies, single-
domain antibodies have enhanced stability and resistance to denaturation, and Shia & Bailey113 
previously incorporated these capture agents into a microcavity-based detection platform. 
Many recent developments in protein detection using microcavity resonators have focused 
on performing multiplexed measurements while improving signal enhancement methods to 
measure ultra-low analyte concentrations and to perform measurements in complex matrices (e.g., 
serum). De Vos et al77 demonstrated multiplexed detection of antibodies using microring 
resonators that captured parallel readout of all sensors using an infrared camera reporting a mass 
sensitivity of 3.4 pg/mm2. Dunn and coworkers66,68 applied WGM imaging to the detection of 
established biomarkers, including tumor necrosis factor α, cancer antigen 125, and osteopontin. 
Using BaTiO3 microspheres of varying sizes, they obtained multiplexed measurements from serum 
samples of these cancer biomarkers with an LOD less than 100 pg/mL, an improvement upon 
enzyme-linked immunosorbent assays (ELISA). In an impressive display of sensor LODs, 
Dantham et al118 demonstrated the label-free detection of a single protein molecules, including 
thyroglobulin and BSA, corresponding to masses of 1 ag and 0.11 ag, respectively. To gain the 
exquisite sensitivity necessary to observe single-molecule binding events, a gold nanoshell was 
used to enhance the optical signal in a similar manner to that discussed earlier in this section for 
single nucleic acid detection.111 
 A major challenge in developing protein detection platforms is addressing biological noise. 
In contrast to nucleic acid analysis, which often involves sample isolation or sequence-specific 
amplification, relevant protein detection applications often involve sensing within complex 
matrices. These matrices, such as serum, contain many off-target protein species that are present 
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at substantially higher concentrations than the target of interest. There have been efforts to 
minimize off-target binding onto the sensor surface,119,120 but these approaches have yet to be 
extended to multiplex sensor operation in clinically relevant samples, such as serum, plasma, and 
other bodily fluids or tissue homogenates. 
Various signal enhancement strategies have been developed to reveal analyte specific 
sensor responses within complex media. Luchansky et al121 used sandwich antibody pairs to 
enhance the signal from proteins in cellular secretions with LODs near 100 pM with an analysis 
time of only 5 min. Bead-based amplification methods can further extend LODs below 100 pg/mL 
and can be incorporated within an assay scheme giving a total dynamic range of over six orders of 
magnitude.122,123 Another method of signal enhancement is the use of enzymatic labels. By 
attaching an enzyme to tracer antibodies in a sandwich immunoassay, the signal from binding 
events on the sensor surface can be amplified by rapid turnover of an enzymatic substrate. This 
method results in assays with sub-pg/mL LODs.124 This enzymatic amplification method has 
subsequently enabled multiplex phosphoprotein measurements with  LODs of 0.6 pM in buffer 
conditions (Figure 1.6).125 The 12-plex phosphoprotein measurements were performed on cell 
lysate and tumor tissue homogenate of primary glioma samples. 
 Aside from nucleic acids and proteins, optical resonator sensors have been applied to the 
detection of other classes of biomolecules. An example of this work is phospholipid modification 
of microgoblet arrays to investigate lipid binding or other lipid-biomolecule interactions.80,126 
Lipid bilayer assembly dynamics were observed by monitoring bilayer formation in real time.127 
This experimental scheme was also used to observe detergent solubilization of lipid bilayers. 
Microspheres bonded to glass using a modified calcium-assisted glass bonding method have been 
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used to study lipid membrane dynamics with embedded gangliosides.65 For this study, lipid 
bilayers were transferred onto the sensor substrate using a Langmuir-Blodgett trough. 
 In addition to these in vitro methods for biomolecule detection, free-floating microsphere 
resonators offer exciting possibilities for in vivo biomolecular imaging. Polystyrene-
divinylbenzene microspheres can be reproducibly fabricated with radii ranging between 5 and 10 
μm and are readily incorporated into eukaryotic cells via endocytosis.85 These particles maintain 
high Q-factors of up to 108;  Q-factors of 104 are maintained even when engulfed by a single cell 
(Figure 1.7). By doping the polymer microspheres with dye, intracellular lasing can be achieved 
from pumping with 1 nJ pulse energy. The lasing wavelength and pump energy threshold are 
dependent on microsphere size, refractive index contrast, and dye dopant, and variants in lasing 
wavelength can be used for specific tagging of individual cells. The narrow spectral linewidth of 
both the WGM resonance and lasing line provide unambiguous cell barcoding at plexities of 
hundreds to thousands of unique probes, which is a major improvement over competing labelling 
methods such as fluorescent dyes and proteins, quantum dots, or plasmonic nanoparticles. Dye-
doped microspheres composed of soft materials, such as injected oils or endogenous lipids, can 
also be used for intracellular lasing.81 Polyphenyl ether (PPE) mixed with Nile red and injected 
into cells forms small droplets ranging from 4 to 20 μm in diameter, and lasing occurs upon pulsed 
excitation with droplets larger than 7 μm. Doped PPE droplets can be used for monitoring the 
dynamics of cytoplasmic internal stress with sensitivities of 20 pN/μm2. In addition to injected 
PPE lipids, endogenous lipids present in adipocytes as spherical droplets can support lasing, 
though at higher excitation energies (Figure 1.7). Injection of collagenase with a lipophilic dye 
into the subcutaneous fat layer of porcine tissue releases adipocytes from the tissue matrix, 
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allowing these adipocytes to form more spherical shapes. Using an optical fiber inserted through 
a needle puncture to excite the released adipocytes enables lasing within tissues (Figure 1.7). 
Micro-Gas Chromatography. Due to the high refractive index contrast between sensor 
and sensing medium, simple sample composition, and improved mass transfer in the gaseous 
phase, gas sensing is an attractive application for optical resonator sensors, particularly in the realm 
of gas chromatography. Using a capillary-based optical ring resonator, Shopova et al128 developed 
the first optical sensor that functioned as a micro gas chromatography. The microcavity localizes 
light onto the interior surface of the capillary allowing gas molecules to simply be flowed, as in a 
standard gas chromatography detection experiment. Scholten et al76 developed an improved 
detector from the capillary-based system for microscale gas chromatography by using an 
optofluidic ring resonator with an optical fiber taper. The system had integrated fluidic 
connections, and signal response was cause by swelling of a 300 nm polydimethysiloxane layer 
lining the sensor cavity. The LOD for steady-state sensing was 0.5 ppm for m-xylene and 
ethylbenzene and <10 ppm for all analytes tested. In a follow-up study,78 the authors further 
developed the microscale gas chromatography system by using a multilayer film composed of 
polyether doped with gold nanoparticles cast onto the inner wall of the resonator structure to 
improve the system response. Baseline separation of five volatile organic compounds was achieved 
in less than 2 min with an LOD of <100 ng. In addition to capillary-and ring-based gas detection 
systems, porous glass microspheres are also promising for gas detection applications.43 
Other Sensing Applications. Though the major focus of WGM sensor development in 
liquid-phase sensing has been the detection of biomolecules, the sensors are generally applicable 
to any type of analyte that can be localized to the sensor surface. Panich et al129 designed a novel 
sensor for Pb(II) detection in aqueous samples. Glass microsphere resonators were coated with 
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aminopropyl trimethoxysilane and subsequently functionalized with glutathione-coated gold 
nanoparticles. Exposure to Pb(II) resulted in a shift in the resonance peak. The sensor was able to 
quantitate Pb(II) concentrations ranging from 2 to 50 nM and operated in the presence of 
potentially interfering alkaline and heavy metal species. Additionally, microcavity sensors as bulk 
refractive index detectors for the detection of liquid chromatographic separations. Unlike 
differential refractometers, microring resonators arrays are compatible with both isocratic and 
gradient separations methods. Proof-of-concept experiments have been performed on small 
molecule therapeutics (e.g., ibuprofen).130 Optical resonators have also been integrated with other 
analytical tools, such as scanning probe microscopy. Using a 45 μm BaTiO3 microsphere attached 
to an AFM cantilever, Wildgen & Dunn131 performed scanning resonator microscopy (SRM). 
Measurements from this hybrid sensor provide topographical mapping as well as a WGM spectrum 
that is sensitive to changes in refractive index occurring both in the solution and on the substrate 
surface. This method resolved a 36-nm-high feature on a glass substrate, and image contrast was 
derived from refractive index measurements that did not couple with sample tomography. Other 
proof-of-concept experiments were performed on polymer films and protein-coated surfaces. 
Though not utilized in this study, future applications of SRM could functionalize the surface of 
the BaTiO3 microsphere with capture agents specific for an analyte of interest on a given substrate, 
enhancing the utility of the technique. 
1.5 Alternative Sensing Mechanisms 
 A new class of active resonator devices using optical gain strategies to achieve detection 
have emerged as an alternative to passive microcavities.132 Much like nanoparticle-induced mode 
splitting for passive resonators, the splitting of laser emission from active resonators can be used 
to monitor binding events at the sensor surface. The pattern of splitting can be detected as a 
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heterodyne beat note, with the beat frequency corresponding to the level of frequency splitting for 
the lasing modes. Active resonators with low lasing thresholds can be fabricated by doping an SiO2 
microcavity with erbium (Er:SiO2).133 An Er3+ ion dopant concentration of 5 x 108 ions/cm3 
produces continuous-wave laser operation, enabling impressive measurements such as: 30-nm 
polystyrene and 20-nm gold nanoparticles in air and a single influenza A virus in water. 
Unfortunately, doping active resonators with rare-earth ions introduces substantial challenges for 
generating scalable, robust devices due to the increased cost of materials and incompatibility with 
standard CMOS fabrication. Özdemir et al134 avoided the use of Er3+ doping by using Raman gain 
within a silica microtoroid to create on-chip microlasers. Raman gain is derived from stimulated 
Raman scattering that occurs with high-power pumping, though the necessary input power can be 
dramatically reduced when coupled with optical microcavities.135 Raman microlasers do not 
require any dopant for low-threshold lasing, which translates into significantly reduced fabrication 
cost. Using this experimental scheme, nanoparticles as small as 10 nm were detected. Though all 
experiments were performed in a dry environment, Raman lasers can also function in liquid 
environments, making their use an intriguing strategy for future sensor development efforts.136  
 On-chip lasing and back-scattered light detection can provide substantial reductions in 
baseline noise, significantly improving LOD in comparison with passive optical resonators with 
wavelength-shift or conventional mode-based sensing mechanisms; however, measurement 
timescales for these devices have been limited to milliseconds or longer. Cavity ring-up 
spectroscopy (CRUS) can be used with optical resonator sensors to achieve ultrafast sensing, 
reducing the timescale of measurements to as little as 16 ns.137 CRUS functions through the abrupt 
turn-on of far-detuned probe pulses. The probe pulses are coupled into the optical microcavity with 
a tapered optical fiber, and because the pulse are detuned away from resonance wavelengths, 
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almost all of the light continues propagating down the optical fiber. The short rise time of the pulse 
results in large spectral broadening, which overlaps with the resonance conditions and introduces 
a small field strength in the optical cavity. The electromagnetic field within the resonator 
constructively interferes with the propagating light, creating a ring-up signal. Potential applications 
of measurements on such precise levels include biological processes such as protein folding or 
enzyme kinetics.138 
1.6 Hybrid Sensors 
 The first single binding events observed with optical resonators were those of 
nanoparticles, using polystyrene beads or viruses as model analytes.33,86,91,92,133,139,140 Novel device 
designs have recently emerged that push the LODs to the level of single protein and single nucleic 
acid binding events by incorporating plasmonic materials into existing WGM sensor designs, 
which can induce large increases in electric field strength through coupling with localized surface 
plasmons. This effectively enhances light-matter interactions within the evanescent sensing 
region.141,142 The most obvious method of combining WGM and plasmonic sensing is to coat a 
WGM with a thin layer of noble metals (e.g., Au, Ag); however, large optical losses due to photon 
scattering substantially reduce the Q-factor for these devices.143 Single plasmonic nanoparticles 
bound to the surface of a microcavity sensor allow for signal enhancement by up to 1,000-fold 
while maintaining high Q-factors. These devices have been used for the detection of single 
nanoparticles, viruses, proteins, and nucleic acids.111,118,142,144 Baaske et al111 were able to 
demonstrate discrimination of single base pair mismatches using such approach, as described 
above and highlighted in Figure 1.5. A theoretical investigation into WGM-plasmonic hybrid 
sensors showed that the nanoparticle would exhibit ideal signal enhancement if placed at periodic 
locations around the equator of a microsphere resonator.144 While this configuration has yet to be 
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experimentally realized, it provides further motivation for the development of this class of hybrid 
sensing devices. 
 Optomechanical devices, another type of hybrid sensor, consist of an optical resonator 
placed on a structure that allows for mechanical oscillations via radiation pressure.145 These 
devices are driven by Brownian fluctuations, which physically displace the resonator, resulting in 
a change in both the path length and resonant frequency of the microcavity. The sensitivities of 
these devices are exquisite, approaching the shot noise limit, but device operation in liquid media 
is challenging due to viscous dampening.145 One approach that avoids viscous dampening is to use 
hollow-core resonator geometries, allowing the solution to flow through the center of the 
structure.146,147 Fong et al148 used a suspended microwheel structure embedded in a microfluidic 
system that allows for stable sensor operation in an aqueous environment. The device is fabricated 
from 200-nm-thick Si3N4, with microfluidic channels formed by etching the SiO2 cladding layer 
(Figure 1.8). Light is coupled into the optomechanical resonator via etched gratings and fabricated 
waveguides. The device impressively allows for observations of thermal Brownian motion, 
making it a promising option for aqueous detection applications. Another demonstration of stable 
optomechanical operation in liquid environments used GaAs disk resonators placed atop an 
AlGaAs pedestal (Figure 1.8).149 Light coupling was achieved with tapered waveguide structures, 
and as many as 100 sensors were fabricated on a single 1 mm × 3 mm chip. The devices were 
stably operated while immersed in water as well as in three perfluorinated liquids with dynamic 
viscosities measuring 3.5, 9, and 30 mPa s, again allowing observations of thermal Brownian 
motion. 
 Though their method is not necessarily a hybrid sensor geometry, the Goldsmith group has 
uniquely utilized microtoroidal resonators in concert with an orthogonal pump bead to perform 
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single-particle absorption measurements.150 Silica microtoroids were coated with multi-walled 
carbon nanotubes. Resonances of the toroid (~1,560 nm) were determined via a tapered fiber 
waveguide while an orthogonal optical pump probe beam at 640 nm was focused and rastered 
across the surface of the microtoroid. When the probe beam was swept over the nanotube, the 
absorption and heat dissipation caused shifts in the toroid resonance due to the thermooptic 
modulation of the refractive index. This photothermal microscopy technique holds promise for the 
analysis of non-luminescent single particles and molecules. Separately, Heylman & Goldsmith 
demonstrated that in the absence of a chromophore the probe laser itself could be used to heat the 
silicon pillar, which in turn could be used to tune the resonance wavelength in a controllable 
fashion.151 However, pillar heating is potentially problematic for single molecule absorption 
measurements. Accordingly, Knapper & Goldsmith recently developed a wafer-scale approach to 
creating silica-pillared, as opposed to silicon-pillared, toroidal resonator; because silica does not 
absorb light in the visible range, it is insensitive to the pump beam.152 Though this approach still 
requires the individual coupling of light into each resonator via a tapered waveguide, the robust 
process of thermal reflowing, as opposed to laser-based reflowing, seems promising for the 
fabrication of high Q-factor microtoroids. 
1.7 Conclusion 
Throughout this review, we have highlighted many examples of optical microcavity 
sensors applied to a variety of challenging analytical problems. Sensor development has reached 
the point where fabrication of ultrahigh Q-factor devices capable of detecting biomolecules at 
nanomolar concentrations or below has become routine. Given the breadth of cavity designs and 
measurement approaches reported to date, it is our belief that the future of microcavity optical 
sensors lies in the application and deployment of these devices to real-world analytical challenges. 
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Fundamental developments certainly remain to be achieved, but the field is sufficiently mature 
that these devices should now be expected to emerge as robust tools that can be applied to 
important chemical and/or biomolecular analysis problems. Given that many of the cavity designs 
described are realized through microfabrication, one key area for expansion is the creation of 
multiplexed sensing arrays, which have broad applications ranging from clinical diagnostics to 
environmental monitoring. The future of microcavity-based devices is bright and their integration 
within robust analytical instrumentation will facilitate their transition from the optical table and to 
real-world-deployable systems that will be powerful tools in the ever-evolving analytical arsenal.  
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1.8 Figures 
 
Figure 1.1. Overview of sensor operation. (a) The transmission spectrum from a tunable laser 
interfaced with a whispering gallery mode resonator results in a characteristic dip in transmittance 
under resonance conditions. Changes to the local refractive index at the sensor surface cause a shift 
in the resonance wavelength (solid red and solid blue lines). In addition to wavelength shifts, 
changes in the quality (Q) factor can occur, with a lower Q factor resulting in a broadening of 
spectral linewidth (δλ, dashed blue lines). (b) Plotting relative wavelength shifts versus time 
produces a characteristic Langmuir binding curve. (c) Optical resonators can be used as sensors in 
protein detection. The schematic shows a protein (white) binding to antibodies (blue) bound to a 
sensor surface. 
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Figure 1.2. Microcavity resonator sensor geometries. Many circular geometries have been used 
for fabrication of whispering gallery mode sensors. Some of the more common designs include (a) 
microtoroids; (b) microrings; (c) microdisks; (d) microgoblets; (e) microspheres, sometimes (f) 
fabricated with attached optical fibers; (g) microcapillaries; and (h) microbubbles. 
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Figure 1.3. Sensing mechanisms for optical microcavity resonators. (a) Fiber optic taper 
coupling requires the precise alignment of an optical fiber with a microcavity sensor. Output can 
be monitored with a photodetector, measuring current over time. Though the alignment can be 
arduous, this method allows for highly efficient coupling (e.g., 106, 119). (b) Grating couplers 
allow for on-chip coupling without the demands of precise fiber alignment, though at the cost of 
lower coupling efficiencies. Output is very similar to fiber optic coupling (e.g., 58). (c) Prism 
coupling can be used for cases in which sensors (e.g., microspheres) are attached directly to a 
surface. The presented example shows fluorescent microspheres that can be used for whispering 
gallery mode imaging (e.g., 65, 68). 
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Figure 1.4. Amplification of nucleic acids for detection in complex media. (a) A schematic of 
the DMP method can be used for detection of mutant sequences with a background of wild-type 
DNA strands. Amplification occurs with the greatest efficiency when the mismatched mutant 
forward primer binds to the matched mutant target (107). (b) Amplification is performed on DMP-
modified sensor chips with the addition of recombinase ( yellow) and polymerase ( green); 
detection was achieved in spiked urine samples. (c) An assay schematic shows the sequential steps 
necessary for mRNA detection: (i ) hybridization of chaperone DNA molecules with target mRNA, 
(ii ) binding of biotinylated linker strands and blocking of the sensor surface, and (iii ) introduction 
of streptavidin-coated beads to bind to biotinylated linker strands. The representative spectrum 
(bottom) shows real-time monitoring of binding events with a sharp increase in sensor response 
upon the introduction of beads. The mRNA transcripts detected using this method were derived 
from RNA extracts from HL-60 cells (108). Abbreviations: DMP, double mismatched primer; 
ISAD, isothermal solid-phase amplification/detection; M, mutation. 
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Figure 1.5. Ultrasensitive detection of nucleic acids. (a) The assay schematic shows the 
incorporation of light into the microsphere cavity via prism coupling and a single nanorod attached 
to the sensor surface. A PDMS microchamber was used as a flow cell for analyte introduction. (b) 
Image of a microsphere fabricated by melting the tip of an optical fiber. (c) An example 
transmission spectrum for the microsphere (without a nanorod attached) showing both TE and TM 
propagating modes. (d) The adsorption of cetyltrimethylammonium bromide–stabilized nanorods 
occurs at a pH of 1.6. The top graph shows the relative shift for the TM mode, and the bottom 
graph shows the change is a measurement of band broadening (δλ). The top inset shows an optical 
micrograph of an excited microsphere with a single nanorod (identified with the arrow) adsorbed 
to the microsphere surface; the nanorod dimensions are shown in the bottom inset. Abbreviations: 
FWHM, full width at half maximum; PBS, phosphate-buffered saline; PD, photodetector; PDMS, 
polydimethylsiloxane; TE, transverse electric; TM, transverse magnetic. Figure adapted with 
permission from Reference 111. 
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Figure 1.6. Multiplex phosphoprotein detection in cell lysate and tumor tissue homogenate. 
(a) Samples from primary surgical glioma isolates or tissue culture were homogenized and lysed. 
(b) Cell lysate was flowed across a microring resonator array modified with antibodies specific for 
phosphoprotein targets. (c) Sample output from a single chip is shown; signal enhancement was 
achieved using a sandwich immunoassay with enzymatic amplification. (d) Phosphoprotein 
expression profiling with the microring resonator platform was used to analyze primary surgical 
glioma specimens. Sorting with unsupervised hierarchical clustering separated two samples 
containing >50% necrotic tissues, as determined from pathology reports. Figure adapted with 
permission from Reference 126. 
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Figure 1.7. Intracellular lasing with polymer microspheres and oil droplets. (a) A schematic 
of the intracellular laser in which optical pumping and detection have been achieved through a 
common optical path from beneath the cell culture dish. (b) Time-lapse microscopy of polymer 
microspheres added to macrophage culture shows internalization of the microspheres. The solid 
arrow indicates a macrophage and the dashed arrow highlights the microspheres. (c) Confocal 
microscopy of stained macrophages and microsphere resonators demonstrates that the 
microspheres are internalized in multiple lines (85). (d ) Soft materials such as oil droplets can be 
used for intracellular lasing. From left to right, lasing with injected oil droplets is shown with a  
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Figure 1.7. (cont.) 
schematic of oil injection, a confocal fluorescence image of a cell with an injected oil droplet (the 
nucleus is shown in blue and the oil droplet in red ), bright field and laser output images from an 
oil droplet with optical pumping [arrows ( yellow) indicating the location of the oil droplet with 
the cell], and a plot of optical output as a function of pump energy. (e) Intracellular lasing can be 
similarly achieved with endogenous lipids, as is shown by, from left to right, an illustration of a 
subcutaneous adipocyte, an optical micrograph of adipocytes from porcine fat, a two-photon 
confocal image of subcutaneous fat tissue after injection of a dye ( yellow), and an image of 
intracellular lasing within porcine tissue (81). Scale bars are 20 µm in panels b and c, 10 µm in 
panel d, and 200 µm (middle left) and 20 µm (middle right) in panel e. Abbreviation: WGM, 
whispering gallery mode. 
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Figure 1.8. Hybrid optomechanical sensors. (a) A scanning electron micrograph (SEM) of an 
optomechanical microwheel resonator with an adjacent coupling waveguide shows the top view 
of the device. (b) An optical image demonstrates an array of microwheel resonators embedded in 
microfluidic channels (blue) (148). (c) An angled-view SEM shows the device structure positioned 
within the microfluidic channel (blue). (d) An optical image shows four disk resonators with 
adjacent tapered waveguides. (e) An angled view SEM depicts GaAs disk resonators (red) atop an 
AlGaAs pedestal. The tapered optical waveguide (red) is behind the GaAs disk (also red). (f) A 
schematic depicts the immersion of the resonators in a liquid droplet. (g) Thermomechanical 
spectra acquired from optomechanical measurements demonstrate resonator motion before (blue) 
and after (red) immersion in liquid (149).   
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2.1 Abstract 
Refractive index-based sensors offer attractive characteristics as non-destructive and 
universal detectors for liquid chromatographic separations, but a small dynamic range and 
sensitivity to minor thermal perturbations limit the utility of commercial RI detectors for many 
potential applications, especially those requiring the use of gradient elutions. As such, RI detectors 
find use almost exclusively in sample abundant, isocratic separations when interfaced with HPLC. 
Silicon photonic microring resonators are refractive index-sensitive optical devices that feature 
good sensitivity and tremendous dynamic range. The large dynamic range of microring resonators 
allows the sensors to function across a wide spectrum of refractive indices, such as that 
encountered when moving from an aqueous to organic mobile phase during a gradient elution – a 
key analytical advantage not supported in commercial RI detectors. Microrings are easily 
configured into sensor arrays, and chip-integrated control microrings enable real-time corrections 
of thermal drift. Thermal controls allow for analyses at any temperature and in the absence of 
rigorous temperature control, obviating extended detector equilibration wait times. Herein, proof 
of concept isocratic and gradient elution separations were performed using well characterized 
model analytes (e.g., caffeine, ibuprofen) in both neat buffer and more complex sample matrices. 
These experiments demonstrate the ability of microring arrays to perform isocratic and gradient 
elutions under ambient conditions, avoiding two major limitations of commercial RI-based 
detectors and maintaining comparable bulk RI sensitivity. Further benefit may be realized in the 
future through selective surface functionalization to impart degrees of post-column (bio)molecular 
specificity at the detection phase of a separation. The chip-based and microscale nature of 
microring resonators also makes it an attractive potential detection technology that could be 
integrated within lab-on-a-chip and microfluidic separation devices.  
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2.2 Introduction 
Refractive index (RI) detectors in high performance liquid chromatography (HPLC) are 
used to analyze samples that lack strong chromophores in ultraviolet (UV) or visible regions and 
are non-fluorescent. The most notable advantages of RI detection are that the technique is non-
destructive enabling downstream analysis, and RI is a concentration dependent bulk property 
allowing for universal detection (i.e., all compounds with polarizable electrons are detectable).1, 2 
The differential refractometer3, 4 was one of the earliest implementations of RI detection in LC, 
and the design has remained popular over the past half century. This device consists of a sample 
and a reference flow cell with the temperature of each cell tightly maintained with a thermostat, 
commonly ≥30°C so as to circumvent background noise from ambient thermal fluctuations. 
Comparing changes in bulk RI of sample versus reference cells with identical mobile phase (MP) 
and temperature allows for sensitivities as low as 10-7 refractive index units (RIU) and detection 
limits of approximately 0.1% sample concentration (e.g., 5 mM for caffeine).2 However, the 
reference cell is also the source of major limitations of RI detection for LC separations, namely 
the inability to perform gradient separations due to insufficient dynamic range and extended 
waiting periods to allow for thermal equilibration of the flow cells. Consequently, these limitations 
have largely restricted the use of the differential refractometer, and RI-based detection in general, 
to specialty applications, such as lipid,5 sugar,6 and protein7 detection for food analysis. 
In the decades following the introduction of RI sensing to the commercial LC detection 
landscape, there have been multiple attempts to improve upon the original design to increase its 
overall applicability. Notable modifications include the elimination of the need to operate at 
elevated temperatures;8 incorporation of a second column and pumping system;9 continuous 
alteration of the laser interrogation angle to adjust for RI changes in MP composition to allow for 
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gradient separations;10 and the use of thermooptic11 and interferometric12-14 methods to increase 
sensitivity.  To date, however, refractometer design modifications have yet to result in significant 
adoption. 
Surface plasmon resonance (SPR), a technology most commonly utilized as a surface 
sensitive biosensor, has previously been interfaced with LC as a detector for oligosaccharide,15 
protein,16, 17 and carbohydrate18-20 analysis. The most notable advantages of SPR over traditional 
RI detectors for LC are the speed at which the detector can achieve a stable baseline (50 minutes 
versus >2 hours for commercial detectors19) and the modification of sensor surface to enhance 
sensitivity. Notably, all implementations of LC-SPR systems have been applied to isocratic 
separations.  
Adapting RI sensing to gradient separations without complicated optics or additional 
pumping systems requires expanding the dynamic range of the sensing modality, removing the 
need for rigorous temperature stabilization, and improving the reproducibility of MP gradients. 
Microcavity photonic devices are high-Q factor optical sensors that allow for label free analyte 
detection.21 While exact size and geometries may vary, these devices provide circular paths around 
which light is repeatedly directed to form a resonant microcavity that support well-defined optical 
modes. The spectral position of the optical modes are extremely responsive to changes in the local 
dielectric environment surrounding the sensor surface. Most analogous to the studies presented 
herein, Fan and coworkers22 previously utilized liquid core optical rings resonators (LCORRs) to 
perform flow speed measurements using electro-osmotic flow and glycerol as a model for use of 
LCORR as a detector for capillary electrophoresis. The LCORR architecture allows for a RI 
detection limit of 10-6 RIU and sensitivity of 20 nm/RIU. More recently, similar devices have been 
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used as a novel detector for microgas chromatography23, 24 and for glucose detection in aqueous 
solutions.25 
Silicon photonic microrings are a chip-integrated version of a microcavity resonator that 
offer advantages in terms of scalability of device fabrication, which allows for sensor arrays to be 
easily constructed. Each individual microring is located next to an adjacent linear waveguide such 
that interference between photons circulating the microring and passing down the linear waveguide 
create a resonant microcavity that supports optical modes only at specific wavelengths, as 
described by Equation 1, 
 𝑚𝑚𝜆𝜆 = 2𝜋𝜋𝜋𝜋𝑛𝑛𝑒𝑒𝑒𝑒𝑒𝑒 [1] 
where 𝑚𝑚 is an integer, 𝜆𝜆 is wavelength, 𝜋𝜋 is the radius of the microring, and 𝑛𝑛𝑒𝑒𝑒𝑒𝑒𝑒 is the effective 
refractive index of the propagating optical mode. Based on Equation 1, the resonant wavelength is 
responsive to changes in the effective refractive index, which is directly affected by changes in the 
bulk solution, as sampled by the evanescent electromagnetic field.26  
Our group has previously applied this technology to the label-free detection of surface-
localized binding interactions mediated through target-specific capture agents that recognize 
particular analytes of interest.27-30. However, microring resonator arrays are also responsive to bulk 
changes in RI. Herein, we demonstrate the application of silicon photonic microring resonator 
arrays as a bulk RI, universal detector for LC separations. Microring resonators are shown to 
monitor large fluctuations in refractive index (e.g., moving from an aqueous to organic solvent) 
and this extremely large dynamic range enables detection across rapid changes in MP. MP 
gradients are reproducible independent of temperature fluctuations, allowing for detection of 
analytes in column eluent from gradient elutions. Moreover, thermal controls are integrated into 
the sensor array, eliminating the need to operate under tightly controlled thermal conditions and 
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obviating extended detector equilibration times. Consequently, microring arrays avoid the major 
pitfalls of RI-based detection while offering bulk RI sensitivity comparable to conventional 
detectors.  
To demonstrate the utility of the sensor in reference to established commercial detectors, 
we performed isocratic separations on well-characterized analytes and gradient elution of analytes 
in pure buffer as well as a more complex matrix of a dissolved liquid gel capsule.  
2.3 Experimental 
Materials. Unless otherwise indicated, all reagents were purchased from Sigma-Aldrich 
(St. Louis, MO) and used as received. Ibuprofen liquid gel capsules (NDC 11673-122-80) were 
purchased from Target Corporation (Minneapolis, MN). Phosphate buffered saline (PBS) was 
reconstituted from Dulbecco’s PBS at 10 mM and the pH adjusted to either 7.4 or 2.3 using 1 M 
HCl. Oxalic acid dehydrate, DL-malic acid, and succinic acid solutions were prepared at various 
concentrations in 10 mM PBS pH 2.3. Ibuprofen and simvastatin solutions were prepared in a 
50:50 mixture of deionized (DI) water and HPLC-grade acetonitrile. A caffeine solution was 
prepared in DI water. 
Instrumentation. Microring Resonators. Sensor array chips and the Maverick M1 optical 
scanning instrumentation were purchased from Genalyte, Inc. (San Diego, CA). Sensor chip 
fabrication and scanning instrumentation operation have been described previously.31 Figure 2.1 
shows a scanning electron microscope (SEM) image of a microring, and provides schematics of 
the sensor geometry as well as an illustration of operation for LC detection. For the experiments 
in this study, 8 active sensor rings were used for monitoring bulk RI response, and 4 rings covered 
by a polymer cladding layer were monitored for use as thermal controls, as they were not exposed 
to flowing solution during detection experiments. 
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Before use, sensor chips were briefly rinsed with acetone and then isopropanol to remove 
a protective photoresist coating, before cleaning with a piranha solution (3:1 H2SO4:30% H2O2) 
for 40 seconds. (Caution! Piranha solutions are extremely dangerous and react explosively with 
organics.) The chips were then sonicated in ethanol for 5 minutes and dried under a stream of 
nitrogen. 
A tunable external cavity diode laser centered on 1550 nm was used to serially probe each 
microring individually, scanning across a 12 nm spectral window. Dips in the transmittance 
through the adjacent linear waveguide at particular laser wavelengths correspond to a resonance. 
Resonance wavelengths for each microring were measured as a function of time and relative shifts 
used to measure small changes in refractive index. The Maverick M1 enables sub-picometer 
resonance wavelength resolution and a noise floor of approximately 0.1 pm, corresponding to a 
bulk RI detection limit of 1.5 × 10-6 and sensitivity based on the determined relationship of 63 
nm/RIU (See Figure 2.2).31 
HPLC. Chromatographic separations were performed using a Dionex Ultimate® 3000 
Binary Analytical System (Thermo Fisher Scientific, Waltham, MA) equipped with a HPG-
3200SD pump, WPS-3000SL analytical autosampler with 100 μL sample loop, TCC-3000SD 
column compartment, MWD-3000 diode array detector, and RefractoMax 521 refractive index 
detector. The RefractoMax is a deflection type RI detector with tungsten filament light source and 
8 µL flow cells (reference and sample cells). MP composition for isocratic separations were 10 
mM PBS pH 2.3, 10 mM PBS pH 7.4, or 90:10 DI water:acetonitrile. Linear MP gradient elutions 
consisted of  90:10 water:acetonitrile to 0:100 or DI water to 1 M NaCl. Columns utilized included 
an Acclaim 120 C18 column (3 μm particle size, pore size of 120 Å, and dimensions of 4.6 mm x 
150 mm), and a Hypersil GOLD® aQ polar endcapped C18 column (1.9 μm particle size, pore 
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size of 175 Å, and dimensions of 4.6 mm x 150 mm). The flow rate when operated in standalone 
mode was 0.600 mL/min and 0.100 mL/min for the LC-microring resonator interface, unless 
otherwise noted. The column oven was set to 40°C and 25°C for the Acclaim C18 and Hypersil 
Gold columns, respectively. The RefractoMax detector was maintained at 30°C. 
HPLC-Microring Resonator Interface. Sensor chips were sandwiched between a cartridge 
holder, 0.007” biaxially-oriented polyethylene terephthalate (Mylar®) gasket, and a 
polytetrafluoroethylene (Teflon®) cartridge top for fluid delivery. The outlet from the HPLC was 
connected to a 0.25 mm flangeless 1/4-28 to ZDV 10-32 PEEK low pressure union to convert from 
HPLC to microring resonator fluidic fittings and a 1/4-28 nut was screwed directly into the Teflon 
cartridge top. This fluidic interface was limited to flow rates between 0.010 and 0.100 mL/min. A 
more complete description and image of the fluidic interface is provided in Figure 2.3. 
Data Analysis. All data analysis was performed using Origin Pro 9.0. Active sensor signal 
responses were adjusted for temperature fluctuations by subtracting responses from 2 or more 
thermal control rings. Thermally controlled data was subsequently averaged, and the average 
responses presented represent between 4 and 8 thermally-corrected sensor rings. While data 
processing and analysis was performed after data acquisition, the data processing could be 
automated and performed either during or immediately following data acquisition. The current 
version of the Maverick data acquisition software enables real time control subtraction and 
averaging of active sensor responses. 
2.4 Results and Discussion 
Isocratic Separations. The interface between the HPLC and microring resonator platform 
is depicted in Figure 2.4. Initially, isocratic elutions were used to establish the utility of the 
microring resonator platform for LC detection. A caffeine solution in water is a common standard 
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for verification of system integrity and is often employed as an internal standard.2, 32 Figure 2.5a 
shows a chromatogram corresponding to the microring resonator-based detection of a 10 mg/mL 
(51.5 mM) caffeine solution at various injection volumes using the Acclaim 120 C18 column and 
a MP of 90:10 DI water:acetonitrile. Peaks corresponding to the injection volume and caffeine 
were baseline resolved at the smallest injection volume of 0.1 μL (corresponding to 1.0 µg of 
caffeine injected onto the column), and the peak area is linearly related to the mass of caffeine 
injected onto the column (See Figure 2.5b). 
As a second demonstration, an equal mass solution of malic acid, oxalic acid, and succinic 
acid was isocratically separated in 10 mM PBS pH 2.3 on a Hypersil GOLD aQ polar capped C18 
column. Peaks for each analyte and the injection were baseline resolved, and Figure 2.5c shows 
sample injections ranging from 5 to 20 μL (between 8.3 and 33.2 μg of each analyte injected onto 
column). Peak area correlates strongly with mass injected onto the column for each analyte, as 
shown in Figure 2.5d. In comparison to RI data from a commercial detector (Figure 2.6), the 
noise levels are slightly higher for the microring resonator platform, most likely due to 
irregularities in MP flow due to imperfect coupling between the HPLC and scanning 
instrumentation, but the sensitivities are comparable. Importantly, improvements in microfluidic 
sample delivery over this initial crude interface should greatly reduce baseline fluctuations. 
Gradient Demonstration and Analysis. Early in the development of HPLC, gradient MPs 
were introduced to increase elution time and sharpen later-eluting peaks.33 Gradient methods 
improve the efficiency of overall method development and minimize the need for complicated 
sample preparation due to interfering species. In addition, large molecules such as proteins and 
oligonucleotides are difficult to resolve with isocratic methods due to the large changes in retention 
times that result from minor changes in MP composition.2 Gradient elution methods have been 
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widely adopted in the LC community and are routinely used when coupled to optical detection 
methods such as UV/visible absorption and fluorescence detection. However, RI-based detectors 
have typically not been amenable to gradient elutions as the overall RI shift surpasses the dynamic 
range offered by commercial detectors. For example, the reported linear dynamic range of the 
RefractoMax detector is 600 μRIU whereas the difference in refractive index (ΔRIU) encountered 
when transitioning from water to methanol at 25°C is 3200 μRIUs at a wavelength of 550 nm. 
Given the importance of the refractive index dynamic range for gradient elution 
separations, we sought to probe the capabilities of the microring sensor array using a variety of 
gradients. Figure 2.7a demonstrates the reproducibility of a linear gradient encountered when 
repeatedly cycling between DI water and an aqueous 1 M NaCl solution. Importantly, the stability 
of the gradient profile in the absence of analyte injection, which is corrected for thermal drift, is 
sufficiently reproducible so that it can simply be subtracted from the response observed during an 
actual separation with the same MP gradient profile. A gradient baseline subtraction cannot be 
performed using commercial instrumentation principally due to the limited dynamic range of the 
detector. Moreover, the low noise floor of commercial detectors depend upon real time subtraction 
of reference flow cell containing an identical mobile phase composition as the sample cell. 
Maintaining identical composition for both flow cells for gradient elutions is currently not possible 
since detectors do not allow for simultaneous flow through each of the cells. Figure 2.8 shows the 
output of a gradient on the RefractoMax detector. Three other tests of gradient elution 
compatibility, which are shown in Figure 2.7b, include transitions from 90:10 water:acetonitrile 
to acetonitrile, DI water to 1 M NaCl, and DI water to dimethylsulfoxide (DMSO). The DMSO 
transition shows an enormous resonance shift of over 7 nm, which corresponds to a 100,000 µRIU 
change in bulk RI. This measured RI change is more than 3 orders of magnitude greater than that 
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offered by commercial detectors and is more than large enough to accommodate any standard 
gradient elution. 
Separation of Simvastatin and Ibuprofen. While the reproducibility and wide dynamic 
range of microring resonators in response to large shifts in RI in the form of gradients were 
demonstrated, it remained to be seen whether small changes in RI associated with the elution of 
analytes could be resolved from a simultaneous signal increase in response to changes in MP 
composition. As with the demonstration of isocratic methods, well characterized, model analytes, 
namely ibuprofen and simvastatin, were used to demonstrate detection of analytes in gradient 
elutions. The gradient employed was intentionally simplistic to ensure all changes in sensor 
response were due to injection, MP changes, or sample elution. The gradient from 90:10 
water:acetonitrile to acetonitrile over 30 minutes showed clearly resolved peaks for the two model 
analytes. A large injection volume of 100 µL was used to demonstrate the upper limit of analyte 
signal. The samples were dissolved in a 50:50 water:acetonitrile solution before injection. Figure 
2.9 shows the separation both before and after subtraction of a reference gradient.  
Analysis of Ibuprofen Liquid Gel. The use of RI based detection is primarily 
advantageous due to its ability to act as a universal detector responding to essentially all analytes 
of sufficient concentration. As such, one application of RI detection is in the chromatographic 
separation of complex sample matrices. In order to demonstrate the application of microring 
resonator arrays for the analysis of a more complex sample, we used an ibuprofen liquid gel 
capsule dissolved in a 50:50 water:acetonitrile solution. While less complex than commonly 
studied matrices, such as serum, cell lysate, or waste water, the ibuprofen capsule served as a 
proof-of-concept demonstration of the detection platform. In addition to ibuprofen, the liquid gel 
capsule also contained (per the manufacturer) FD&C green no. 3 (an organic dye), gelatin, mineral 
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oil, pharmaceutical ink (composed of alcohols, shellac, titanium dioxide, and propylene glycol),34 
polyethylene glycol, potassium hydroxide, water, sorbitan, and sorbitol.14 Figure 2.10a shows the 
separation of capsule components dissolved in a 50:50 water:acetonitrile solution using a MP 
gradient from 90:10 water:acetonitrile to acetonitrile over 30 minutes. By comparison with a 10 
mg/mL (48.5 mM) ibuprofen solution, the matrix components give a broad response surrounding 
the injection peak. However, the ibuprofen peaks are comparable between the 10 mg/mL stock 
and the dissolved capsule. Figure 2.10b is the same separation with an identical gradient (no 
injection) subtracted. For reference, data acquired using a commercial UV/Vis detector for an 
identical separation is provided in Figure 2.11. 
2.5 Conclusion 
In stark contrast to commercial RI detectors, the vast dynamic range and integrated thermal 
correction capabilities of microring resonator sensor arrays make them uniquely amenable for high 
performance LC detection. Specifically, this platform allows for operation without extended 
thermal equilibration time, operation at ambient temperature, and eliminates the need to 
simultaneously acquire reference and sample data, as is the case for traditional refractometers. 
Furthermore, the broad dynamic range of microring resonators firstly allows for RI-based detection 
of eluents during gradient elution separations, which are essential to many contemporary LC 
protocols. Looking forward, improvements in the liquid handling interface as well as automation 
of data processing will likely reduce sensor noise, increase efficiency and sensitivity, and simplify 
detector operation for the end user. The potential use of microring resonators in LC might be 
further developed by modifying sensor surfaces to enhance target-specific sensor sensitivity (e.g., 
via capture agent immobilization) or to perform quasi-2-D separations (e.g., via silane chemistry) 
that utilize differentially-functionalized sensors that are matched (or mismatched) to column 
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surface chemistry with interaction kinetics reporting on the chemical properties of eluting species. 
Finally, since the sensor array has a small footprint (4 mm x 6 mm), the sensors hold potential for 
incorporation into lab-on-a-chip separation devices as a chip-integrated technology for direct 
analyte detection. 
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2.6 Figures 
 
Figure 2.1. Chip layout and operating principles. (A) A scanning electron microscopy (SEM) 
image of one of the microrings with adjacent waveguide is provided. The 4 mm x 6 mm silicon-
on-insulator chips contains 132 individually addressable microrings in an array format. 
Additionally, 4 rings covered in a fluoropolymer cladding layer serve as thermal control rings, and 
4 exposed rings (i.e., no cladding layer) that lie outside the fluidic channels serve as leak sensors. 
The areas highlighted with blue indicate fluidic channels. For the interface with HPLC, only the 
top fluidic channel was used. (B) Light propagating down the linear waveguide via total internal 
reflectance couples into the microring under specific resonance conditions described by Equation 
1. Light coupling into the rings results in a spectrally-narrow dip in transmission. (C) While 
typically operated with a modified sensor surface, the microring resonator array is sensitive to bulk 
RI changes. When the bulk RI surrounding the ring (evanescent field with 𝟏𝟏/𝐞𝐞 distance of 63 nm) 
changes, the resonant wavelength with shift by approximately 63 nm/RIU.  
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Figure 2.2. Bulk RI sensitivity. A plot of relative shift in wavelength versus change in RI shows 
strong linearity. The adjusted r-squared value is >0.997 with a slope of 63.3 ± 0.1 nm/RIU. (N = 
3 and error bars are ± SD).  
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Figure 2.3. Fluidic interface. The outlet from the HPLC diode array detector was connected to 
the inlet of the cartridge assembly via a 0.25 mm flangeless 1/4-28 to ZDV 10-32 PEEK low 
pressure union. PEEK and stainless steel tubing types were used for HPLC fluid delivery, and 
PTFE tubing was used for the connection from the union to the cartridge assembly. In order from 
bottom to top, the cartridge assembly consists of an aluminum cartridge holder, SOI sensor chip, 
Mylar fluidic gasket, and Teflon cartridge top. The cartridge assembly allows for multiple flow 
configuration, and 2 PEEK plugs are used to block the unused fluidic channel. The optical scanning 
window allows for the sequential interrogation of each microring using a tunable diode laser. 
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Figure 2.4. Outline of instrument setup. For all runs, UV/Vis absorption data was acquired 
followed by downstream detection using the microring resonator platform. For comparison 
experiments, the effluent was directed to a commercial RI detector.  
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Figure 2.5. (A) A 2 μL injection of 10 mg/mL (58.5 mM) caffeine onto an Acclaim C18 column 
shows a simple isocratic separation using the microring resonator arrays as a bulk RI detector. (B) 
Plot of peak area versus injection volume shows the reproducibility of peak area and linearity of 
mass injected onto the column and sensor response (N = 3 and error bars represent ± standard 
deviation). (C) Various injection volumes of a mixture of 12.4 mM malic acid, 18.4 mM oxalic 
acid, and 14.1 mM succinic acid (each at 1.66 mg/mL) dissolved in 10 mM PBS pH 2.3. The 
Hypersil Gold polar-capped C18 column was used. (D) Plot of peak area versus injection volume 
is similar to panel B, showing a linear relationship with slopes varying slightly dependent upon 
the analyte. 
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Figure 2.6. Commercial RI detector data for organic acid separation. (A) Various injection 
volumes from 5 to 20 μL of 7.46 mM malic acid, 11.1 mM oxalic acid, and 8.47 mM succinic acid 
dissolved in 10 mM PBS pH 2.3. The column used for separations was Hypersil Gold polar-capped 
C18 column. (B) Plot of peak area versus injection volume shows a linear relationship with slopes 
varying slightly dependent upon the analyte. The results are very similar to those obtained using 
the microring resonator arrays as detector.  
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Figure 2.7 (A) A series of 4 identical salt gradients is shown. The MP begins with DI water to 1 
M NaCl and back to DI water. A dotted line is added to emphasize gradient reproducibility. (B) 
Gradients for 3 different MP compositions are shown: (1) water to DMSO, (2) water to 1 M NaCl, 
and (3) 90:10 water:acetonitrile to acetonitrile. Inset shows a zoomed in plot of the NaCl and 
acetonitrile gradients. 
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Figure 2.8. Gradient on Commercial RI Instrument. A gradient from DI H2O to acetonitrile 
over 20 minutes demonstrates the incompatibility of gradients with currently available setups.  
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Figure 2.9. (A) A 100 μL injection of 2.5 mg/mL (12.1 mM) ibuprofen and simvastatin in 50:50 
water:acetonitrile followed by gradient elution LC separation (90:10 water:acetonitrile to 
acetonitrile). (B) Data from panel A referenced to an identical MP gradient without a sample 
injection. Inset shows a zoomed in plot of the ibuprofen and simvastin peaks.  
76 
 
 
Figure 2.10. (A) A 20 μL injection of an ibuprofen liquid gel capsule dissolved in 20 mL of 50:50 
water:acetonitrile. A 20 μL injection of 10 mg/mL (48.5 mM) ibuprofen stock is provided for 
reference. (B) Data from panel A referenced to an identical MP gradient without a sample 
injection.  
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Figure 2.11. UV/VIS data from ibuprofen liquid gel separation. A 20 μL injection of a 
ibuprofen liquid gel capsule dissolved in 20 mL of 50:50 water:acetonitrile monitored at 220, 260, 
550, and 700 nm.  
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Chapter 3 
 
Rapid, Multiplexed Phosphoprotein Profiling Using Silicon 
Photonic Sensor Arrays 
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3.1 Abstract 
Extracellular signaling is commonly mediated through post translational protein 
modifications that propagate messages from membrane-bound receptors to ultimately regulate 
gene expression. Signaling cascades are ubiquitously intertwined and a full understanding of 
function can only be gleaned by observing dynamics across multiple key signaling nodes. 
Importantly, targets within signaling cascades often represent opportunities for therapeutic 
development or can serve as diagnostic biomarkers. Protein phosphorylation is a particularly 
important post translational modification that controls many essential cellular signaling pathways. 
Not surprisingly, aberrant phosphorylation is found in many human diseases, including cancer, 
and phosphoprotein-based biomarker signatures hold unrealized promise for disease monitoring. 
Moreover, phosphoprotein analysis has wide-ranging applications across fundamental chemical 
biology, as many drug discovery efforts seek to target nodes within kinase signaling pathways. For 
both fundamental and translational applications, the analysis of phosphoprotein biomarkers targets 
is limited by a reliance on labor-intensive and/or technically challenging methods—particularly 
when considering the simultaneous monitoring of multiplexed panels of phosphoprotein 
biomarkers. We have developed a technology based upon arrays of silicon photonic microring 
resonator sensors that fills this void, facilitating the rapid and automated analysis of multiple 
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phosphoprotein levels from both cell lines and primary human tumor samples requiring only 
minimal sample preparation. 
3.2 Introduction 
 The post translational modification of proteins is an essential process through which 
extracellular recognition events can be communicated from receptor activation through signaling 
cascades to ultimately control transcription.1 Phosphorylation-driven kinase signaling is perhaps 
the most common post translational modification utilized in extracellular signaling.2 Not 
surprisingly, aberrant regulation of phosphorylation is implicated in many diseases,3-5 including 
cancer, yet a thorough understanding of phosphorylation dynamics can reveal interventional 
opportunities. Disease altered signaling cascades provide important targets for both current and 
emerging therapeutic agents,6-8 while also representing diagnostic or prognostic biomarker 
signatures that are predictive of patient response to particular treatment regimens. However, the 
interconnectivity and redundancy between and within kinase signaling cascades often gives rise to 
resistance against many chemotherapeutic strategies.9-13 This crosstalk also limits the diagnostic 
utility of any single phosphoprotein-based biomarker. Importantly, a more comprehensive survey 
of disease-altered kinase signaling can only be achieved by simultaneously analyzing multiple 
phosphoprotein signatures, effectively probing across multiple intersecting cascades to reveal the 
functional significance of aberrant pathway activation. 
 Despite clear applications in both fundamental chemical biology and translational clinical 
diagnostics, robust multiplexed phosphoprotein analysis remains an unmet analytical challenge. In 
spite of notorious shortcomings in terms of throughput, plexity, and quantitative capability, 
electrophoretic methods (e.g., western blot) remain the gold standard for phosphoprotein 
expression analysis.14,15 A number of impressive advances have been proposed to increase 
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throughput and reduce reagent and sample consumption,16-22 but these methods are still at 
relatively early stages of development and have yet to find widespread adoption. Reverse phase 
protein arrays (RPPA), a miniaturized dot-blot immunoassay with low sample input requirements, 
allow for many samples to be simultaneously interrogated for the presence of a single protein 
target, and the method has found utility in clinical trials.9,23,24 However, this approach is not well-
suited for molecular diagnostic applications requiring simultaneous assaying of a single sample 
for multiple phosphoprotein targets. A handful of new antibody-based technologies have also 
emerged in recent years for multiplex protein analysis—a number of which have taken advantage 
of the spatial and/or PCR-based multiplexing capacity of DNA-antibody complexes.25-29 These 
technologies, while requiring the synthesis of a DNA-antibody conjugate, have shown impressive 
limits of detection and multiplexing capacity. Though it is worth pointing out that antibody cross-
reactivity typically limits multiplexing to ≤ 20 protein targets within a single sample volume. 
Higher levels of multiplexing require the sample to be partitioned into separate reaction volumes. 
A notable exception is an 88-plex assay for cell surface proteins.30 However, this analysis only 
targeted the outside of an intact cell and was not subjected to the complex milieu intracellular 
content, and therefore did not require the application of sandwich pairs for higher specificity. 
As an alternative analysis current methods for multiplexed protein detection, we have 
developed a silicon photonic detection technology that allows for the routine and robust analysis 
of biomarker targets from single samples.30-32 Chip-integrated arrays of silicon photonic microring 
resonators are refractive index sensitive devices that have optical properties that can be monitored 
to reveal the binding of biomolecules to target-specific capture agents (Figure 3.1). Microring 
resonators support optical resonances at specific wavelengths, as defined by: 
𝜆𝜆 = 2𝜋𝜋𝜋𝜋𝑛𝑛eff
𝑚𝑚
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where λ is the wavelength of light, m is an integer, 𝜋𝜋 is the radius of the microring, and 𝑛𝑛𝑒𝑒𝑒𝑒𝑒𝑒 is the 
effective refractive index of the propagating optical mode. When functionalized with target-
specific capture agents (e.g., antibodies, cDNA, aptamers), analyte binding-induced changes in 
𝑛𝑛𝑒𝑒𝑒𝑒𝑒𝑒 are detected as shifts in resonance wavelength. Importantly, this silicon-based technology 
allows for high levels of multiplexing, is cost effective, highly scalable, and supports enhanced 
assays with demonstrated limits of protein detection as low as 500 fM.32 
The chief advantages of this technology are the ease of use, rapid analysis times, scalable 
chip fabrication and functionalization, and robust and reproducible sensor operation. In contrast to 
our previous efforts, this work reports the highest ever levels of multiplexing using a silicon 
photonic sensor, and the first demonstration of detection from cell lysate and resected tumor 
samples. Importantly, sensor substrates are prepared in batch using well-established microspotting 
techniques. Chips are then simply loaded into a cartridge and fitted with a pre-cut and 
automatically aligned gasket. This is in contrast to many other reports that require custom 
microfluidic device fabrication and alignment. The assay is also completely automated using an 
integrated pumping system so that all that is required is minimal sample preparation (e.g., cell lysis 
following standard methods). Overall, this type of rapid, scalable, and high throughput method for 
probing levels of multiple phosphoproteins from single samples could provide new insights into 
functional and coordinated aspects of disease altered signaling, revealing underlying drivers of 
cancer progression and informative therapeutic opportunities. 
Given the aforementioned needs in both chemical biology and clinical diagnostics, we 
report the first application of this silicon photonic technology to multiplexed phosphoprotein 
analysis. Sensor arrays functionalized with monoclonal antibodies specific for 12 kinase cascade-
related targets were utilized to rapidly (<2 h) obtain a multiplexed phosphoprotein profile from 
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both glioblastoma cell line models and primary surgical glioma specimens. Spatial multiplexing is 
achieved by selective immobilization of individually addressable microring sensors with capture 
antibodies using a commercial microspotter. The method is reproducible, requires low sample 
input (<104 cells), and was used to monitor dynamic phosphorylation in cell lines responding to 
stimulatory and inhibitory treatments. Applying this technology to primary surgical glioma 
specimens, the resulting multiplexed phosphoprotein signature allowed for the rapid 
discrimination of growing tumor from necrotic tissue—actionable information that, given the 
rapidity of the assay, could potentially be integrated in near real-time within the clinical decision 
making process.  In general, this multiplexed detection platform, which can be customized to any 
set of protein targets to which capture agents can be directed, will find broad utility in the 
monitoring of dynamic cell signaling processes in both fundamental biological and translational 
diagnostic applications. 
3.3 Results and Discussion 
General Detection Scheme. The general workflow for multiplexed phosphoprotein 
profiling consists of sample processing (i.e., tissue homogenization and cell lysis), rapid data 
acquisition, and semi-automated data analysis (Figure 3.2).  Sensor chips were covalently 
functionalized via microspotting with 12 monoclonal antibodies specific for protein epitopes 
within targets of interest (Figure 3.3), including 10 phosphorylation sites. Each antibody was 
immobilized onto eight independently addressable sensors, providing on-chip technical replicates, 
and phosphoprotein detection was accomplished using an enzymatically-enhanced sandwich 
immunoassay format (Figure 3.4).32 After loading the chips into the sensor scanner, whole cell 
lysates from either cultured glioblastoma cell lines or surgically resected glioma tissue specimens 
were flowed across the sensor chips. The sandwich immunocomplex assembled on each sensor 
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surface consisted of the capture antibody and antigen, biotinylated tracer antibody, and a 
streptavidin-horseradish peroxidase conjugate. Protein detection was achieved by monitoring the 
resonance wavelength shift associated with the enzymatic conversion of 4-chloro-1-napthol (4CN) 
to the insoluble 4-chloro-1-napthon (4CNP) product, which was deposited onto the sensor surface. 
Targets to be detected (Table 3.1) were selected due to their key roles in the 
PI3K/AKT/mTOR and MAPK/ERK pathways, which are aberrantly regulated in many cancers. 
For multiplex protein detection in cell lysate, relevant antibody pairs (Table 3.2) were validated 
and covalently immobilized onto sensor chips using standard bioconjugate chemistry and 
piezoelectric microspotting. The panel of proteins was then simultaneously detected using the 
described enzyme-enhanced sandwich immunoassay format. The reproducibility of the assay was 
demonstrated across multiple biological replicates, and notable differences in phosphoprotein 
expression were observed between different cell lines. 
Sensor Characterization Using a Model Protein. Recombinant β-catenin prepared in 
running buffer was used as an initial model system to characterize sensor performance (Figure 
3.5a). These results, fit to a logistic function, indicated a ~3.5-order of magnitude linear dynamic 
range and a limit of detection and quantitation of 0.6 pM and 1.3 pM, respectively (Table 3.3). 
Analysis of β-catenin from within cell lysate showed that this protein could be reliably detected 
with a sample input of less than 10,000 cells (Figure 3.5b). For reference, fine needle aspirate 
biopsies consistently yield >500,000 cells,33 and typical cell culture protocols yield >106 cells. 
While not a focus of this study, which centers on phosphoprotein analysis, absolute quantitation 
using this platform is achievable for targets that have readily available standards. 
Validation of Antibody Pairs. Identification and screening of antibody sandwich pairs 
with sufficient specificity and affinity for targets of interest is a major limitation for all 
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immunoassay detection platforms, and there have recently been public calls for dramatic 
improvements and standardization of antibodies used for research applications 
(http://www.nature.com/news/1.16827). Without such standardization, rigorous antibody 
screening procedures are necessary to identify suitable antibody targets. A major advantage of the 
microring resonator platform is the ability to monitor real-time binding events, and the fact that 
antibody validation can be carried out directly on the same platform on which the final assay will 
be performed. In contrast to end-point assays, where operators are blind until the conclusion of the 
multi-step assay, the real-time signal observed in microring detection experiments can reveal 
problematic assay steps. An example of binding events for each step of the protein expression 
profiling assay is provided in Figure 3.6. See Materials and Methods for a detailed description 
of antibody validation procedures.  
Phosphoprotein Profiling of Glioblastoma Cell Lines. The ability to discriminate 
heterogeneities across samples of similar composition is a vital tool for translation of the platform 
into a workable tool both for research and clinical settings. To test the performance of the 
multiplexed assay, five model glioblastoma cell lines were analyzed: U-87 MG, U-343 MG-a, U-
251 MG, LN-229, and T98-G. Prior to analysis, cell lysate samples were diluted to 50 μg/mL total 
protein content as determined by a bicinchoninic acid (BCA) assay to ensure a constant sample 
input across multiple samples. These cell lines were grown using standard tissue culture, lysed 
under non-denaturing conditions, and analyzed on the microring resonator platform. Within a 
single 2 h experiment, the 12-plex phosphoprotein analysis can be performed (Figure 3.7a). Of all 
the examined targets, Ser780 and Ser807/811 retinoblastoma (Rb) phosphorylation sites showed 
the greatest variance between individual cell lines (Figure 3.7b). Rb is a tumor suppressor protein 
known to be functionally inactive in many cancer types, such as osteosarcoma and small-cell 
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carcinoma.34 Activated forms of Rb block the progression of cell cycle from G1 to S phase by 
inhibiting E2F transcription factors.35 Cyclin dependent kinase (Cdk) phosphorylation inactivates 
Rb, typically causing the cell to advance into S phase DNA replication.36 Inactivation of Rb, as 
appears to be the case in the T-98-G cell lines (Figure 3.7a), can induce quiescent cells to re-enter 
the cell cycle, initiating cancerous growth.37 However, Rb is neither necessary nor sufficient for 
cancer development, as is seen by the low levels of phosphorylation in both the U87 and U343 cell 
lines.  
When presented in the form of a heat map, data normalization is performed for each target 
of interest, and this method allows for facile comparison between model glioma cell lines. 
Categorization of samples based on protein profiles has the potential for downstream applications 
in a clinical setting for sub-classification of glioma in patients, as was previously accomplished 
using miRNA expression levels.38 In general, the assay is highly reproducible (Figure 3.8) with a 
technical variance <3% for analyses of cell lysate samples. The biological variance, determined 
by analysis of lysate from three cultures of cells from across different passages of the same cell 
line was determined to be <18%. 
In addition to detecting basal phosphoprotein levels, we also utilized this multiplexed 
platform to monitor dynamic changes in expression in response to four different cell treatments. 
Cells were cultured in the presence of vascular endothelial growth factor (VEGF), epidermal 
growth factor (EGF), rapamycin, or wortmannin. Cells cultured in media both with and without 
10% fetal bovine serum (FBS) were analyzed as references.  Interestingly, LN-229 and U-87 MG 
cell lines demonstrated differential responses to treatment in culture (Figure 3.9a). For instance, 
rapamycin treatment results in a dramatic shift in the phospo-S6 ribosomal protein kinase levels 
for the Ser235/236 site in both cell lines. However, for that same treatment, U87 cells showed a 
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mild upregulation in phospho-Akt and phospho-mTOR levels in comparison to LN-229 cells. 
These examples of heterogeneous cell line responses to treatment suggest the potential application 
of this platform for assessing tumor status and monitoring in vitro therapeutic response. 
Analysis of Primary Surgical Glioma Specimens. Cell lysates derived from established 
cell lines in culture provided a proof-of-concept for the phosphoprotein profiling using the 
microring resonator platform, but the method should also be applicable to tumor tissue 
homogenates if it is to serve as a useful diagnostic platform. To that end, primary surgical glioma 
specimens were homogenized and lysed following the same protocol as the cell culture samples. 
For the analysis of tumor tissue homogenates, the technical variance was <6% (Figure 3.10). In 
general, the surgical glioma samples had reduced phosphoprotein expression levels compared to 
cultured cell lines,39 so a higher total protein concentration was used for all tumor samples (150 
μg/mL). The multiplexed phosphoprotein analysis was performed as described and the resulting 
expression levels used as input for clustering via Euclidean distance. Notably, glioma tissue 
homogenates were clearly distinguished from isolated primary glioma stem-like cell samples 
(Figure 3.11). Furthermore, two samples (21225 and 43096) showed widespread reduction in 
protein phosphorylation, and clustered together separate from the other glioma samples (Figure 
3.9b). A review of pathology reports indicated that these two samples uniquely had extensive 
necrosis (>50% necrotic tissue). Necrosis can occur via several mechanisms, including both p53-
dependent and independent pathways.40-43 In the context of GBM, necrosis via radiation injury is 
commonly encountered in recurrent disease and is often difficult to distinguish from actively 
growing tumor using many non-invasive imaging approaches,40,44 complicating surgical 
intervention. While beyond the scope of this paper, it is important to note that the 2 h timeframe 
of our multiplexed assay might provide useful information to pathologists regarding molecular 
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tissue/tumor heterogeneity, which in turn might help guide the surgical decision making process 
intraoperatively. 
3.4 Conclusion 
We have utilized silicon photonic microring resonator arrays to dynamically monitor 
phosphoprotein levels using both cultured glioblastoma cell lines and surgical human glioma 
specimens. This multiplexed technology can simultaneously determine expression levels of 
multiple targets in less than 2 h using sample inputs compatible with many basic science and 
clinical detection applications. In addition to monitoring differences in phosphoprotein levels from 
glioblastoma cell lines cultured in the presence or absence of stimulatory and inhibitory factors, 
this technology revealed differences between surgical glioma specimens. Because 
phosphorylation-dependent pathway activation plays an important role in tumor growth and 
resistance, the rapid and broad-based analysis of phosphoprotein patterns as outlined here could 
provide useful diagnostic and therapeutic information beyond that which can be inferred from 
genomic or transcriptomic studies. 
Using phosphoprotein levels, we could stratify samples that had extensive tissue necrosis, 
identified as having reduced levels of phosphoprotein targets. Importantly, this rapid 
discrimination of growing tumor from necrotic tissue provides actionable information that could 
potentially be integrated in near real-time within the clinical decision making process. In this report 
we describe the simultaneous detection of 12 protein targets; however, the plexity of the panel can 
be further increased and, for example, could include comprehensive profiling of both 
phosphorylated and non-phosphorylated forms of selected targets. In general, this multiplexed 
detection technology, which can be applied to any panel of protein biomarkers to which high 
affinity capture agents can be directed, will find utility throughout both fundamental biological 
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and clinical applications that seek to simultaneously probe expression levels of multiple protein 
targets, including those focusing on dynamic processes such as pathway activation and therapeutic 
regulation. 
3.5 Materials and Methods 
Reagents. Unless indicated otherwise, all reagents were purchased from Sigma Aldrich 
and were used as received according to manufacturer’s protocol. The following reagents were 
purchased from Thermo Scientific: (bis[sulfosuccinimidyl]) suberate (BS3) homobifunctional 
amine-to-amine crosslinking agent (#21585), streptavidin horseradish peroxidase (SA-HRP) 
conjugate (#21130), 1-step chloronaphthol solution containing 4-chloro-1-naphthol (4-CN) and 
propriety peroxide-containing buffer (#34012 or NC0544546), and StartingBlock (PBS) blocking 
buffer (#37548). 3-aminopropyltriethoxysilane (APTES) was from Gelest (#SIA0610.1). DryCoat 
assay stabilizer was from Virusys (#AG066-1). Recombinant β-catenin was from abcam 
(#ab63175). PBS buffer (10 mM) with 0.1% BSA and 0.05% Tween-20 (PBST/B) was used as a 
running buffer for all experiments on the microring resonator platform. All antibodies were 
purchased from Cell Signaling Technology (Table 3.2) as custom formulations in 10 mM PBS. 
Biotinylation of tracer antibodies was performed using the EZ-Link NHS-PEG4-Biotion reagent 
from Thermo Scientific (21329). 
Microring Resonator Instrumentation, Chip Fabrication, and Operation. Maverick 
M1 optical scanning instrumentation, control software, and sensor array chips were purchased 
from Genalyte Inc. (San Diego, CA). Sensor fabrication and operation have been previously 
described.30,45 Briefly, sensor chips are batch fabricated on a silicon-on-insulator (SOI) wafer, and 
submicron features (e.g., grating couplers, waveguides, and microrings) are generated via deep 
UV lithography and reactive ion etching. A perfluoropolymer cladding layer is added to the entire 
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chip surface via spin coating, and annular windows are etched over 132 of 136 rings. The exposed 
rings are termed active, and the remaining 4 rings are used as controls to correct for thermal drift. 
The chips come coated with a protective 1 μm thick photoresist layer, which is removed prior to 
use by immersing first in an acetone bath immediately followed by rinsing the chip in isopropanol. 
Sensor interrogation is performed using an external cavity tunable diode laser centered at 
1550 nm coupled via fiber optics to a free-space optical scanner.45 The scanner focuses and steers 
the optical beam to serially probe each of the 136 rings while sweeping the laser wavelength 
through a suitable spectral window. Light is coupled into microrings via chip-integrated grating 
couplers. A 30 μm microring is adjacent to the waveguide, and light couples from the waveguide 
into the ring only under resonance conditions (described above). When functionalized with an 
appropriate capture agent, binding-induced changes in 𝑛𝑛eff lead to shifts in the resonance 
wavelength, which can be used to quantitatively detect biomolecular targets. Resonance 
wavelength shifts are monitored as a function of time and reported in units of pm. Additional 
instrumental specifications and a more exhaustive description of operation has been previously 
reported.45 
Array Surface Functionalization. Capture biomolecules are covalently immobilized onto 
the ring surface into a spatially multiplexed array using robotic microspotting. After removal of 
the protective photoresist layer, chips are silanized in a 1% APTES solution in acetone for 2 
minutes, followed by 2 minute rinses in acetone and then isopropanol. The chips are then briefly 
(<10 s) rinsed in water and dried under a N2 gas stream. Chips are subsequently loaded into the 
microarrayer. Each cluster of 4 active microrings was spotted with a 2 mM acetic acid solution 
containing 5 mM BS3 crosslinker. Antibody solutions of 400 μg/mL in 10 mM PBS with 5% 
glycerol were then spatially arrayed onto individual clusters of four microrings on the chip surface. 
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Spotting locations were randomly assigned across each channel of the sensor array (Figure 3.3). 
Spotted chips were then transferred to a humidity chamber for 1 h. The chips were next coated 
with DryCoat by gently pipetting the solution across the chips surface. The chips were then 
transferred to a desiccator at 4°C for storage. 
 Lower plexity chips utilized for antibody validation, cross reactivity screening, and -
catenin detection standardization were fabricated using identical attachment chemistries; however, 
solutions were spotted by hand rather than using the robotic microspotter. 
Antibody Validation Protocol. Selection of antibody targets for screening was guided by 
recommendations from commercial vendors in order to ensure that epitopes for each component 
of the antibody sandwich did not overlap. In addition to vendor recommendations, various research 
facilities (e.g., RPPA Core Facility – Functional Proteomics, MD Anderson Cancer Center, 
www.mdanderson.org) provide databases containing antibodies that have undergone extensive 
screening procedures that were useful in selecting successful antibody clones. 
In order to validate recommended antibody pairs for protein detection in cell lysate on the 
microring resonator platform, antibodies were purchased from vendors in a custom formulation in 
a 10 mM PBS buffer. Custom formulations were necessary to ensure that no species were present 
that would interfere with either surface conjugation of biotinylated of tracer antibodies. On-target 
capture antibodies and an off-target control antibody (e.g., mouse IgG isotype control) were 
functionalized onto a chip following the methodology described above. When available, reference 
protein standards were used as positive controls. When no standard was available, as is the case 
for the phosphoprotein targets, cell lysates isolated from the 5 model glioma cell lines were used 
as reference samples. An antibody hit was considered valid when the following were observed: (1) 
on-target signal significantly above off-target control, (2) concentration-dependent signal response 
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(typically undiluted, 1:10, and 1:100 cell lysate dilutions), (3) statistically insignificant signal for 
on-target and off-target antibodies for negative control experiments, and (4) western blot 
experiments indicated a single band at the appropriate molecular weight using the same antibody 
clone.  
While the absolute minimum signal for a validation target is the limit of quantitation 
(LOQ), which was experimentally determined to be an 11.5 pm shift based off of the signal and 
standard deviation of a blank response (Figure 3.6).  Practically, all qualifying targets provided a 
net shift of at least 300 pm above background. Two types of negative control experiments were 
used: (1) removal of on-target tracer antibodies from the standard assay and (2) removal of diluted 
whole lysate form the standard assay. The combination of the two negative control runs ensured 
that tracer antibodies would only form the antibody sandwich when target analyte is present. 
Additionally, the off-target control capture antibody ensured that the tracer antibodies did not bind 
to cell lysate proteins that non-specifically adsorb to the sensor surface. Non-specific adsorption 
is also prevented by blocking the sensor surface with a carrier protein (see below). The western 
blot validation ensured that the antibody targets correctly bound the target of interest without cross 
reactivity (Figure 3.11). A major benefit of using a sandwich immunoassay is that cross-reactivity 
will only be observed if there is off-target or non-specific binding during both the capture and 
tracer steps in the assay. 
For all cases, antibodies were tested in both sandwich configurations to determine which 
provided the best performance (e.g., run 1: A as capture, B as tracer; run 2: B as capture, A as 
tracer). Additionally, antibodies were validated using western blotting for lysate samples from at 
least 3 cell lines. 
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Protein Expression Profiling. Twelve-plex protein expression profile chips were spotted 
as described above. For each run, flow was coupled to the sensor surface via a fluidic cartridge 
assembly (Figure 3.12). Sensor chips were sandwiched between an aluminum cartridge holder, a 
0.007” laser cut biaxially oriented polyethylene terephthalate (Mylar) gasket, and a 
polytetrafluorethylene (Teflon) cartridge top. Solvent was delivered to the cartridge assembly from 
via a 0.25 mm flangeless ¼-28 fitting screwed directly into the cartridge top. PEEK plugs were 
used to cap unused fluidic ports. The entire cartridge assembly was then loaded into the Maverick 
system. 
 For all steps in the assay, the flow rate was 30 μL/min. The assay consisted of (1) 
StartingBlock protein blocking step  (10 min), (2) rinse with 10 mM PBST/B (10 min), (3) 20 min 
cell lysate (50 µg/mL in 10 mM PBST/B, 20 min), (4) protein blocking with StartingBlock (10 
min), (5) rinse with 10 mM PBST/B (2 min), (6) tracer antibodies (1 µg/mL in PBST/B, 10 min), 
(7) rinse with PBST/B (2 min), (8) streptavidin HRP conjugate (2 µg/mL in 10 mM PBST/B, 10 
min), (9) 1-step chloronaphthol solution (25 min), and (10) rinse with 10 mM PBST/B (10 min). 
The total assay time was 117 minutes; however, the assay can be shortened further through 
optimization of blocking and reagent loading steps. For example, a non-optimized 45 min assay 
was successfully carried out, but with <25% loss in signal. 
Data Analysis. All data analysis was performed using Origin 9.1 (OriginLab Corporation, 
Northampton, MA) as well as a custom program for semi-automated data analysis. For analysis of 
protein and phosphoproteins in cell lysate, the net shift resulting from the enzymatic signal 
enhancement during the 25 min chloronaphthol oxidation step was used as assay readout. For each 
target, the data represents averaged responses from 4-8 replicate measurements on a single chip, 
corresponding to either 1 or 2 clusters of 4 microrings responding to a given target. Sensor 
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calibration data, determined using β-catenin in PBST/B buffer, was plotted as sensor response 
(measure in Δpm) versus time and fit to the logistic function (Figure 3.5 and Table 3.3): 
𝑓𝑓(𝑥𝑥) = 𝐴𝐴1 − 𝐴𝐴21 + � 𝑥𝑥𝑥𝑥0�𝑝𝑝 + 𝐴𝐴2 
where A1 is the initial value (pm), A2 is the final value (pm), x is the analyte concentration 
(pM), x0 is the center value (inflection point, pM), and p is the power parameter affecting the slope 
of the linear portion of the fit surround the inflection point.  
To generate expression heat maps, the data from the 12-plex protein expression profile was 
normalized by row to the average response for that target across the samples of interest according 
to the equation: 
log2 𝑥𝑥 − ?̅?𝑥?̅?𝑥  
where 𝑥𝑥 is target signal for a single sample, and ?̅?𝑥 is the mean target signal for a sample set. Data 
visualization was performed using Gene-E (broadinstitute.org/cancer/software/GENE-E/). The 
heat map data is also presented in Tables 3.4-3.6 as the standard score (i.e., z-score) to indicate 
the deviation from the mean for each. 
Cell Culture and Treatments. Model glioma cell lines were obtained from ATCC (U-87 
MG [HTB-14], LN-229 [CRL-2611], T98-G [CRL-1690]) or Cell Line Service (U-251 MG 
[300385], U-343 MGa [300365]). For comparison of untreated samples, cells were cultured in 
Dulbecco’s Modification of Eagle’s Medium (DMEM, Corning, #10-013-CV) supplemented with 
10% FBS (VWR, #1400-500) and 1% Penicillin-Streptomycin (Life Technologies, #15070-063). 
Cells were sub-cultured at ~80% confluency using 0.05% Trypsin-EDTA (Life Technologies, 
#25300-062) for cell detachment and re-seeded at 2 x 106 cells/mL. 
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 For treatments, cells were cultured using the same method as untreated cells for one 
passage cycle. Cells were then starved in serum-free media for 6 h immediately prior to treatment. 
One of the following reagents was supplemented into serum-free DMEM media for each of the 
four treatments: VEGF (Cell Signaling Technology, #8065SC) at 200 ng/mL, EGF (Cell Signaling 
Technology, #8916SC) at 200 ng/mL, wortmannin (Cell Signaling Technology, #9951S) at 200 
nM, or rapamycin (Cell Signaling Technology, #9951S,) at 100 nM. Two control treatments were 
also performed consisting of: serum-free DMEM with 200 μL DMSO added as a loading control 
and DMEM supplemented as described for untreated samples. Cells were harvested and lysed after 
18 h of treatment. 
 Cell lysis was performed following the manufacturer’s protocol using the cell lysis buffer 
containing protease and phosphatase inhibitors (Cell Signaling Technology, #9803S), 
supplemented with phenylmethanesulfonyl fluoride (PMSF) as a protease inhibitor (Cell Signaling 
Technology, #8553S). The buffer contains 1% Triton X-100 (Fisher, #BP151-100), a non-ionic 
detergent, for cell lysis. The use of non-ionic detergent ensures that the capture antibodies do not 
denature upon exposure to cell lysate solution, as has been observed when using lysis buffers 
containing sodium dodecyl sulfate (SDS) or other ionic detergents. Ionic detergents could be used 
though; however, an additional step of detergent removal would need to be incorporated into the 
workflow. 
During the lysis protocol, a small fraction (50 μL) was set aside to determine the total 
protein concentration using a bicinchoninic acid (BCA) assay (Fisher, #PI-23227) following the 
manufacturer's protocol. All lysate from cell culture was analyzed at 50 μg/mL total protein 
concentration. 
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Preparation of Primary Glioma Samples. All primary surgical glioma samples were 
collected at Brigham and Women's Hospital under authorized IRB protocols. Samples were 
homogenized and lysed according to the same protocol as the cell culture samples. Total protein 
levels were determined using a BCA assay (see above), and all samples were analyzed at 150 
μg/mL. 
Western Blot. Cell lysate samples were quantified with a BCA assay (see above) and 
brought to similar final concentrations. Samples were electrophorectically separated via SDS-page 
with 4-20% MINI PROTEAN TGX gels (Bio-Rad, # 4561093). Gels were loaded with a visible 
protein ladder for transfer visualization (Bio-Rad, #161-0374) and biotinylated protein ladder (Cell 
Signaling Technology, #7727) for chemiluminescent signaling. Proteins were transferred to 
nitrocellulose membranes (Cell Signaling Technology, #12369) via standard methods using the 
Mini Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad, #1703930).  The blots were blocked 
with 5% w/v nonfat dry milk in 50 mM tris-buffered saline (TBS) with 1% Tween-20 (TBST) for 
1 h. Membranes were incubated with primary antibody overnight at 4⁰C following manufacturer’s 
protocols. All antibodies were used at a 1:1000 dilution unless otherwise specified by the 
manufacturer. Blots were washed three times in 15 mL of TBST prior to an incubation step (1 h, 
RT) with secondary anti-rabbit or anti-mouse IgG and anti-biotin, all HRP-linked Antibody 
(1:1000 in 5% w/v nonfat dry milk in TBST, Cell Signaling Technology, #7074, 7075, & 7076). 
Blots were rinsed again with 15 mL of TBST three times prior to imaging with chemiluminescence 
using either LumiGlo® chemiluminescent reagent and peroxide SignalFire™ ECL Reagent (Cell 
Signaling Technology, #7003, 6883).  
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3.6 Tables and Figures 
Table 3.1. List of protein targets 
 
Target Pathway 
β-Catenin Wnt/β-Catenin 
phospho-Rb Ser780 cell cycle 
phospho-Rb Ser807/811 cell cycle 
phospho-Akt Ser473 PI3K/AKT 
phospho-Akt Thr308 PI3K/AKT 
S6 ribosomal protein PI3K/AKT & translation 
phospho-S6 Ser235/236 PI3K/AKT & translation 
phsopho-S6 Ser240/244 PI3K/AKT & translation 
TSC1/2 PI3K/AKT 
phospho-TSC2 Thr1462 PI3K/AKT 
phospho-mTOR Ser2448 PI3K/AKT 
phospho-p44/42 MAPK (Erk1/2) Thr202/Tyr204 RAS/RAF/MAPK 
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Table 3.2. Antibodies for protein targets 
Target Clone Role Catalog Number 
β-Catenin D10A8 Capture 8480 
β-Catenin L87A12 Tracer 2698 
Tuberin/TSC2 D93F12 Tracer 4308 
Tuberin/TSC2 28A7 Capture/Tracer 3635 
Phospho-TSC2 Thr1462 5B12 Capture 3617 
S6 Ribosomal Protein 5G10 Capture/Tracer 2217 
S6 Ribosomal Protein 21A12 Tracer 2355 
Phospho-S6 Ser235/236 D57.2.2E Capture 4858 
Phospho-S6 Ser240/244 D68F8 Capture 5364 
mTOR 7C10 Tracer 2983 
Phospho-mTOR Ser2448 D9C2 Capture 5536 
Akt (pan) C67E7 Tracer 4691 
Akt (pan) 11E7 Tracer 4685 
Phospho-Akt Ser473 D93 Capture 4060 
Phospho-Akt Thr308 L32A4 Capture 5106 
p44/42 MAPK (Erk1/2) 137F5 Tracer 4695 
Phospho-p44/42 MAPK (Erk1/2) 
Thr202/Tyr204 
D13.14.4E Capture 4370 
Rb 4H1 Tracer 9309 
Phospho-Rb Ser780 D59B7 Capture 8180 
Phospho-Rb Ser807/811 D20B12 Capture 8516 
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Table 3.3. Logistic fit parameters for β-catenin protein standard curve 
Model Logistic 
Equation 𝒚𝒚 = 𝑨𝑨𝟐𝟐 + 𝑨𝑨𝟏𝟏 − 𝑨𝑨𝟐𝟐
𝟏𝟏 + � 𝒙𝒙𝒙𝒙𝟎𝟎�𝒑𝒑 
Reduced 𝝌𝝌𝟐𝟐 0.03698 
Adj. 𝒓𝒓𝟐𝟐 0.9986 
 Value Standard Error 
𝑨𝑨𝟏𝟏 (𝜟𝜟𝒑𝒑𝜟𝜟) 1.91847 0.55574 
𝑨𝑨𝟐𝟐 (𝜟𝜟𝒑𝒑𝜟𝜟) 15184.89437 348.45725 
𝒙𝒙𝟎𝟎 (𝒑𝒑𝒑𝒑) 71.76693 8.31686 
𝒑𝒑 1.13617 0.02733 
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Table 3.4. Standard scores (z-score) corresponding to the heat map form Figure 3.7a 
 
U87 LN228 T98 U343 U251 
Beta-Catenin 0.14 -0.13 1.35 0.09 -1.46 
p-Akt S473 -0.50 -0.66 1.60 -0.79 0.35 
p-Akt T308 -0.27 -1.02 1.60 -0.53 0.23 
p-mTOR S2448 -0.97 -1.19 0.94 0.73 0.49 
p-p44/42 MAPK -0.35 -0.14 1.63 -1.10 -0.03 
p-Rb S780 -0.09 -0.14 1.68 -0.49 -0.96 
p-Rb S807/811 -1.43 -0.16 0.25 -0.03 1.37 
p-S6 S235/236 -1.49 0.34 1.10 -0.45 0.50 
p-S6 S240/244 -1.22 0.09 1.22 -0.76 0.67 
p-TSC2 T1462 0.23 -0.79 1.32 -1.18 0.42 
S6 0.20 -0.13 1.55 -0.46 -1.15 
TSC2 0.48 -0.99 -0.34 -0.65 1.50 
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Table 3.5. Standard scores (z-score) corresponding to the heat map form Figure 3.9a 
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β-Catenin 1.27 -0.45 0.39 0.86 0.82 1.66 -1.44 -0.63 -0.13 -1.30 -0.28 -0.77 
p-Akt S473 -0.54 0.92 -0.97 1.13 -1.54 -1.34 0.47 1.36 0.14 -0.21 1.05 -0.47 
p-Akt T308 -0.57 -1.64 -0.10 1.87 -0.49 0.30 -0.18 1.08 -0.38 -0.56 1.39 -0.73 
p-mTOR S2448 0.53 -1.30 0.13 1.75 -1.48 -1.10 -0.01 0.09 0.90 -0.81 0.98 0.34 
p-p44/42 MAPK 0.35 -1.81 0.09 1.08 -0.81 0.45 -0.92 1.83 -0.61 -0.71 0.55 0.49 
p-Rb S780 0.53 1.11 0.63 1.51 0.96 0.75 -0.86 -0.69 -1.08 -0.67 -1.30 -0.89 
p-Rb S807/811 0.82 1.11 0.59 1.21 0.75 1.07 -0.87 -0.90 -1.10 -0.47 -1.35 -0.87 
p-S6 S235/236 -0.69 0.42 -0.51 0.18 -1.58 -0.56 1.30 1.12 1.08 0.01 -1.58 0.80 
p-S6 S240/244 -0.16 0.13 -0.77 0.45 -1.96 0.15 1.05 1.41 1.13 -0.34 -1.33 0.24 
p-TSC2 T1462 0.71 1.77 0.38 0.51 -0.09 1.27 0.28 -0.97 -0.65 -1.47 -1.19 -0.55 
S6 (5G10) -0.11 0.15 -0.32 2.61 -0.28 0.49 -1.23 -0.54 -1.07 -0.62 0.40 0.51 
TSC2 1.18 -0.95 0.75 1.35 0.50 1.32 0.05 -0.76 -0.77 -1.59 -0.40 -0.68 
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Table 3.6. Standard scores (z-score) corresponding to the heat map form Figure 3.9b 
 
30304 21985 21225 86941 98131 43096 
Beta-Catenin 0.47 -0.86 1.34 0.76 -0.53 -1.18 
p-Akt S473 -1.29 0.61 0.19 1.52 -0.29 -0.74 
p-Akt T308 0.34 0.99 -1.15 0.78 0.39 -1.35 
p-mTOR S2448 -1.04 0.31 0.16 1.61 0.05 -1.09 
p-p44/42 MAPK -0.81 -0.15 -0.32 1.93 -0.70 0.05 
p-Rb S780 -1.03 1.10 -0.05 1.25 -0.23 -1.05 
p-Rb S807/811 0.06 1.93 -0.84 -0.59 -0.11 -0.45 
p-S6 S235/236 0.27 1.18 -1.11 1.06 -0.40 -1.01 
p-S6 S240/244 -0.93 0.25 0.16 1.77 -0.34 -0.90 
p-TSC2 T1462 0.47 1.09 -1.60 0.04 0.72 -0.71 
S6 1.18 -0.73 0.61 0.90 -0.99 -0.96 
TSC2 1.63 -0.70 -0.58 -0.53 0.87 -0.68 
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Figure 3.1. Operating principles for microring resonator sensors. (A) A scanning electron 
microscope (SEM) image shows a 30 μm active microring with an adjacent linear waveguide. (B) 
Light is coupled onto the chip via a grating coupler and propagates down the linear waveguide via 
total internal reflectance. Under resonance conditions, light couples into the adjacent microring, 
resulting in a narrow dip in the transmittance past the microring, which is measured by a 
photodetector after coupled off-chip by a second grating coupler. (C) Shifts in the resonant 
wavelength occur due to changes in the refractive index near the surface of the ring. The schematic 
example depicts a target protein binding to a capture antibody, resulting in a shift of the resonance 
to a longer wavelength. 
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Figure 3.2. Protein detection scheme for multiplexed phosphoprotein profile. (A) Cells 
harvested either from human glioma cell lines in culture or from primary resected tumor specimens 
were homogenized and lysed. (B) Samples were then flowed across a 4 x 6 mm silicon sensor chip 
containing a 132-element microring sensor array functionalized with target-specific capture 
antibodies. (C) Resonance wavelength shifts observed from an enhanced sandwich immunoassay 
correspond to the concentration of each target in the sample. Error bars represent ± s.d. (n = 8 
technical replicates) (D) Resonance wavelength shifts can be displayed as a heat map to reveal 
heterogeneity between samples. 
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Figure 3.3. Sensor array capture spotting map. The 4 x 6 mm silicon photonic chip contains 
132 active rings and 4 thermal controls. Active rings are arranged in clusters of 4, and the chips 
contains 32 clusters of rings. Unlike active rings, thermal control rings are covered with a 
fluoropolymer cladding layer. The chip schematic shows the layout for antibody spotting using a 
robotic microspotter. The fluidic path across the chip is also highlighted by the dashed lines. 
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Figure 3.4. Enzymatically-enhanced assay scheme. Multiplexed protein detection in cell lysate 
is a 2 h assay consisting of 3 binding steps and enzymatic signal enhancement.  The assay consists 
of (1) chip functionalization and protein blocking steps, (2) analyte capture from cell lysate, (3) 
binding of biotinylated tracer antibody, (4) binding of SA-HRP conjugate to biotinylated tracer, 
and (5) enzymatic signal enhancement via oxidation of 4CN to the insoluble product, 4-
chloronaphton. The top panel shows results from on-target (blue) and off-target (orange) for 
detection of β-catenin in 10 mM PBST/B buffer. Each trace represents an individual sensor.  
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Figure 3.5. Sensor characterization using a protein standard (A) Serial dilutions of 
recombinant β-catenin standard were used to assess sensor performance across 5 orders of 
magnitude in 10 mM PBST/B buffer. The net shift from the enzymatic signal enhancement step 
with the net shift from off target mouse IgG isotype control was used as readout. The sensor has a 
linear dynamic range of 3.55-log with a limit of detection (LOD) of 0.6 pM (solid horizontal black 
line) and limit of quantification (LOQ) of 1.3 pM (dashed horizontal black line). The data was fit 
to a logistic function (red trace, adj. r-squared > 0.99). Error bars, s.d. (n = 3). (B) The minimum 
sample input for detection of β-catenin cell lysate was determined. The minimum input is between 
1000 and 10,000 cells, whereas typical yield of most biopsy methods is >100,000 cells, including 
fine needle aspirates. The data was fit to a logistic function with adj. r-squared of 0.985. Error bars 
represent ± s.d. (n = 3). 
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Figure 3.6 Visualization of real-time binding events of β-catenin. The response from β-Catenin, 
shown in blue, can be seen for each of the binding events during the assay. The inset shows analyte 
binding (in buffer) to capture antibodies, biotinylated tracer antibodies binding to captured analyte, 
and streptavidin-horseradish peroxidase (SA-HRP) binding to the biotinylated tracer. The final 
step visible in the larger plot shows the oxidation of 4CN, resulting in the large increase in signal 
between 50 and 60 min. Error bars represent ± s.d. (n=8 technical replicates). The orange trace 
shows data from the on-chip thermal control sensor.  
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Figure 3.7. 12-plex phosphoprotein analysis of glioma cell lines. (A) The multiplex 
phosphoprotein analysis of 5 model glioma cell lines grown in standard tissue culture reveals 
difference in protein phosphorylation. The data is normalized across rows and fit to a log-2 scale 
(n = 3). The bar graph represents a single multiplexed detection experiment on the microring 
resonator platform for 12-plex phosphoprotein analysis of the U87 MG cell line. (B) Differences 
in protein phosphorylation for four targets (β-catenin, phospho-Akt Ser 473, phospho-Rb Ser 
807/811, phospho-S6 Ser 240/244) across five cell lines. Error bars represent ± s.d. (n = 3 different 
samples per cell line). * significant at p < 0.05, ** significant at p < 0.01, and *** significant at p 
< 0.001. 
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Figure 3.8. Technical and biological variance of platform for detecting in tissue culture and 
tumor homogenate samples. (A) Analysis of identical samples from LN-229 cell lysate shows 
an average technical variance of 2.3% (N = 3). (B) Triplicate measurements of a single patient 
sample show average technical variance of 5.9%. (C) Cell lysate analysis from the U87 cell line 
collected at different passage numbers shows an average biological variance of 17.9%. For all 
panels, error bars represent ± s.d. (n=3 different sensor substrates).  
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Figure 3.9. Multiplexed phosphoprotein profiling of treated cell lines and primary surgical 
glioma specimens. (A) Dynamic phosphoprotein expression profiling of U87 MG and LN-229 
cell lines in response to 4 different treatment regimens (VEGF, EGF, rapamycin, and wortmannin) 
with (-)-serum and (+)-serum serving as references. (B) Isolated primary samples from six glioma 
patients were analyzed for the 12 protein targets and sorted via unsupervised hierarchical clustering 
based on Euclidean distance. The dashed regions highlight two samples that clustered together 
that, in contrast to the other samples, were identified in pathology reports as being composed of 
>50% necrotic tissue. 
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Figure 3.10. Phosphoprotein-based clustering of primary glioma tumor specimens. 
Unsupervised hierarchical clustering was performed for the 6 resected glioma tumor specimens 
and 2 primary glioma stem cells lines. The clustering reveals two key findings: (1) primary stem 
cell lines have demonstrate key differences between resected tumor specimens (double-lined 
outline) and (2) patient samples 21225 and 43096 were clustered as separate from the rest of the 
patient samples (dashed outline). We do not which to imply conclusive sorting capabilities based 
on such a small patient cohort, but the results provide promising result for the application of the 
technology to a clinical setting. Analysis time for each sample is <2 h, and the method was highly 
reproducible with an average coefficient of variance for the 12 targets was 5.9%. 
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Figure 3.11. Validation of antibody pairs with western blotting. All antibodies were validated 
against cell lysate from 3 different glioma cell line models. For all images, the layout from left to 
right is as follows: biotinylated protein ladder, U87, LN-229, and U-251.The hyphenated boxes 
represent antibody pair used for analyte detection on the microring resonator platform. Antibody 
sandwich pairs were validated for (A) S6 ribosomal protein, (B) Akt, (C) retinoblastoma protein 
(Rb), (D) mTOR, (E) p44/42 MAPK (F) β-catenin, and (G) tuberous sclerosis 2 (TSC2). 
 
118 
 
 
Figure 3.12. Fluidic interface and cartridge assembly. Fluidic control is achieved by 
sandwiching the chip between a chip holder and fluidic gasket that is laser cut into a U-shaped 
channel. In order from bottom to top, the cartridge assembly consists of an aluminum cartridge 
holder, SOI sensor chip, Mylar fluidic gasket, and Teflon cartridge top. The cartridge assembly 
allows for multiple flow configuration, and 2 PEEK plugs are used to block the unused fluidic 
port. The optical scanning window allows for the sequential interrogation of each microring using 
a tunable diode laser. 
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Monitoring Signaling Networks with Phosphoprotein Profiling 
of Patient-Derived Xenografts 
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4.1 Abstract 
Emerging cancer therapies target signaling networks that are overexpressed in cancers. One 
of the most commonly targeted pathways is the PI3K/Akt/mTOR network because it is commonly 
overactive in many solid tumors. We have developed a phosphoprotein detection panel mapped 
around this signaling cascade using microring resonator arrays as the detection platform. We used 
the panel to monitor signaling dynamics of PI3K/Akt/mTOR signaling in response to treatment 
with targeted therapeutics utilizing patient derived xenograft explants of glioblastoma tumors 
grown in culture. The treatments were: (1) the EGFR inhibitor erlotinib, (2) the PI3K pathway 
inhibitor GNE-317, (3) the dual PI3K/mTOR inhibitor apitolisib, and (4) the CDK4 inhibitor 
palbociclib. The phosphoprotein panel was able to monitor signaling dynamics that were unique 
to treatment time and sample. Distinct phosphoprotein profiles were observed as a function of 
mutational status of the the xenograft samples, and the extent of pathway inhibition was dependent 
on treatment times, with minimal inhibition of signaling observed after 1 h of treatment. This 
detection panel is substantially higher throughput than global pathway monitoring techniques, such 
as proteomics with mass spectrometry or gene expression analysis with next generation 
sequencing. 
4.2 Introduction 
Glioblastoma (GBM) is a the most common brain tumor in adults with survival times rarely 
extending beyond 15 months for patients under standard-of-care treatment.1,2 The aggressiveness 
of GBM has motivated extensive efforts to reveal the molecular underpinnings driving its 
emergence and proliferation.3–6 Through these investigations, the tyrosine kinase signaling 
pathway was shown to be highly altered at the genomic level in the vast majority of GBM cases. 
Several targeted therapeutics have been developed aiming to exploit the disrupted tyrosine kinase 
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signaling.7 To date, these precision medicines have failed to translate this better understanding of 
molecular pathogenesis into substantially improved patient outcomes. The limited success with 
these targeted therapies has been attributed to a number of causes, such as tumor heterogeneity, 
pathway redundancy, effects of the tumor microenvironment, and an incomplete understanding of 
drug or target-specific effects on cellular proliferation.7–10 The next steps for precision medicine 
applied to the treatment of GBM are likely to require improved patient selection with combination 
therapies tailored to tumor specific signaling aberrations. 
The promise of precision medicine hinges upon accurate screening of patient populations 
to identify patients with a specific molecular pathogenesis that matches with a targeted therapy.11–
13 Many of the techniques used to profile GBM initially were discovery-based, global approaches 
designed to provide comprehensive assessments of tumor status.3–6 These technologies, including 
next generation sequencing (NGS) and microarray technologies, were aimed to maximize the small 
amount of information extracted from the tumor sample in order to comprehensively analyze of 
the tumor. Such approaches are necessary for the discovery phase of biomarker development to 
identify the molecular drivers of pathogenesis. However, implementing these technologies as 
routine diagnostic tools is challenging because actionable clinical interpretations can be masked 
among the broad swath of biological information these discovery-based approaches provide.14 
Most applications of NGS in the clinic use the genomic information as a baseline that provides a 
historical record of mutations contributing to cancer development.15 In some cases, measurements 
at the level of the genome or transcriptome result in an incomplete representation of the phenotypic 
state as a result of various post-transcriptional regulation processes.16 As such, an adequate 
assessment of tumor state will likely require metabolic or proteomic information to provide 
clinically actionable indicators of tumor state as functional diagnostics.  
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In contrast to static diagnostics, functional diagnostics perform multiple measurements of 
a tumor in response to perturbation, such as treatment with targeted therapeutics.15 The application 
of functional diagnostics has grown in tandem with targeted therapies to improve the pairing of 
patients with drugs. Functional diagnostics can be divided into two categories. The first uses ex 
vivo culture or in situ measurements of tumor cells to assess the effectiveness of a drug regimen, 
and drug effectiveness is often measured by tumor volume or assays of cell viability.15 These 
approaches include cultivation of circulating tumor cells,17,18 patient-derived organoids or 
organotypic cultures,19–21 patient-derived xenografts (PDXs),22–24 and tumor microdosing for in 
situ screening.25,26 The second category of functional diagnostics uses target-engagement or 
pathway-activation to assess susceptibility of a tumor to a given treatment.15 Examples of this 
approach include kinase-pathway profiling with an RNAi knockout screening,27, single-cell 
phosphoprotein detection with flow cytometry to assess pathway activation,28 and peptide 
microarrays to measure kinase-specific activity in tumor cell lysate.29,30  
To add to the functional diagnostics toolbox, we have developed a multiplexed 
phosphoprotein detection platform for profiling pathway activity in response to targeted 
therapeutics. The platform consists of arrays of silicon photonic microring resonators for 
multiplexed phosphoprotein detection, and we have previously applied this platform for DNA,31 
RNA,32,33 and protein detection applications.34–36 We use a PDX model of GBM to assess the 
effectiveness of various targeted therapies at multiple time points. The phosphoprotein panel 
centers on the PI3K/Akt/mTOR signaling pathway, which has elevated signaling in up to 88% of 
GBM tumors.5,37,38 We are able to observe perturbations in the signaling networks in response to 
treatment with genetically distinct PDX models, demonstrating variable activity in response to the 
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same targeted therapy. These results suggest the viability of this platform as a functional diagnostic 
tool for targeted therapy screening. 
4.3 Experimental 
Materials and Reagents. Unless otherwise indicated, all reagents were purchased from 
Thermo Fisher Scientific. Erlotinib, apitolisib (GDC-0980), GNE-317, and palbociclib were 
purchased from MedChem Express. All antibodies were purchased from Cell Signaling 
Technologies, and sandwich pairs with clonal information are provided in Table 1. All antibodies 
were purchased from Cell Signaling Technology as custom formulations in 10 mM PBS. 
Biotinylation of tracer antibodies was performed using the EZ-Link NHS-PEG4-Biotin reagent 
following manufacturer-recommended protocols. 
Cell Culture and Treatments. Human GBM xenografts were established in mice 
following previously described methods.39 Briefly, primary tumors from patients undergoing 
surgical treatment were serially passaged in mice for continued propagation.   Short term explant 
cultures derived from these xenografts were grown in DMEM culture media supplemented with 
10% fetal bovine serum. To minimize any PDX alterations caused by the brief culture, cells were 
passaged no more than twice prior to treatment. Two xenograft lines were used in this study: 
GBM6 and GBM26. 
Four small molecule drugs were used for treatments: erlotinib, apitolisib, GNE-317, and 
palbociclib. Table 2 provides the structure and target for each treatment.  Each treatment was 
dissolved in DMSO and added to DMEM to a final concentration of 1 μM. DMEM with 10% FBS, 
serum-free DMEM, and DMEM with 0.1% DMSO were used as controls. Cells were lysed using 
Cell Lysis Buffer (Cell Signaling Technology) following the manufacturer's recommended 
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protocol. Treatment time points were collected at 1 h and 24 h. After lysis, cells were centrifuged 
at 14,000 xg for 15 min at 4°C. After centrifugation, the supernatant was stored at -80°C prior to 
analysis. 
Microring Resonator Array Instrumentation, Chip Fabrication, and Sensor 
Operation. The Maverick M1 optical scanning instrumentation, instrument control software, and 
sensor array chips were purchased from Genalyte Inc. Details regarding sensor fabrication and 
instrument operation have been described elsewhere.40,41 Briefly, sensor arrays were batch 
fabricated on silicon-on-insulator wafers, and optical features were generated using deep-UV 
lithography and reactive ion etching. A perfluoropolymer cladding layer was spin coated onto the 
chip surface, and annular windows were etched over the active sensing regions to remove the 
protective cladding layer. 
The sensor array contained 136 individually addressable microring structures. The rings 
were arranged in clusters of 4 microrings with 32 clusters per chip. The microrings were 30 μm in 
diameter with a linear waveguide immediately adjacent to each microring. For interrogation of a 
single microring sensor, light was coupled from a tunable external cavity diode laser centered at 
1550 nm coupled to a free-space optical scanner via fiber optics. The optical scanner directs light 
onto the chip, and the light couples into the microring resonator sensor under resonance conditions 
determined by the effective refractive index (neff) at the sensor surface. Changes in neff result in 
shifts in the resonant wavelength (λr) corresponding to binding events at the sensor surface are 
measures as a function of time. Changes in λr as a function neff can be described in terms of 
resonator geometry as: 𝑚𝑚𝜆𝜆𝑟𝑟 = 2𝜋𝜋𝜋𝜋𝑛𝑛eff, where L is the circumference of the microring resonator 
and m is an integer corresponding to the longitudinal cavity mode. 
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Array Surface Modification. Sensor array chips utilized for 12-plex phosphoprotein 
detection were modified using a robotic microspotter to spatially array target-specific capture 
antibodies. For lower plexity measurements such as antibody screening, sensor modification was 
performed by hand-spotting reagents onto the sensor surface. Microspotting and hand-spotting for 
sensor modification follow the same approach for covalent attachment of antibodies to the sensor 
surface. Upon receipt, sensor array chips have a protective photoresist layer that must be removed 
prior to chip functionalization. The photoresist was removed by first immersing the chip in an 
acetone bath followed by isopropanol. The chip was then dried under a N2 stream. 
After removing the photoresist layer, chips were immersed in a bath of acetone with 1% 3-
Aminopropyltriethoxysilane (APTES). APTES was purchased from Gelest. After rinsing with 
acetone, the chips were placed into the microspotter. A homobifunctional amine-to-amine cross-
linking agent (bis[sulfosuccinimidyl]) suberate (BS3) was dissolved in 2 mM acetic acid solution 
to a final BS3 concentration of 5 mM, and each cluster of rings was spotted with the BS3 solution. 
A solution with the specific capture antibody diluted to 400 μg/mL in 10 mM phosphate buffered 
saline (PBS) pH 7.4 with 5% glycerol was then spotted over the cluster of rings. Figure 5.1 
provides a spotting map for the 12-plex phosphoprotein array. After an incubation step of 
approximately 1 h in a humidity chamber to prevent droplet evaporation, the clusters were spotted 
with a commercially available stabilizing solution containing a blocking protein (DryCoat, 
Virusys). The stabilizing solution prolongs the storage time of the chip and the addition of the 
blocking protein reduces nonspecific binding during sensor operation. 
Antibody Validation. The identification of target specific antibodies with minimal cross-
reactivity is a vital step in the development of our phosphoprotein detection panel, as it is with the 
development of any affinity-based detection platform. The protocol for antibody validation has 
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been described in detail previously.35 Briefly, initial selection of antibody sandwich pairs were 
carefully chosen based upon guidance from publicly available antibody databases (see 
https://goo.gl/DKKUjh for a list of databases) along with guidance from commercial vendors. To 
minimize batch-to-batch variability, only monoclonal antibodies were used in the panel.  
If available, standards were used as positive controls against an off-target antibody. For 
phosphoproteins, standards were most often unavailable. In such cases, the antibodies were 
screened on the microring resonator platform using cell lysate samples thought to contain the target 
of interest. In order to move on to further validation, the sandwich pair must have: (1) on-target 
signal in cell lysate, (2) concentration-dependent signal in cell lysate (performed by diluting the 
cell lysate prior to analysis), and (3) minimal off-target signal for control antibodies on the same 
sensor chip. Western blot experiments were then performed on these antibody pairs to ensure there 
was no observed off-target bands. 
Multiplexed Phosphoprotein Detection. Prior to analysis with the microring resonator 
platform, the total protein content of all samples was determined with a bicinchoninic acid (BCA) 
assay. Samples were diluted to 150 μg/mL total protein content for phosphoprotein detection. The 
total instrument operation time with the microring resonator platform is 67 min. Prior to data 
acquisition, sensor chips were loaded into a cartridge assembly. The chip was sandwiched between 
a chip holder made of anodized aluminum as the base, a 0.007 in laser cut biaxially oriented 
polyethylene terephthalate (Mylar) gasket, and a polytetrafluorethylene (Teflon) cartridge top. The 
gasket creates distinct fluidic channels that allow for analysis of up to 32 targets with a single 
sample or simultaneous analysis of 2 samples with up to 16 targets. The cartridge top provides the 
interface between the sensor chip and the assay reagents loaded into a 96-well plate. The platform 
contains integrated fluidics for automated reagent delivery from the well plate. 
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Running buffer for all phosphoprotein detection experiments on the microring resonator 
platform was 10 mM PBS with 0.1% BSA and 0.05% Tween-20 (PBST/B), and running buffer 
for all steps was flowed at 40 μL/min. Prior to data acquisition, the chip surface was rinsed in a 
proprietary solution (Starting Block, ThermoFisher) to block the chip prior to introducing the cell 
lysate sample by flowing at 40 μL/min for 8 min. After blocking, the assay consisted of: (1) a 3 
min running buffer rinse, (2) starting data acquisition simultaneous with a 2 min of running buffer, 
(3) cell lysate at 30 μL/min for 10 min, (4) a 2 min running buffer rinse, (5) biotinylated tracer 
antibody diluted to 1 μg/mL in PBST/B flowing at 30 μL/min for 10 min, (6) a 2 minute running 
buffer rinse, (7) streptavidin-horseradish peroxidase complex diluted to 2 μg/mL in PBST/B at a 
flow rate of 30 μL/min for 10 min, (8) a 2 min running buffer rinse, (9) a proprietary 
chloronaphthol-containing substrate solution (ThermoFisher) at a flow rate of 30 μL/min for 10 
min, (10) a 5 min running buffer rinse, (11) end of data collection and an additional 3 min running 
buffer rinse. The assay is summarized in Table 3. 
Western Blots. The total protein content of cell lysate samples was determined using a 
BCA assay to determine appropriate loading concentrations for gel electrophoresis. Each lane was 
loaded with 20 μg of protein. Samples were separated using a denatured sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) with precast 4-20% MINI PROTEAN TGX gels 
(Bio-Rad). In addition to cell lysate samples, the gels were loaded with a visible protein ladder for 
transfer visualization (Bio-Rad) and a biotinylated protein ladder (Cell Signaling Technologies) 
for chemiluminescent imaging. After gel electrophoresis, samples were transferred to a 
nitrocellulose membrane (Cell Signaling Technology) using the Mini Trans-Blot Electrophoretic 
Transfer Cell (Bio-Rad) following the recommended protocol from the manufacturer. After 
transfer, the nitrocellulose membrane was blocked with with 5% w/v nonfat dry milk in 50 mM 
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tris-buffered saline (TBS) with 1% Tween-20 (TBST) for 1 h. During this time, antibodies were 
diluted in a blocking solution containing either 5% w/v nonfat dry milk or 5% BSA w/v in TBST 
following the manufacturer’s recommended dilution and blocking conditions. The blocked 
nitrocellulose membranes were incubated overnight with primary antibodies. After incubation 
with primary antibody, the membranes were washed with 15 mL of TBST for 5 min each, and 
membranes were then incubated with secondary anti-mouse or anti-rabbit IgG along with anti-
biotin for staining the biotinylated protein ladder. All secondary antibodies were HRP-conjugates 
and diluted 1:100 in 5% w/v nonfat dry milk in TBST. The membranes were again rinsed in TBST 
three times for 5 min each prior to imaging. For chemiluminescent imaging, SignalFire ECL 
Reagent (Cell Signaling Technologies) was used. 
Data Analysis. All data analysis was performed using the R coding language version 3.3.2 
and RStudio: Integrated Development for R version 1.0.136. The code used for data analysis is 
provided in the the Supplementary Information and freely available on GitHub (insert GitHub link 
here). The GitHub hosted code is continuously improved and updated, and may no longer precisely 
match the code used in the current study. 
4.4 Results and Discussion 
Cell Line Characteristics. Two primary xenograft lines were were used for this study: 
GBM 6 and GBM 26, and each line has been extensively characterized in previous studies.42,43 
Relevant to the current study, GBM 6 harbors a mutation of EGFR corresponding to the deletions 
of exons 2 through 7, referred to as EGFRvIII.44,45 EGFRvIII is commonly observed in 
glioblastoma and corresponds to a poorer prognosis caused by increase proliferation and tumor 
invasiveness.46,47 GBM 6 also expresses wild-type PTEN, a key tumor suppressor protein in the 
PI3K/Akt/mTOR signaling cascade.42 In comparison, GBM 26 has a missense mutation at the 289 
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position of EGFR with an alanine-to-threonine substitution and does not contain the truncation of 
the extracellular domain as with EGFRvIII.42 GBM 26 also lacks PTEN expression caused by 
homozygous PTEN gene activation. 
Inhibition of EGFR with Erlotinib. Erlotinib is a potent inhibitor of EGFR and blocks 
the ATP binding domain of EGFR with an IC50 of 20 nM in vitro, preventing autophosphorylation 
of EGFR.48, and the treatment is approved for the treatment of non-small-cell lung cancers 
(NSCLC).49,50 Despite multiple clinical trials exploring the efficacy of erlotinib for treating GBM, 
improvements in patient survival have not matched the success observed with NSCLC.51,52 GBM 
6 has been previously shown to not have erlotinib sensitivity.42 In the same study, mice with 
intracranial tumors from the GBM 26 xenograft line did not show extended survival times with 
GBM 26 treatment. 
Distinct profiles for each of the cell lines are observed when examining the phosphoprotein 
profiling from the microring resonators for downstream signaling in response to the EGFR 
inhibition with erlotinib. The phospho-Akt, phospho-S6 ribosomal protein, phospho-mTOR, and 
phospho-MAPK levels for the GBM 6 remain unchanged as a function of erlotinib treatment, 
whereas those for GBM 26 show a marked decrease from the 1 h to 24 h time points and in 
comparison to the control treatment of media without serum (Figure 5.2). The full phosphoprotein 
signaling data are provided in Figure 5.3. 
Inhibition of PI3K. GNE-317 is an inhibitor of the PI3K pathway that is of interest for the 
treatment of GBM due to its ability to pass the blood brain barrier (BBB).53 In previous studies, 
treatment with GNE-317 has been shown to rapidly and substantially reduce pAkt and pS6 
signaling upon administration in orthotopic models of GBM.53 In the present study, GNE-317 
treatment of both GBM 6 and GBM 26 resulted in substantial reduction in downstream markers of 
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PI3K signaling (Figure 5.4). These results are in line with previous studies that indicated potent 
inhibition of PI3K signaling in response to treatment with GNE-317. Additionally, GBM 26 
appears to show more rapid and pronounced reduction in PI3K signaling as compared to GBM 6. 
These results are interesting given the PTEN status of each line. The GBM 26 cell line is known 
to have lost PTEN expression, which reduces the cellular regulation of PI3K signaling, and the 
phosphoprotein profiling suggests more pronounced response to PI3K pathway inhibition. The 
phosphoprotein panel for all targets measured are provided in Figure 5.5. 
Apitolisib was also used as an inhibitor of the PI3K signaling pathway. This drug is a dual 
inhibitor of class I PI3K and of mTOR with current interest in the treatment of solid tumors.54 
However, in comparison to GNE-317, apitolisib shows reduced BBB penetration.53 The pAkt 
signaling appears to be largely unchanged after treatment with apitolisib for GBM 6, though there 
is significant reduction for other markers in the pathway, including pGSK-3β and pS6 (Figure 
5.6a). In contrast, GBM 26 appears to show near complete collapse of all markers downstream of 
the apitolisib targets (Figure 5.6b). See Figure 5.7 for the full panel of phosphoprotein levels 
measured for apitolisib treatments. 
Inhibition of Cyclin-Dependent Kinases. Palbociclib is an inhibitor of cyclin-dependent 
kinases CDK4 and CDK6 that is approved for the treatment of both estrogen receptor-positive and 
HER2-negative breast cancer.55,56 Given the success of palbociclib with breast cancers, there is 
interest in applying it to the treatment of brain cancers, such as GBM.57 A recent investigation by 
Jansen et al58 indicated that PDK1 may play a role in developing resistance to CDK4/6 inhibitor 
therapy as applied to breast cancer. This is potentially indicative of activation of the 
PI3K/Akt/mTOR pathway and prevention of cell cycle arrest with CDK4/6 inhibitor alone. These 
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results indicate that our phosphoprotein panel is potentially well-suited to study resistance to 
palbociclib or other CDK4/6 inhibitors. 
Palbociclib is likely a good candidate for treatment of GBM 6 as indicated by sharp 
reductions in signal observed for pRb relative to control samples (Figure 5.8). pRb signal was 
substantially reduced even after the 1 h treatment and the level of reduction increased at the 24 h 
time point (Figure 5.9). Reduced pRb was also observed for the GBM 26 samples, although the 
change was less pronounced because these cells already demonstrated substantially reduced pRb 
in control samples (Figure 5.9). There do not appear to be any marked upregulations in PI3K 
signaling in comparison to the control, but the resistance mechanism observed in the study by 
Jansen et al was only observed after prolonged treatment with CDK4/6 inhibitors.58 
Comparison of Microring Resonators to Other Multiplex Protein Detection 
Technologies. A number of approaches have been used for protein and phosphoprotein detection 
for tumor analysis. A comprehensive review of diagnostic protein detection technologies is beyond 
the scope of the present study, though these technologies have been reviewed recently.59–61 Single- 
and multiple-reaction monitoring mass spectrometry (MS) are targeted proteomic approaches that 
sacrifice the global breadth other MS-based approaches can achieve in exchange precise 
quantitation and higher sample throughput.62,63 Affinity-based methods include multiplexed 
enzyme-linked immunosorbent assays (ELISA),64 reverse-phase protein arrays (RPPAs),65–67 
antibody microarrays,68,69 and bead-based microarrays.70–73 The advantages of the platform include 
real-time monitoring of binding events, integrated fluidic handling for semi-automated sensor 
operation, and low limits of detection (LODs) extending to 100s of fg/mL for protein detection 
applications. In comparison to the approaches described above, the microring resonator platform 
offers a reduced assay time of 1-2 h, which is an improvement upon most array-based methods. In 
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addition, the use of a sandwich immunoassay can result in enhanced specificity in comparison to 
a single antibody-antigen interaction. The limitations of the microring resonator platform include 
lower sample throughput than the RPPA platform since only a single sample is analyzed per assay 
and the reliance on antibody pairs precludes the detection of targets where those pairs are 
commercially available. 
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4.5 Tables and Figures 
Table 4.1. Antibodies from phosphoprotein panel 
Target Clone Role Cat. No. 
Phospho-GSK-3β Thr389 D85E12 Capture 5558 
GSK-3β D5C5Z Tracer 12456 
Phospho-p70 S6 Kinase Thr389 108D2 Capture 9234 
p70 S6 Kinase 49D7 Tracer 2708 
p-PDK1 Ser241 C49H2 Capture 3438 
PDK1 D4Q4D Tracer 13037 
Phospho-S6 Ser235/236 D57.2.2E Capture 4858 
Phospho-S6 Ser240/244 D68F8 Capture 5364 
S6 Ribosomal Protein 5G10 Tracer 2217 
Phospho-mTOR Ser2448 D9C2 Capture 5536 
mTOR 7C10 Tracer 2983 
Phospho-Akt Ser473 D93 Capture 4060 
Phospho-Akt Thr308 L32A4 Capture 5106 
Akt C67E7 Tracer 4691 
Phospho-p44/42 MAPK Thr202/Tyr204 D13.14.4E Capture 4370 
p44/42 MAPK 137F5 Tracer 4695 
Phospho-Rb Ser780 D59B7 Capture 8180 
Phospho-Rb Ser807/811 D20B12 Capture 8516 
Rb 4H1 Tracer 9309 
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Table 4.2. Small molecule treatments for xenograft samples 
Drug Name Type Target Company Structure 
Ibrance 
(Palbociclib)  
Small 
Molecule  
CDK4 Pfizer 
 
Tarceva 
(Erlotinib) 
Small 
Molecule 
EGFR Roche 
(Genentech) 
 
GNE-317 Small 
Molecule 
PI3K Roche 
(Genentech) 
 
GDC-0980 Small 
Molecule 
PI3K Roche 
(Genentech) 
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Table 4.3. Phosphoprotein detection assay 
Reagent Flow Rate 
(μL/min) 
Time  
(min) 
Starting Block 40 8 
Running Buffer 40 3 
Running Buffer [Start Scan] 40 2 
Cell Lysate (150 μg/mL) 30 10 
Running Buffer 40 2 
Tracer Antibody (1 ug/mL) 30 10 
Running Buffer 40 2 
SA-HRP (2 ug/mL) 30 10 
Running Buffer 40 2 
4-Chloronaphthol Solution 30 10 
Running Buffer [Stop Scan] 40 5 
Running Buffer 40 3 
 
 
 
 
Figure 4.1. Spotting map of phosphoprotein detection panel.  
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Figure 4.2. Treatment of xenograft samples with erlotinib. Phosphoprotein levels of GBM 6 
(A) and GBM 26 (B) cells treated with the EGFR inhibitor erlotinib for pAkt Thr308, pAkt Ser473, 
pMAPK Thr202/Tyr204, pmTOR Ser2448, pS6 Ser235/236, and pS6 Ser240/244 indicate the 
extent of suppression of the signaling cascade downstream of EGFR.
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Figure 4.3. Treatment of xenograft samples with erlotinib - expanded panel. This is the full 
phosphoprotein panel separated by cell line and time points. 
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Figure 4.4. Treatment of xenograft samples with GNE-317. Phosphoprotein levels of GBM 6 
(A) and GBM 26 (B) cells treated with the PI3K pathway inhibitor GNE-317 were monitored over 
time. This is a selected panel of pAkt Thr308, pAkt Ser473, pGSK-3β Ser9, pmTOR Ser2448, pS6 
Ser235/236, and pS6 Ser240/244 from the full phosphoprotein panel as an indication of 
suppression of the PI3K/Akt/mTOR signaling cascade.
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Figure 4.5. Treatment of xenograft samples with GNE-317 - expanded panel. This is the full 
phosphoprotein panel separated by cell line and time points for treatment with GNE-317. 
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Figure 4.6. Treatment of xenograft samples with apitolisib. Phosphoprotein levels of GBM 6 
(A) and GBM 26 (B) cells treated with the dual PI3K/mTOR inhibitor Apitolisib (GDC0980) were 
monitored over time. This is a selected panel of pAkt Thr308, pAkt Ser473, p-GSK-3β Ser9, 
pmTOR Ser2448, pS6 Ser235/236, and pS6 Ser240/244 from the full phosphoprotein panel as an 
indication of suppression of the PI3K/Akt/mTOR signaling cascade.
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Figure 4.7. Treatment of xenograft samples with apitolisib - expanded panel. This is the full 
phosphoprotein panel separated by cell line and time points for treatment with Apitolisib. 
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Figure 4.8. GBM 6 and GBM 26 phosphoprotein levels with no treatment. This is the full 
phosphoprotein panel separated by cell line and time points for no treatment. 
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Figure 4.9. Treatment of xenograft samples with palbociclib. Phosphoprotein levels of GBM 6 
(A) and GBM 26 (B) cells treated with the CDK4 inhibitor Palbociclib were monitored over time. 
This is a selected panel of pGSK-3β Ser9, pPDK1, pRb Ser780, and pRb Ser807/811 from the full 
phosphoprotein panel as an indication of disruption of cell cycle signaling.
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5.1 Abstract 
Membrane proteins remain an analytical challenge because of their poor activity under 
non-native conditions, limited solubility in aqueous solutions, and low expression in most cell 
culture systems. Nanodiscs represent a potential solution to those challenges as they are soluble, 
protein-stabilized phospholipid bilayers that provide a native-like environment and have been 
widely used to study membrane proteins. Capitalizing on sample preservation and small volume 
processing inherent to miniaturization and microfluidics, we have developed a method for 
incorporation of membrane proteins into Nanodiscs that combines Nanodisc assembly and 
purification into an integrated microfluidic platform we call μNAP (microfluidic Nanodisc 
Assembly with Purification). Our approach simplifies bulk scale membrane protein incorporation 
into Nanodiscs from a multi-stage protocol encompassing several hours to days into a single 
platform that outputs purified Nanodiscs in less than one hour. To demonstrate the μNAP’s utility, 
we have incorporated Cytochrome P450 into Nanodiscs of variable size and composition. This 
approach enables tremendous depth for optimizing the incorporation of membrane proteins by 
using microfluidic gradients to rapidly screen Nanodisc components. 
5.2 Introduction 
Membrane proteins play pivotal roles in cellular processes as the primary units of 
biomolecule transport and cellular communication. Because of their importance, membrane 
proteins are the most common targets for pharmaceutical agents.1,2 Key to the study of membrane 
proteins is maintaining protein function in vitro. Purified membrane proteins exhibit substantially 
reduced activity outside of a native lipid bilayer environment, primarily because of protein 
misfolding under aqueous conditions.3–7 Soluble lipid bilayer systems, such as protein-lipid 
micelles and liposomes act as a water-soluble and semi-native environment, which allows 
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characterization of many membrane proteins.4,8,9 Though these systems have been used 
extensively for structural and functional studies with membrane proteins, notable limitations 
remain. For instance, liposome preparations often have high viscosities or are turbid, a major 
challenge for cell-free expression systems and in biophysical interrogation of protein activity.10,11 
Proteins solubilized in detergent micelles often demonstrate structural changes caused by the non-
native environment.5 
Nanodiscs are soluble, protein stabilized discoidal lipid bilayers and an alternative to 
liposomes and micelles for membrane protein studies.12 They vary in size from 6-17 nanometers 
in diameter and offer a native-like lipid bilayer environment for incorporation of membrane 
proteins. Nanodiscs are remarkably homogenous and stable in aqueous solutions in comparison to 
liposomes, micelles, or other soluble lipid bilayer systems, such as those made with styrene-maleic 
acid copolymers.13–15 Beyond bilayer and protein stability, Nanodiscs have added advantages of 
access to both sides of the bilayer and precise control of bilayer composition, stoichiometry, and 
size.16–18 The size of Nanodiscs is determined by the length of amphipathic helical protein belts, 
known as membrane scaffold proteins (MSP), that wrap around the discoidal phospholipid bilayer 
that contributes to the stability to the nanoparticle. MSPs are modifications of apolipoprotein, 
ApoA1, with tunable lengths and engineered residues for facile bioorthogonal reactivity. Control 
over the size of Nanodiscs allows for the incorporation of mono- or dimeric membrane proteins or 
even the incorporation of multiprotein complexes, which can be vital for maintaining protein 
function.19–21 The enhanced functionalities of Nanodiscs have resulted in their wide adoption as 
the preferred lipid bilayer mimetic system across diverse facets of membrane protein biology.12,22 
Conventional Nanodisc assembly is achieved by solubilizing phospholipids and membrane 
proteins with detergents in the presence of a membrane scaffold protein (MSP). Upon removal of 
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detergent, Nanodiscs self-assemble with MSP wrapping around a discoidal phospholipid bilayer 
with an integrated membrane protein.16,23 A variety of membrane proteins have been incorporated 
into Nanodiscs, demonstrating the generality of the platform.12,22,24 Though previous work serves 
as a useful guide for incorporating a new protein into Nanodiscs, the optimal conditions for 
Nanodisc assembly with a novel protein of interest must be determined experimentally - a 
challenge common to all solubilization systems. Previous approaches to novel protein assembly 
into Nanodiscs require serially screening through the range of conditions to optimize Nanodisc 
assembly and preserve protein function. Optimization typically requires screening several 
detergents and phospholipids as well as determining ideal ratios of reagents (e.g., phospholipid to 
MSP ratio). This laborious task often consumes unacceptably large amounts of starting material, 
which precludes the study of many membrane proteins that are difficult to express or can only be 
found at low levels.  
Despite rigorous efforts to simplify protein expression and extraction with better 
engineered DNA constructs and expression systems, the stable and active incorporation of proteins 
into Nanodiscs remains the rate limiting step for many membrane protein studies.6,25 Recombinant 
protein expression is  notoriously challenging, with low yields and limited stability substantially 
hampering research efforts.7,26,27  Expanding the application of Nanodiscs to these challenging, 
valuable proteins of interest demands an alternative approach capable of optimizing membrane 
protein incorporation while consuming minimal amounts of sample. Microfluidic technologies 
have emerged as a robust and reliable approach to mimic and improve upon bulk scale protocols 
in molecular biology.28–30 Capitalizing on the precise fluidic handling of minuscule reagent 
volumes, these approaches can shrink sample volumes to the nanoliter scale and often reduce 
analysis times by similar magnitudes. In addition to miniaturization, parallelization and modularity 
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have been used to improve protein processing and characterization.31–35 This study describes an 
integrated platform for Nanodisc assembly and purification called μNAP (microfluidic Nanodiscs 
Assembly with Purification, Scheme 5.1). 
The μNAP platform achieves Nanodisc assembly on the microfluidic scale without 
observed loss of Nanodisc composition or incorporated membrane protein activity. The 
microfluidic approach shortens the time of Nanodisc assembly and reduces the consumption of 
membrane protein sample. The purification module of the μNAP platform can be directly 
interfaced with Nanodisc assembly, and the platform size is tunable, allowing processing of larger 
sample inputs. Importantly, the platform incorporates multiple inlets for on-chip reagent mixing at 
user-defined ratios. The multiport design can be applied to systems where prolonged reagent 
mixing results in deleterious effects, such as reduced protein activity after exposure to detergents. 
In addition, dynamically altering reagent mixing ratios over time creates microfluidic gradients 
that can be used to sweep through the range of possible conditions for membrane protein 
incorporation into Nanodiscs in a single experiment. This approach (Scheme 5.1) enables 
unprecedented depth for the optimization of Nanodisc assembly. The utility of the the platform is 
demonstrated by characterization of Nanodiscs without incorporated protein (termed empty 
Nanodiscs) of variable lipid composition and with the incorporation of Cytochrome P450, a protein 
extensively well-characterized using Nanodiscs.11,12 
5.3 Results and Discussion 
Design of the μNAP Platform. The μNAP platform is modular and can be divided into 
two primary functions: (1) Nanodisc assembly and (2) purification of assembled Nanodiscs. The 
Nanodisc assembly consists of (1) reagent inlets, (2) a larger inlet for loading resin material, (3) a 
packed bed of detergent removal resin, and (4) an outlet for the collection of Nanodiscs (Figure 
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5.1a). Mixing of Nanodisc reagents can be performed either on- or off-chip. For on-chip mixing, 
the devices include multiple reagent inlets and a serpentine mixing chamber with alternative jutting 
structures to ensure efficient mixing (Figure 5.1b). The bead bed consists of capture structures at 
the inlet and outlet of the bed along with posts for structural support throughout the bed. The 
current design uses a three-port reagent inlet for on-chip mixing and a bed volume of either 20 or 
60 μL, though the modularity of the platform allows for significant variation of individual device 
design tailored to the experimental demands (Figure 5.2). Flow through the various device designs 
was visualized with dye, demonstrating rapid and efficient mixing for multiport devices (Figure 
5.3). Nanodiscs assemble spontaneously upon removal of detergent, which is demonstrated for 
two types of bile-salt detergents: sodium cholate and 3-((3-cholamidopropyl) dimethylammonio)-
1-propanesulfonate (CHAPS) (Figure 5.4). The composition of detergent removal resin is 
proprietary, but the resin has been shown to efficiently remove a wide variety of detergents with 
high recovery of protein.36 A variety of detergents have been used for lipid solubilization and 
Nanodisc assembly, and detergent choice is typically dictated by the stability of the membrane 
protein target.4,12 
The purification module is designed and fabricated in a similar fashion as the Nanodisc 
assembly device. Conceptually, both rely on microstructures to capture bead-based resins to 
perform the device functions. The module employs affinity purification to selectively capture and 
elute Nanodisc material. The purification module can be integrated directly downstream of the 
Nanodisc assembly module or as a standalone device. The standalone design consists of a (1) 
single inlet, (2) a packed bed of affinity purification resin, and (3) an outlet for the collection of 
purified Nanodisc material (Figure 5.1c). Directly interfacing assembly and purification modules 
requires an additional set of inlet and outlet ports with a flow direction perpendicular to the flow 
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from the assembly module (Figure 5.1d). In the present study, Ni-nitrilotriacetic acid (Ni-NTA) 
agarose resin is used as the affinity resin for purification, although other purification systems are 
compatible with the current design (e.g., immunoaffinity purification). 
For both modules, microfluidic devices were fabricated from polydimethylsiloxane 
(PDMS) stamps bonded to glass using a standard soft lithography approach.[REF, whitesides 
paper and nature protocol] Briefly, a master mold was fabricated using 2-D photolithography with 
silicon wafers and an epoxy-based negative photoresist. PDMS stamps were made from the master 
molds and plasma bonded to glass. 
Microfluidic Nanodisc Assembly. Proof-of-concept experiments were performed to 
demonstrate microfluidic assembly of Nanodiscs without incorporation of a membrane protein. In 
addition to providing a less complex system for assessing Nanodisc assembly, Nanodiscs of 
precise lipid composition are useful mimics of a lipid bilayer for interrogating protein-lipid 
interactions that are fundamental to a number of biological processes, such as the blood 
coagulation cascade.37–39 These initial experiments were performed using both 1,2-dimyristoyl-sn-
glycero-3-phosphocholine (DMPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC). For these experiments, two varieties of MSP were used, either MSP1D1 or MSP1E3D1. 
MSP1D1 results in Nanodiscs of 9.7 nm in diameter with 120 to 160 lipids per Nanodisc, 
depending on the packing density of the lipids. Each Nanodisc consists of two MSPs, resulting in 
a lipid:MSP ratio of 60:1 to 80:1 for MSP1D1. MSP1E3D1 results in Nanodiscs of 12.7 nm in 
diameter with lipid:MSP ratios ranging from 120:1 to 150:1.16 
The Nanodisc reagents were mixed off-chip and then flowed across the packed bed of 
detergent removal resin. The single-port inlet device design is used with off-chip reagent mixing, 
and Nanodisc assembly takes place immediately upon removal of detergent as the solution flows 
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across the packed bed. Size exclusion chromatography (SEC) was used to assess Nanodisc purity, 
size, and dispersity (Figure 5.5a-b). The chromatograms show a single, narrow peak at the 
appropriate elution times relative to a mixture of protein standards. As an orthogonal validation of 
Nanodisc assembly, atomic force microscopy (AFM) was used. (Figure 5.5c). Eluent was taken 
directly from the assembly module, and no further preparation or purification was performed prior 
to AFM analysis. Nanodisc dispersity was also analyzed with dynamic light scattering (DLS) 
(Figure 5.5d). Nanodisc assembly was not dependent upon device flow rate, ranging from 1 
μL/min to 100 μL/min (Figure 5.6). The detergent removal capacity for the most commonly used 
assembly module (60 μL bed volume) is approximately 1 mg of detergent, determined 
experimentally with both sodium cholate and CHAPS (Figure 5.4). Once the detergent capacity 
is reached for a given bed volume, the detergent removal resin can be regenerated by rinsing with 
methanol. Nanodisc assembly can be performed repeatedly on a single device with no observable 
degradation in Nanodisc quality. 
For the single port detergent removal module, all reagents are combined off-chip. The 
multi-port detergent removal device design allows on-chip reagent mixing so that the Nanodisc 
components are only combined immediately before detergent removal and Nanodisc assembly. A 
device with three inlet ports (Figure 5.2b) was used for Nanodisc assembly with both DMPC and 
POPC. The three inlets were used to flow: (1) detergent solubilized phospholipids, (2) MSP, and 
(3) running buffer. There were no observed differences in Nanodisc quality as compared to 
premixing with single port devices (Figure 5.7).  
Using the multi-port design, the composition of the Nanodiscs can be altered by changing 
the flow rates from each of the ports. A simple example of this is to change the flow rate of running 
buffer to tune the final concentration of Nanodiscs formed with the device. The inlet flow rates 
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can be dynamically tuned over time to generate microfluidic gradients for Nanodisc assembly. To 
demonstrate this capability, we used a programmable syringe pump to dynamically change the the 
lipid composition of Nanodiscs over time. Nanodisc lipid composition was determined by using a 
fluorescent phospholipid. For these experiments, the phospholipids were DMPC and 1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (LR-PE). 
For the 3-port inlet, the flow rate for the MSP containing inlet was held constant, the DMPC inlet 
was decreased, and the fluorescent lipid was increased  over the course of the microfluidic gradient 
(Figure 5.8a). The fluorescence intensity associated with the LR-PE lipid steadily increased with 
elution volume (Figure 5.8b). Tunable lipid composition constructed with microfluidic gradients 
could prove a valuable tool for protein-lipid interactions, such as the blood coagulation 
cascade.38,39  
Incorporating Cytochrome P450 3A4 into Nanodiscs. To demonstrate the μNAP 
platform’s utility for the incorporation of membrane proteins into Nanodiscs, cytochrome P450 
3A4 (CYP3A4) was used as a model system. Cytochromes P450 are ubiquitous membrane-
associated proteins that predominantly serve as oxidase enzymes in electron transfer chains.40 
CYP3A4 is the most abundant cytochrome P450 expressed in the human liver and small intestines. 
Approximately half of small molecule pharmaceuticals are thought to be metabolized by 
CYP3A4.41 CYP3A4 tends to aggregate in solution after isolation and purification, but the 
incorporation of CYP3A4 into Nanodiscs prevents aggregation in addition to allowing precise 
control over the protein’s oligomeric state.42 The role of CYP3A4 in drug metabolism has 
motivated a wide variety of studies incorporating CYP3A4 into Nanodiscs.11,42–47 As such, 
CYP3A4 is an attractive model system for assembly of proteins into Nanodiscs using the μNAP 
platform. 
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Using the single port inlet device, the CYP3A4 protein was found to readily incorporate 
into Nanodiscs (Figure 5.9a). The heme cofactor found in CYP3A4 provides a useful 
spectroscopic tool for observing protein incorporation in Nanodisc. When the CYP3A4 active site 
is unoccupied, the heme cofactor absorbs at 417 nm, a spectrally quiet region for Nanodiscs 
without CYP3A4 incorporation. SEC characterization of Nanodisc assembly was performed by 
scanning at 280 nm for general protein absorbance and at 417 nm for the heme cofactor of 
CYP3A4. The Nanodisc elution peak shows strong absorbance at 280 nm, indicative of Nanodisc 
assembly along with absorbance at 417 nm, indicating CYP3A4 incorporation. The hydrodynamic 
radius of Nanodiscs with incorporated CYP3A4 is expected to be slightly larger than Nanodiscs 
with DMPC and MSP alone, which results in the 417 nm peak center shifting to an earlier elution 
than the 280 nm peak center. 
The activity of membrane proteins often decreases after prolonged exposure to detergents.4 
For particularly sensitive classes of membrane proteins, the exposure to potentially denaturing or 
deactivating detergents should be minimized. The multi-port Nanodisc assembly module 
minimizes membrane protein exposure to detergents by combining Nanodisc reagents on-chip 
immediately before Nanodisc assembly. Comparison of on-chip mixing using a multiport device 
and off-chip mixing using a single inlet device as analyzed with SEC shows CYP3A4 
incorporation is readily achieved with both methods (Figure 5.10). 
On-Chip Purification after Nanodisc Assembly. As described above, the Nanodisc 
assembly module produces well-formed Nanodiscs of homogenous distribution. The incorporation 
of membrane proteins into Nanodiscs, as with all other lipid bilayer systems, does not result in the 
incorporation of all solubilized membrane proteins into Nanodiscs. As such, membrane protein 
aggregates that can interfere with downstream assays of membrane protein structure of function 
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will remain in the sample after Nanodisc assembly. Often the most time-consuming process when 
using Nanodiscs for membrane protein studies is purification.23 Two approaches are typically 
combined for this process: affinity purification and fractionation with SEC. Each step can result in 
loss of Nanodisc product or dilution of Nanodiscs, requiring additional processing steps to achieve 
the desired Nanodisc concentration. To improve the purification process, we designed an affinity 
purification module for the μNAP platform, as described above (Figure 5.1c-d). Ni-NTA was used 
for affinity-based purification. MSP1D1 and MSP1E3D1 scaffold proteins have N-terminal His-
tags to allow for efficient Nanodisc purification (Scheme 5.2). 
 The binding capacity of Ni-NTA is approximately 1 mg protein per 1 mL of resin . 
Therefore, when the purification module is operated as a standalone unit (i.e., not directly 
interfaced with the assembly module), Nanodiscs collected from multiple assembly devices can be 
purified using a single purification device. A comparison of Nanodiscs with incorporated CYP3A4 
before and after purification is provided in Figure 5.9b. The SEC analysis of unpurified Nanodiscs 
shows an aggregate peak that elutes prior to the main Nanodisc peak, likely corresponding to 
CYP3A4 aggregates. The aggregates are not retained on the affinity purification column, and do 
not appear in SEC analysis after purification. 
Spectroscopic Studies and Activity Assay with CYP3A4 Containing Nanodiscs. 
Nanodiscs with incorporated cytochromes P450 have been used previously for spectroscopic 
investigations into substrate binding.11 In these studies, characteristic spectroscopic shifts are 
monitored as a function of substrate concentration. Small molecule binders of CYP3A4 are 
classified as type I or type II, as determined by the resulting spectroscopic shifts. The spectral 
changes are a result of spin state of the 3d electrons of the Fe3+ in the heme cofactor. Type I binders 
induce a change in the coordination of Fe3+ from six- to five-coordinate with a corresponding 
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decrease in the Soret absorption band (417 nm) and increase in absorbance at 390 nm.48 To 
demonstrate type I binding with CYP3A4-containing Nanodiscs assembled with the μNAP 
platform, bromocriptine, a type I binder of CYP3A4, was titrated into the Nanodisc solution 
resulting in a reduction in the absorbance at 417 nm and an increase at 390 nm (Figure 5.11a). 
Type II binders of CYP3A4 have an unobstructed nitrogen atom that coordinates with Fe3+ 
resulting a six-coordinate geometry at the activation site and a shift in maximal absorbance from 
417 nm to 422 nm. Imidazole is a type II binder of CYP3A4 and is present in the elution buffer 
for the purification module. Figure 5.11b shows the absorbance spectrum for CYP3A4 containing 
collected from the purification module before and after dialysis to remove imidazole. Taken 
together, these results represent proof-of-concept for spectroscopic investigation of proteins 
incorporated into Nanodiscs assembled with the μNAP platform. 
5.4 Conclusions 
Nanodiscs have emerged as the preferred system for investigations of membrane protein 
structure and function. The primary benefits of Nanodiscs as a native-like lipid bilayer mimic are 
precise control over Nanodisc size and composition as well as long term stability. The μNAP 
platform reproduces the Nanodisc assembly and purification processes on a microfluidic scale that 
produces the same quality of Nanodiscs as bulk processes but consuming fractional amounts of 
precious membrane protein material. Additionally, the μNAP design incorporated multiport inlets 
that can be used for on-chip reagent mixing immediately prior to Nanodisc assembly to maximize 
the likelihood of generating Nanodiscs with functional membrane proteins. By independently 
tuning the flow rate of individual reagents over time with microfluidic gradients, Nanodiscs of 
variable composition can be assembled within a single experiment. This expands the current 
toolset for Nanodiscs, which could prove vital when screening novel membrane proteins with 
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unoptimized conditions for incorporation into Nanodiscs. The next steps for the microfluidic 
platform will be to form Nanodiscs from more variable starting materials, such as whole cell 
lysates. Nanodisc assembly with cell lysates have been made previously as Nanodisc libraries.49,50 
These libraries have been shown to accurately reflect the membrane proteome. Nanodisc library 
generation could particularly benefit from the μNAP approach as many of these samples will have 
limited material that requires small volume processing abilities. 
5.5 Experimental Methods 
Materials. Amerlite XAD-2 hydrophobic beads, ethylenediaminetetraacetic acid (EDTA), 
dimethyl sulfoxide, 3-[(3-Cholamidopropyl)dimethylammonio]-1- propanesulfonate (CHAPS), 
sodium cholate, and all other chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA) 
unless otherwise indicated. Pierce Detergent Removal Resin was purchased from ThermoFisher 
Scientific (Waltham, MA, USA). The phospholipids 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1-palmitoyl-2-oleoyl- sn-glycero-3-phosphocholine (POPC), and 1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Liss Rhod 
PE) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). The membrane scaffold 
proteins (MSP) used were MSP1D1 and MSP1E3D1, which were expressed and purified as 
previously described.16,17 Cytochrome P450 3A4 (CYP3A4) was expressed from the NF-14 
construct in the pCWOri+ vector with a histidine affinity tag. CYP3A4 was purified and 
incorporated into Nanodiscs as previously described.47,51–53 All buffers were prepared with 
deionized water and filtered prior to use. 
Microfluidic Design & Fabrication. Microfluidic device masters were designed using 
AutoCad (Autodesk Inc., San Rafael, CA), and photomasks were printed by CAD/Art 
Services,Inc.(Bandon, OR, USA). SU-8 2100, an epoxy-based negative photoresist, was purchased 
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from Microchem (Westborough, MA, USA) and used to fabricate masters according to standard 
2D-photolithography methods.54 Device features were designed to be 200 μm in height, which was 
validated with profilometry. Polydimethylsiloxane (PDMS) was purchased from Momentive 
(Waterford, NY, USA) under the name RTV615 silicone rubber kit. The two-part mixture was 
combined 10:1 monomer:initiator, thoroughly mixed, and degassed under vacuum prior to pouring 
onto the negative master mold. PDMS was cured at 70°C for a minimum of 1 h. Device stamps 
were cut out of the PDMS mold, and access ports were added using Integra Miltex biopsy punches. 
Stamps were cleaned with Scotch Magic Tape to remove dust and other particulates prior to 
bonding to glass slides. 
Silastic tubing with an inner diameter of 0.040” (Dow Corning, Midland, MI, USA) was 
used for the bead filling port, and 0.022” inner diameter Teflon tubing (Cole-Parmer, Vernon Hills, 
IL, USA) was used for all other ports. Filling of the bead bed was performed using either a custom 
built pressure system or manually with a disposable syringe attached to the Silastic tubing. For 
manual filling, a density-balanced bead slurry was prepared from Pierce Detergent Removal Resin, 
Optiprep density gradient medium, and water. To prevent the loss of beads, the bead inlet tubing 
was clamped with a hemostat. 
Microfluidic Nanodisc Assembly. Prior to Nanodisc assembly, all devices were washed 
with a methanol rinse of at least 20 min at 30 μL/min followed by a water rinse of at least 10 min 
at the same flow rate. Detergent bead beds could be regenerated first rinsing device with water for 
10 min and then following the same washing procedure for new devices. The lower limits of 
rinsing times were not determined, but wash times could likely be shortened. Phospholipids used 
for Nanodisc assembly were stored in chloroform at -20°C. Prior to use, the phospholipids were 
dried to a lipid film and stored under vacuum for a minimum of 4 h. Nanodisc reagents were 
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prepared in Standard Disc Buffer (20 mM Tris HCl pH 7.4, 0.1 M NaCl, 0.5 mM EDTA, and 
0.01% NaN3). In cases where temperature control was needed, the microfluidic device was placed 
directly into a temperature controlled environment. For our experiments, that was needed only for 
Nanodisc assembly with POPC lipids, which is optimum at 4°C. For POPC experiments, the 
devices were placed on ice. 
Nanodisc Assembly with Single Port Devices. Reagents for Nanodisc assembly were 
prepared according to desired ratios for lipid:MSP and MSP:CYP3A4. Table 5.1 provides an 
example reagent sheet for Nanodisc assembly with a single port device. Reagents were mixed 
immediately prior to Nanodisc assembly, loaded into a syringe, and flowed through the device. 
The typical flow rate used for single port devices was 30 μL/min controlled by a Pump 11 Pico 
Plus Elite Dual Syringe Pump from Harvard Apparatus (Holliston, MA, USA). The eluent was 
collected in fractions from 5-100 μL and analyzed with SEC and/or AFM. 
Nanodisc Assembly with Multi-Port Devices. Multi-port devices were prepared following 
the sample protocol as single port devices. The reagents were divided into three syringes: (1) lipid 
with detergent, (2) MSP with detergent, (3) either buffer or membrane protein of interest. An 
example reagent sheet for a multi-port device is provided in Table 5.2. Reagent concentrations 
were determined such that optimal reagent ratios were achieved when all syringes flowed at the 
same rate, usually 10 μL/min for each syringe. Gradient experiments were performed by changing 
the flow rate of one of the syringes. The Pico Plus Elite pumps can be programmed with linear 
gradients for automated gradient experiments. See Figure 5.8 for additional details on the 
microfluidic gradients. 
Colorimetric Quantitation of Detergent Removal. The amount of either sodium cholate 
or CHAPS in a solution can be determined colorimetrically by oxidation of the detergents with 
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concentrated sulfuric acid. To quantitate the detergent removal capacity of the devices, detergent-
containing solutions were flowed across the packed beds of the devices and fractions were 
collected from the eluent. The concentration of detergent in each fraction was quantified according 
to a previously described method (Figure 5.4).55 
Nanodisc Characterization by Size Exclusion Chromatography. Eluent fractions 
collected from the microfluidic devices were characterized by size exclusion chromatography 
(SEC) to assess the quality of Nanodisc assembly. Fractions were injected onto a Superdex 200 
Increase 3.2/300 or 10/300 column (GE Healthcare, Pittsburgh, PA, USA). The 3.2/300 column 
was operated at a flow rate of 0.75 mL/min, and the 10/300 column was operated at a flow rate of 
50 μL/min. Absorbances were monitored at 280 nm to monitor Nanodisc formation and 417 nm 
to monitor CYP3A4 incorporation into Nanodiscs. The following protein standards were used with 
the associated known hydrodynamic radius: Thyroglobulin (17 nm), Ferritin (12.2 nm), Bovine 
Liver Catalase (10.4 nm), and Bovine Serum Albumine (7.1 nm). 
Nanodisc Characterization by AFM. Characterization of Nanodiscs with atomic force 
microscopy (AFM) was performed with a Cypher ES Environmental AFM (Asylum Research, 
Santa Barbara, CA, USA) equipped with a fluid cell. To prepare the surface for Nanodisc analysis, 
mica was glued to a stainless steel disc and cleaned with cellophane tape. Nanodiscs were diluted 
between 10 and 100 fold, and 10 μL of diluted sample was applied to the mica surface. The surface 
was then rinsed with 10-20 μL of imaging buffer (10 mM Tris-HCL pH 7.4, 0.15 M NaCl, 10 mM 
MgCl2). A PAP pen (Ted Pella Inc,. Redding, CA, USA) was used to circumscribe an area of mica 
with a hydrophobic border, which was used to prevent flow of solution off of the mica. After 10 
min, 5-10 mL of imaging buffer was passed through the cell to remove any unadsorbed material. 
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The sample was then mounted onto the imaging stage. Contact imaging was performed under 
imaging buffer with a thin-legged 310 μm cantilever with a nominal spring constant of 0.01 N/m. 
Nanodisc Purification with Affinity Chromatography. A slurry of Ni-NTA agarose 
resin was prepared in water. Using a syringe, methanol and water of sufficient volume to 
completely fill the device (approximately 100 μL each) were pushed through the device by hand. 
A syringe was then filled with Ni-NTA slurry and an 18 gauge needle was attached to the syringe 
with silastic tubing securely nested over needle. The silastic tubing was inserted into the filling 
port, and the resin bed was filled by applying steady pressure to the syringe plunger. Once the 
device was filled, the silastic tubing was clamped immediately above the filling port with either a 
hemostat or cable tie. To prepare the filled device for purification, the device was washed with 4 
bed volumes of water followed by 8 bed volumes of Purification Buffer (250 mM NaH2PO4, pH 
8.0 50 mM NaCl) at a flow rate of 30 μL/min. The Nanodisc solution was then flowed across the 
packed bed at a flow rate of 10 μL/min. Then, the device was washed with the Wash Buffer (250 
mM NaH2PO4, pH 8.0 50 mM NaCl, and 10 mM imidazole) at 30 μL/min for 6 bed volumes. After 
washing, 5 bed volumes of Elution Buffer (3 M imidazole ) were flowed through the device at 10 
μL/min. Elution fractions were collected typically at volumes between 5 and 60 μL. The protein 
content of each fraction was determined using a Qubit 3.0 Fluorometer (ThermoFisher) following 
manufacturer-recommended protocol. The purification modules were washed with 0.5M NaOH 
flowing at 30 μL/min for 30 min and could be reused after a washing.. To reuse, the device was 
prepared following the same protocol as a newly filled device. 
According to the manufacturer (Sigma), Ni-NTA resin can bind 5-10 mg of protein per mL 
of resin.The standard device design has 60 μL of resin. At a Nanodisc concentration of 30 μM (60 
μM MSP), there is ~0.135mg of MSP per 90 μL fraction collected from a single device. This 
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equates to more than 3 fractions (90 μL fraction from a standard Nanodisc assembly device) per 
60 μL Ni-NTA device. Fractions containing 0.5 mg/mL total protein content or greater were 
combined into a single fraction. For subsequent spectroscopic analysis, imidazole was removed 
from the fractions using 3.5 kDa MWCO filter (ThermoFisher) according to manufacturer-
recommended protocols. SDB was used as dialysis buffer. 
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5.6 Tables, Schemes, and Figures 
Table 5.1. Sample Nanodisc preparation sheet for single port device 
Filled Nanodisc Formation with POPC and MSP1E3D1 
User Inputs 
 
Total Sample Volume (μL) 100 
[MSP1E3D1] (μM) 125 
CYP3A4 Stock Concentration (μM) 26.4 
MSP1E3D1:CYP3A4 Ratio 10 
POPC:MSP1E3D1 Ratio 120 
[POPC] stock (mM) 35.4 
Dried POPC (μL) 200 
[POPC] after addition of detergent (mM) 50 
Desired final [Cholate] (mM) 20 
Desired [CYP3A4] (μM) 3.4   
CYP3A4 Preparation Calculations 
 
nmol of CYP 3A4 0.3 
Final [CYP3A4] (μM) 3.4   
MSP1E3D1 Preparation Calculations 
 
nmol of MSP1E3D1 3.4 
Final [MSP1E3D1] (μM) 34   
Lipid Preparation Calculations 
 
nmol of POPC 408 
Final [POPC] (μM) 4080   
Reagents Volume (μL) 
100 mM Cholate into Lipid Film 141.6 
SDB Buffer with 0.1% Emulgen 913 38.6 
CYP3A4 Stock 12.9 
MSP1E3D1 stock 27.2 
50 mM POPC Stock 8.2 
SDB Buffer 1.3 
100 mM Cholate Stock 11.8 
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Table 5.2. Sample Nanodisc preparation sheet for a 3-port device 
3-Port Nanodisc Assembly with DMPC and MSP1D1 
User Inputs 
 
Total Sample Volume (μL) 400 
[MSP1D1] (μM) 175 
DMPC:MSP1D1 Ratio 80 
[DMPC] stock (mM) 36.9 
Dried DMPC (μL) 200 
Desired [DMPC] (mM) 50 
Desired final cholate concentration 20 
Desired final MSP concentration 50   
MSP1D1 Preparation Calculations 
 
nmol of MSP1D1 20 
Final [MSP1D1] (μM) 50   
Lipid Preparation Calculations 
 
nmol of DMPC 1600 
Final [DMPC] (μM) 4000   
Instructions Volume (μL) 
0: 100 mM Cholate Stock into Lipid Film 147.6 
1: MSP1D1 stock into Tube #1 114.3 
1: SDB(-) Buffer into Tube #1 19 
2: 50 mM DMPC Lipid Stock into Tube #2 32 
2: 100 mM Cholate Stock into Tube #2 48 
2: SDB(-) Buffer into Tube #2 53.3 
3: SDB(-) Buffer Tube #3 133.3   
Syringe ID Flow Rate (μL/min) 
Total device flow rate 30 
MSP1D1 Syringe (1) 10 
DMPC Lipid Syringe (2) 10 
Buffer Syringe (3) 10 
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Scheme 5.1. Microfluidic Nanodisc assembly module. 
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Scheme 5.2. Microfluidic Nanodisc purification module. 
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Figure 5.1. μNAP platform device designs. (A) A single-port device consists of reagent and 
detergent removal bead inlets, a bead bed with integrated posts for structural support, and an outlet 
for Nanodisc elution. (B) The multi-port device contains the same components as the single-port 
with the addition of multiple reagent inlets and a mixing channel. Both devices have a bead bed 
volume of 60 μL and yields 0.1-2 nmol of Nanodiscs. (C) The purification devices feature multi-
directional flow for loading of Nanodiscs formed using devices from A or B. (D) Interfacing 
Nanodisc self-assembly and purification can be achieved as a single, integrated platform.  
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Figure 5.2. Additional device designs for the μNAP platform. The bed volume of both assembly 
and purification can be tuned to the desired application. (A) The smallest device designed was 10 
μL, and this bed volume can be interfaced with either a single or multiport inlet. (B) This 
alternative design consists of a larger total bed volume of 120 μL with four beds. Each bed bed is 
packed individually and can be filled with either detergent removal resin or affinity purification 
resin. (C) Another large volume device (120 μL) consists of two packed beds interfaced with a 
multiport inlet for on-chip reagent mixing. 
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Figure 5.3. Flow visualization of 3 port mixing device. The multiport device design used on-
chip reagent mixing prior to Nanodiscs assembly upon detergent removal. The alternating juts 
result in efficient mixing, as visualized with die in this image.  
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Figure 5.4 Detergent removal device capacity. Elution fractions collected from single port and 
multiport devices collected from flowing 1% CHAPS (black and blue dots), 20 mM sodium cholate 
(red and green dots), and treated with concentrated sulfuric acid show increased absorbance once 
the detergent removal capacity is reached. This plot shows the detergent removal capacity for a 
device bed volume of 60 μL. The detergent removal capacity for both detergents is >90 μL, which 
corresponds to 1.5 μmol (0.9 mg) CHAPS and 1.8 μmol (0.78 mg) sodium cholate. 
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Figure 5.5. Microfluidic self-assembly with empty Nanodiscs. SEC analysis of Nanodiscs 
formed from a single-port device with DMPC and a DMPC:MSP ratio of 80:1 (A) and POPC and 
a POPC:MSP ratio of 60:1 (B) with MSP1D1. Approximate Nanodisc concentrations for each are 
25 μM. (C) Atomic force microscopy (AFM) of DMPC Nanodiscs formed with the Nanodisc 
assembly module without prior purification show Nanodiscs of appropriate dimension with no 
evidence of large lipid aggregates. (D) Dynamic light scattering (DLS) analysis of DMPC 
Nanodiscs indicating a single, monodisperse peak corresponding to Nanodiscs. 
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Figure 5.6. Assembly of Nanodiscs at various device flow rates. Size exclusion chromatograms 
(SEC) for DMPC Nanodiscs with MSP1D1 formed at variable flow rates indicate minimal to no 
effect on overall Nanodisc quality.  
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Figure 5.7. Comparison of mixing versus no mixing. Nanodiscs formed with either a multiport 
(3-port) and single port devices using MSP1D1 and sodium cholate as detergent both result in 
Nanodiscs in monodisperse and Nanodiscs that co-elute when analyzed with SEC. There was no 
observed decline in Nanodisc quality when prepared at RT using DMPC lipids(A) or at 4°C using 
POPC lipids (B).  
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Figure 5.8. Microfluidic gradient with fluorescent lipids. (A) The flow rate for lipid-containing 
syringe was increased continuously at a rate of 0.1 μL/s2 for the syringe containing DMPC with 
0.05%  Liss Rhod PE and -0.1 uL/s2 for DMPC only syringe. The syringe with MSP was held at a 
constant flow rate of 10 μL/min. (B) The fluorescence with a maximum at 590 nm shows an 
increase in intensity as a function of flow rate. This corresponds to an increasing fluorescent lipid 
content and, thus lipid bilayer composition, over the course of the microfluidic gradient.  
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Figure 5.9. Incorporation of CYP3A4 into Nanodiscs. A comparison of Nanodiscs made with 
DMPC, MSP1D1, and CHAPS as detergent with and without the incorporation of CYP3A4 at a 
ratio of MSP:CYP3A4 of 20:1 with SEC at 280 nm (A) and 417 nm (B). The chromatograms 
indicate Nanodiscs of approximately equivalent size. The chromatogram at 417 nm shows an 
absorbance for the Nanodiscs with CYP3A4 with minimal signal for the empty Nanodiscs. (C-D) 
A comparison before and after purification of CYP3A4 filled Nanodiscs before and after 
purification demonstrates the impact of the purification module as assessed using SEC analysis 
again at 280 nm (C) and 417 nm (D). These Nanodiscs were made with POPC, MSP1E3D1, and 
cholate as detergent.  
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Figure 5.10. Incorporation of CYP3A4 into Nanodiscs with a 3 port assembly device. 
CYP3A4 incorporation into DMPC and MSP1D1 Nanodiscs using a 3 port assembly device 
measured at both 280 nm and 417 nm with SEC show incorporation of CYP3A4 into the Nanodiscs 
as indicated by the co-elution of the 417 nm and 280 nm peaks. No Nanodisc purification was 
performed prior to SEC analysis. 
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Figure 5.11. Spin shift assays for Nanodiscs filled with CYP3A4. (A) UV/Vis absorption 
spectra demonstrate the low to high spin shift induced by the binding of bromocriptine (BCT), a 
type I CYP3A4 binder. Binding of BCT results in a decrease in the absorbance maximum of 417 
nm and an increase at 390 nm. (B) Imidazole, a type II CYP3A4 binder, induces a shift in the 
absorbance maximum for CYP3A4 from 417 nm to 422 nm. 
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6.1 Introduction 
 In the preceding chapters, I have presented three distinct projects: (1) multiplexed protein 
detection with microring resonator arrays, (2) the development of a microfluidic platform for 
Nanodisc assembly and purification, and (3) combining the microring resonator array platform 
with separations technologies. Although these projects might seem unrelated, they are unified 
behind the goal of expanding the toolbox of precision medicine. These projects have laid the 
groundwork for future work that could expand the capabilities of each and bring them closer to 
clinical application. The following sections will detail my proposals for the next steps, specifically 
highlighting the innovative potential applications that I find most promising. 
Because of my efforts and many of the lab members who developed these technologies 
before me, our lab now has a solid grasp over the optimal methods to perform multiplexed 
detection of biomarkers in nearly any biological sample. Certainly, technological hurdles remain 
and new barriers will be revealed with further investigation, but the lab is poised to answer 
fundamental biological questions and to solve clinical problems at a scale that I have looked toward 
since first joining the team. I am greatly excited to watch as the lab heads down these auspicious 
paths soon. 
6.2 Multiplexed Protein Detection with Microring Resonator Arrays 
Most of the studies carried out on the microring resonator array platform have been proof-
of-concept, seeking to demonstrate multiplexed biomolecule detection with a novel set of 
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biomolecules or in an analytically challenging matrix. Most of the “low-hanging fruit” in this area 
has been picked, and future project are primed to apply the technology in hypothesis-driven 
studies. Specifically, the phosphoprotein detection panels are an established platform as a reliable 
tool for monitoring signaling networks, and the throughput of the platform enables dynamic 
pathway profiling over the course of a given treatment. For instance, most anticancer drugs in the 
pharmaceutical pipeline aim to inhibit a key regulatory protein known to be dysregulated in certain 
cancers. However, resistance to these targeted therapies is commonly observed. Emerging 
resistance can be observed by monitoring any activity of proteins downstream of the targeted 
protein to determine if the tumor overcomes pathway inhibition. By monitoring multiple signaling 
pathways simultaneously, resistance to therapies via alternative signaling mechanisms could be 
observed over time. These types of studies are performed routinely in the development of new 
cancer drugs, although they commonly rely on cumbersome, low throughput methods like western 
blotting. 
A challenge of multiplexed biomarker panels is accurately interpreting the biological 
implications of the data. Heatmaps are a common method for representing highly multiplexed 
measurements such as gene expression from next generation sequencing, and hierarchical 
clustering can be integrated into the sample plots with dendrograms. Although they provide a 
straightforward approach to represent multiplexed measurements across multiple analyses and 
treatments, heatmaps or similar two dimensional plots are challenging to translate to facile clinical 
interpretations. To improve the clinical utility of multiplex protein measurements, I propose 
integrating network reconstruction algorithms with signaling pathway profiling. Network 
reconstructions that reflect a tumor’s phenotype can more easily point to a therapeutic regimen 
that could redirect the pathway signaling to reverse a pathological state, such as stopping the 
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growth and proliferation signaling of a tumor. There has already been substantial work in network 
reconstruction from global profiling strategies like NGS, protein microarrays, and proteomic 
approaches. The next steps for the protein profiling panel with the microring resonator platform is 
to determine algorithms for network reconstruction from these targeted profiling approaches, as 
opposed to the more cumbersome global detection methods. 
From an analytical perspective, the microring resonator platform is well suited for multiple 
biomolecule detection on a single sensor chip. Given the success the lab has had with nucleic acid 
detection, particularly for miRNAs, integrating analysis of multiple biomolecule classes from a 
single sample could prove to be a promising path. Much of the fundamental biology remains 
undiscovered for the interactions of miRNA cascades and the impact these miRNAs have on 
signaling networks. Consequently, investigating the correlations between miRNAs and 
phosphoprotein signaling could reveal undiscovered facets of cancer biology. Such a discovery 
approach is likely to be challenging for correlating measurements with changing phenotype, but 
the potential impact of these findings likely justifies those efforts. 
6.3 Microfluidic Tools for Nanodiscs 
 Nanodiscs have become the preferred method for in vitro studies of membrane proteins, 
and Chapter 6 outlines a novel platform for microfluidic Nanodisc assembly and purification 
known as μNAP. The benefits of the μNAP platform include low consumption of sample, rapid 
Nanodisc assembly and purification, and on-chip reagent mixing with microfluidic gradients. 
These benefits enable screening of optimal conditions for membrane protein incorporation by 
dynamically tuning the composition of the lipid bilayer over the course of Nanodisc assembly. The 
next steps are to apply this platform to compelling membrane protein targets and unexplored 
biological samples, such as tumor biopsies. Instead of forming Nanodiscs with incorporated 
205 
 
membrane protein from an isolated and purified sample, libraries can be formed of Nanodiscs that 
have been shown to be representative of the membrane proteome of the sample. The libraries also 
maintain the functional activity of incorporated membrane proteins. As such, the functional 
activity of membrane proteins from low input samples can be screened. An example application 
of this method is determining the sensitivity of Nanodisc libraries from tumor samples to targeted 
therapies. For instance, receptor tyrosine kinases (RTKs) are commonly overexpressed across 
many tumor types, and hyperactivity of RTK signaling contributes to tumor growth and 
proliferation. To combat RTK’s role in tumor growth and proliferation, several targeted 
therapeutics have been developed. However, tumors rapidly develop resistance to RTK inhibitors, 
and RTK susceptibility to inhibitors can be difficult to predict, even if the mutational status of an 
RTK is known. The ability to functionally screen RTKs from tumor biopsies could better guide 
treatment decisions, selecting for targeted therapies that demonstrate reduced protein activity. 
 There are also technological developments for the μNAP platform that could improve its 
functionality. For instance, the affinity purification could be improved by integrating 
immunoaffinity purification methods to isolate protein targets of interest with no engineered 
affinity tag. In combination with existing assembly and purification modules, immunoaffinity 
purification could result in the isolation of Nanodiscs containing the membrane protein of interest, 
which currently requires bulk purification and isolation methods, such as size exclusion 
chromatography (SEC) and spin columns that are not compatible with low sample inputs. 
Additional modules that could be integrated into the μNAP platform are on-chip SEC or other size-
based separation/isolation methods, such as on-chip electrophoresis. To assess incorporation of 
proteins into Nanodiscs or to determine Nanodisc heterogeneity, the samples collected from the 
μNAP platform must be analyzed with various off-chip methods, such as SEC, dynamic light 
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scattering, absorbance/fluorescence spectroscopy, and microscopic methods (e.g., atomic force or 
transmission electron microscopy). On-chip analysis could substantially improve the utility of the 
μNAP platform. The most straightforward approach to achieve on-chip analysis is incorporating 
on-chip separations with integrated UV/Vis absorbance. 
 The assembly module of the platform relies on efficient detergent removal that results in 
Nanodisc self-assembly. This process is similar to the assembly protocol of other soluble lipid 
bilayer mimetic systems, such as those made with styrene-maleic acid (SMA) copolymers known 
as or with Saposin A protein in place of the membrane scaffold protein (MSP) used in Nanodisc 
assembly. SMA copolymer or Saposin A can likely be used in place of MSP to make these 
alternative lipid bilayer systems using our microfluidic approach. 
 Finally, all the work to date on the μNAP platform has used polydimethylsiloxane (PDMS) 
plasma sealed to glass slides as the materials system. This approach is useful for rapid prototyping 
applications, but the low elastic modulus of PDMS resulted in device failure when high pressures 
were applied to the device during bed packing. An alternative material and fabrication approach 
with stiffer materials could improve device durability and reproducibility. Fabrication with hot 
embossing and thermoplastics (e.g., polycarbonate, polystyrene) would likely be a more robust 
material system yielding longer device lifetimes. Thermoplastics are easier to scale up to batch 
fabrication, offering a more tractable alternative to use our platform for labs who do not have 
experience with microfabrication techniques. 
6.4 Integrating Electrophoresis with Microring Resonator Arrays 
The push toward micro total analysis systems (μTAS) has driven the development of 
impressive capabilities for on-chip sample handling and processing, substantially improving 
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standard detection workflows by minimizing user intervention and vastly reducing reagent 
consumption. However, many of these devices still rely on off-chip detection methods for sample 
analysis, particularly when multiplexed sample analysis is required. The microring resonator 
platform has been extensively characterized and demonstrated as a robust tool for multiparametric 
sensing across a range of biomolecules. Integrating on-chip electrophoretic separations with the 
microring resonator array platform could represent a powerful detector for μTAS development and 
provide key improvements for the microring resonator platform in terms of reagent consumption, 
device footprint, detection limits, and sensor operation. 
The current microfluidic interface for reagent delivery to microring resonator arrays (M1, 
Genalyte) uses vacuum driven flow with alternating syringe pumps. This approach allows for 
optimum reagent delivery from a pre-filled 96-well plate and is minimally prone to leaks because 
poor fluidic seals result in no reagent flow. Minimal leakage and automated reagent delivery 
simplifies the implementation of the microring resonator platform in a clinical setting, in which 
leakage of biohazardous material is highly problematic. However, the fluidic system is suboptimal 
regarding reagent consumption and delivery of analyte to the sensor surface. Integrating 
electrophoresis into the microring resonator platform has the potential to dramatically reduce 
sample and reagent consumption, reduce instrument footprint by eliminating external syringe 
pumps, and optimize detection limits with an improved flow profile. These improvements could 
be realized while preserving the benefits of the existing pumping system. 
The current cartridge assembly consists of three components: (1) a polytetrafluoroethylene 
(PTFE) cartridge top for interfacing reagents from a well-plate with the microfluidic assembly, (2) 
a polyethylene terephthalate (PET) gasket that creates fluidic channels to direct reagents across the 
sensor chip, and (3) an anodized Al cartridge base that supports and sensor chip. The cartridge 
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assembly locks into place on the instrument with friction fitting. The secure fit of the cartridge 
assembly into the instrument ensures precise alignment with a variability of <500 μm, which is 
important for sensor chip registration with the optical scanner. Any improvements to the fluidic 
system must maintain this alignment precision to ensure facile operation. Initial efforts have been 
made using 3D printing of the cartridge tops and bases and using the PET gasket from the previous 
setup. The latest designs are hosted on GitHub (https://github.com/JamesHWade/EMRA). Several 
materials systems and printing approaches are available for 3D printing. The initial challenges with 
electrophoresis prototypes have been channel clogging or poor feature resolution below 400 μm. 
An emphasis should be placed on minimum feature size for future device prototyping. 
Once a design successfully allows for a fluidic interface with integrated electrodes for 
electrophoretic control, the platform should be used to mimic successful protein and nucleic acid 
detection methods previously developed in lab. This will provide a baseline for directly comparing 
electrophoretic versus syringe-driven flow. Additionally, on-chip separations add an additional 
dimension to analyte detection by correlating sensor response with electrophoretic migration time 
across the sensor surface. Time correlated sensor response could be particularly valuable for 
sensing in complex sample matrices, such as cell lysate or serum. Resolving binding events in 
complex matrices could eliminate the need for signal amplification, such as the enzyme 
amplification approached previously used in the lab. This could substantially reduce analysis time, 
an important consideration for downstream clinical integration. 
 
